|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/7/9 ¤U¤È 01:01:06²Ä 2883 ½g¦^À³
|
¥xÆW¨È·à±d¨göt ! ¦ý»ù®æ¤£·|°ª©ó ADR Asln §é»ù«á 11¶ô¥ª¥k ! ¥i¯à¦b8¶ô~9¶ô¦h´N·|°±¦í¤F ! ¤£¹³¦X¤@µL·Q¹³ªÅ¶¡ ! ¥i±¤ªü ! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/9 ¤W¤È 11:55:50²Ä 2882 ½g¦^À³
|
¦PMOA ¤TÃľú¥v---×¥¿4. Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ,¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C ¦å²G¤¤ASLAN004 ÃĶq 1mg/L, ´N¥i¥H§¹¥þ§í¨î¡A60¤½¤çÅé«x8%=4.8 L ¦å²G , ²z½×¤W¦å²G¤¤ ¥§¡«O«ù4.8mg ,´N¥i§¹¥þ§í¨î ¬°¦P¯Å®t¤@Ó¶q¯Å(10¿)¥H¤W¥ÎÃĶq. Dupilumab ,¤¤¤å¥é³æ¡A600mg°_©l¶q¡A²Ä7¤Ñ¦å²G¤¤ ÃĶq ¥§¡70ug/ml=70mg/L, 70x4.8=326mg 2019/12/05 ¤½¥¬ ASLAN004 ªvÀø ¤T¦ìAD ,200mg/¨C¶g¤@°w(4-6¶g)¡AEASI ¥§¡°´T71%, ¶W¶Vdupilumab 2a Á{§É ,300mg/¨C¶g¤@°w(600mg°_©l¶q)¡A²Ä¤¶g¥§¡EASI ¥§¡°´T67% . ------------------- 2020/06/29 ªÑªF·|³ø§i : p¹º2022¦~ASLAN004 °µ§¹2b ´Á¤¤¤@««×ADÁ{§É¦A±ÂÅv . ¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/9 ¤W¤È 11:17:12²Ä 2881 ½g¦^À³
|
¦PMOA ¤TÃľú¥v---×¥¿4. Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, 2017/08/08 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ, ¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î ¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C ¦å²G¤¤ÃĶq 1mg/ml, ´N¥i¥H§¹¥þ§í¨î¡A¬°¦P¯Å®t¤@Ó¶q¯Å(10¿)¥H¤W¥ÎÃĶq 2019/12/05 ¤½¥¬ ASLAN004 ªvÀø ¤T¦ìAD ,200mg/¨C¶g¤@°w(4-6¶g)¡AEASI ¥§¡°´T71%, ¶W¶Vdupilumab 2a Á{§É ,300mg/¨C¶g¤@°w(600mg°_©l¶q)¡A²Ä¤¶g¥§¡EASI ¥§¡°´T67% . ------------------- 2020/06/29 ªÑªF·|³ø§i : p¹º2022¦~ASLAN004 °µ§¹2b ´Á¤¤¤@««×ADÁ{§É¦A±ÂÅv . ¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/9 ¤W¤È 09:15:59²Ä 2880 ½g¦^À³
|
º¸®É¡A¥@´L°Ýºû¼¯¸×¡G¡u¦¼±ý¨£¦p¨Ó¡A¬°¥H¦óµ¥Æ[¦p¨Ó¥G¡H¡v ºû¼¯¸×¨¥¡G¡u¦p¦ÛÆ[¨¹ê¬Û¡AÆ[¦ò¥çµM¡C §ÚÆ[¦p¨Ó«e»Ú¤£¨Ó¡A«á»Ú¤£¥h¡A¤µ«h¤£¦í)¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/9 ¤W¤È 06:48:45²Ä 2879 ½g¦^À³
|
¦ô ¥¼¨ÓASLANªº±ÂÅvª÷±N¹F25e¬ü¤¸¡C ¬O¦Xx FBxxx5.3e¬ü¤¸ªº4.7¿ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/9 ¤W¤È 05:57:04²Ä 2878 ½g¦^À³
|
¥«³õ¥D¤O¤j¤j ¨È·à§é²{È21e¬ü¤¸¡C(¥¼¨Ó销°â°ªÂI50e¬ü¤¸¡AÀøµ{¦¨¥»»´©ö¬°dupilumab 60%) ²{¦b¤°»ò³£¤£¥Î°µ¡C ¬O¦XxFBxxx§é²{Ȫº3¿¡C ¨È·à³Q¨ÖÁÊ»ùȶW¶V¦Xx¾ãÓ¤½¥q¡C 21/13.3=¬ù1.5¿ (°²³]ONxxx¬OFB8xx¦P级¡A¤GÃħé现ȦXp约13.3»õ¬ü¤¸¡A¥i¾P°â°ªÂI¦Xp20»õ¬ü¤¸ 13.3¡Ñ3.5=46.5e¬ü(ªñº¡¨¬ÂI) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 10:55:29²Ä 2877 ½g¦^À³
|
¦PMOA ¤TÃľú¥v---×¥¿3: Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, 2017/08/08 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ, ¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î ¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C ------------------- p¹º2022¦~°µ§¹2b ´ÁADÁ{§É¦A±ÂÅv . --¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 10:31:12²Ä 2876 ½g¦^À³
|
¦PMOA ¤TÃľú¥v---×¥¿2: Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î ¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C ------------------- p¹º2022¦~°µ§¹2b ´ÁADÁ{§É¦A±ÂÅv . --¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 10:03:23²Ä 2875 ½g¦^À³
|
¥xÁÞ¤j, ·s¦X¬ù¦p¤U: ®Ú¾Ú¨È·à±d2019 ¦~5¤ë31¤é»PCSL ×q±ÂÅv¦X¬ù¡A¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C 2019¦~5¤ë31¤é×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù, ¨È·à±d¤w¶RÂ_ , ¤£»Ý¦A»PCSL§Q¼í§¡¤À. ------------------ §¹¥þ¥¿½T. ¥¼¨Ó¦A±ÂÅv , ¥u¶·©T©w¤ä¥ICSL : ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î ¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/8 ¤U¤È 09:52:46²Ä 2874 ½g¦^À³
|
¤Ñ©R¤j ·PÁ´£¨Ñ«D±`Â×´Iªº¸ê°T¤À¨É 2862½g¤À¨É®É¤Ñ©R¤j´£¨ì2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À §Ú¦A¦¸¬Ý2019¦~5¤ë31¤é¤½¥q¤½§i·s»D, ½T©w×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù¡C ¤]´N¬O»¡¨È·à±d2019¦~5¤ë31¤é»P CSL×q±ÂÅv¦X¬ù¡A¨ú±o ASLAN004 ©ó©Ò¦³¾AÀ³¯g¤§¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q¡A×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó 2014¦~5¤ëñq¤§¦X¬ù,(¨È·à±d¤w¶RÂ_,¤£»Ý¦A»PCSL§Q¼í§¡¤À)(¤Ñ©R¤j¥i¦A½T»{¤@¤U) ¦X¬ù: ®Ú¾Úì¦X¬ù¤º®e¡A¨È·à±d-KY À³ºÉ¬ãµo ASLAN004 ¦Ü·§©À©ÊÅçÃÒ(proof-of-concept)§¹¦¨¤§¸q°È¨Ã´M§ä°õ¦æ¤T´ÁÁ{§É¸ÕÅç¤Î°Ó«~¤Æ¤§¦X§@¹Ù¦ñ¡CCSL ±N¥i¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J¤§ 40%¦Ü 50% ·s¦X¬ù¦p¤U: ®Ú¾Ú¨È·à±d2019 ¦~5¤ë31¤é»PCSL ×q±ÂÅv¦X¬ù¡A¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C 2019¦~5¤ë31¤é×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù, ¨È·à±d¤w¶RÂ_ , ¤£»Ý¦A»PCSL§Q¼í§¡¤À ³oºâ¤£ºâ¬O¦n®ø®§ ? ¶Rötº¦15¿ªºªÑ²¼¦w¥þ ÁÙ¬O¶R ¨È·à±d ¯E¹© ¤¤¸Î ¦w¥þ ? ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 07:27:39²Ä 2873 ½g¦^À³
|
¬ü°êªñ1000¸U¤H¡A±wªÌ ¤¤¡Ð««×AD(²§¦ì©Ê¥Ö½§ª¢). Dupilumab ¦¬ªº¤T´ÁÁ{§É,¥§¡¦~ÄÖ36·³¡A¥§¡¤w±wAD 28¦~¡C ¥Ø«eDupiumab ¾P°â²Öp43»õ¬ü¤¸¡A¦@18¸U¤H¦~¡C(2017¦~ /Q3~2020¦~Q1) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 07:20:15²Ä 2872 ½g¦^À³
|
ASLAN004 »ù値¦ôp𢑥¾ã: ¤@¡B2019,05.31 ¨È·à±d»PCSL, ¨Ì¾Ú¦UºØ±ø¥ó¹F¦¨,¥]¬ADupilumab 50»õ¬ü¤¸¾P°â°ªÂI¡AASLAN004 ¯à¤O,¨ä¥LÄvª§¹ï¤â¯à¤O¡A§PÂ_¥¼¨ÓASLAN004 ¾P°â°ªÂI30»õ¬ü¤¸,¬°¥þ²y°Ó·~¤Æ¦X¬ù±ø¥ó°ò¦¡C¦ôp¨â®a¤½¥q¥i±o10»õ¬ü¤¸§é²{È¡C ¤G¡A2020¦~7¤ë8¤é¡A (1)¸gDupilumab ¥¼¨Ó¾P°â°ªÂI¡A³QREGN«Å§i¥i¹F¨ì110»õ¬ü¤¸¡A¥«³õ»{¦P¡Aªñ6Ó¤ëªÑ¥«¥«È¤jº¦300»õ¬ü¤¸. (2)¥BASLAN004 200mg/¨C¶g¤@°w EASI¥§¡°´T71%(4-6¶g) ,¶W¶V¦Pdupilumab 2a Á{§É¡A300mg/¨C¶g¤@°w¡A°_©l¶q600mg. ASLAN004 ¤ô±i²î°ª¡A Ävª§¤O¦Ü¤Ö¥H200mg/¨C¤G¶g¤@°w,P<0.001 ¡A¥§¡Àøµ{¦¨¥»dupilumab 60% ¡AµLµ²½¤ª¢°Æ§@¥Î¡AÀø®Ä¬Û·í¡C ¡X¡X¡X¡X µ²½×: ASLAN004 ¦A±ÂÅv¡A¾P°â°ªÂI´£°ª¨ì¦~50»õ¬ü¤¸¡A¬O¦X²zªº¹w¦ô. ¦ôp¥Ø«e³Q¨ÖÁʧé²{Ȭ°¨È·à¿W±o21»õ¬ü¤¸¡A¥t¥~CSL¥i±o15»õ¬ü¤¸¡C ¥¼¨Ó2002¦~2b ADÁ{§É§¹¦¨¡A¨È·à¥i¥[4»õ¬ü¤¸§é²{È¡A¦Xp25»õ¬ü¤¸¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦X¤@FB825 4¤ë15¤éñ¬ù¡A³Ì°ªÁô§t¾P°âª÷ÃB¦b10.6»õ¬ü¤¸¡A§é²{È6.66»õ¬ü¤¸¡C ¨È·à²{¦b§é²{È 10e~21e¬ü¤¸¡A¬O¦X¤@ FB825 §é²{È150%~300%, ¥ª¥k¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 04:43:22²Ä 2871 ½g¦^À³
|
ASLAN004 ¥þ¥@¬É75%¬ü°ê¤H¦b¥Î¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/7/8 ¤U¤È 04:38:59²Ä 2870 ½g¦^À³
|
¦Ñ·à¯d¦b¥xÆW¤£·|¤ñ¥h¬ü°ê®t,¥B¯d¦b¥xÆW¦¬®×¯f¤H¬°¨Î,¦]¥þ¥@¬É¥u¦³¥xÆW¤£¨ü¬Ì±¡¼vÅT.... ¥Í§Þ±ø¨Ò¦A©µ¤Q¦~ www.chinatimes.com/newspapers/20200708000179-260202?chdtv |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 04:10:55²Ä 2869 ½g¦^À³
|
ASLAN MOA ªýÂ_IL4(¤¶¥Õ¯À4¸¹)/IL14 (¤¶¥Õ¯À14¸¹) ¤§¶¡°T®§¶Ç»¼¡C ASLAN004 ¹vÂIIL13 ¨ü¾¹. ¤¶¥Õ¯ÀIL13 ¬Oªø¦b¬õ¦å²y¤W±: ¥¿±`±¡§Î¤U¡A¬õ¦å²yªº¹Ø©R¬ù¬°120¤Ñ¡F¬õ¦å²y¥Ñ°©Åè»s³y§¹¦¨¡A¶i¤J¦å²G´`Àô¡At³d¹B¿é®ñ®ð¨ìÅ餺¦U¾¹©x¡A¨ì¦Ñ¤Æ¥¢¥h¥¿±`®ðÅé¥æ´«ªº¯à¤O«á¡A¥Ñºôª¬¤º¥Ö¨t²Îªº§]¾½²ÓMt³d²M°£¡A¥§¡¥þ¨ªº¦å²G40¬íÄÁ§Y¥i¸g¹L¤ßŦ¤@¦¸¡A¤ßŦ¨C¦¸¦¬ÁY¬ù¿é¥X70²@¤É¦å²G¡C ¬õ¦å²y¡G ¥Dn§t¦³¦å¬õ¯À¡A¥iÄâ±a®ñ¡]¤G®ñ¤ÆºÒ«h¬O¥Ñ¦å¼ß¨Ó¹B°eªº¡^¡A¥§¡ 1 Ó¬õ¦å²y¥i¬¡ 120 ¤Ñ¡A¦Ñªº¬õ¦å²y¦b¨xŦ©ÎµÊŦ¤¤³Q§]¾½±¼¡A¦å¬õ¯À¤]·|³Q¤À¸Ñ¥XÅK½è¡A¦Ó¦A§Q¥Î¡C¤@¯ë°·±d¨k©Ê¬õ¦å²y¬ù540¸UÓ¡þ¥ß¤è²@¦Ì¦å²G¡A¤k©Ê¬ù¦³480¸UÓ¡þ¥ß¤è²@¦Ì¦å²G¡Aªø´Á¦í¦bªÅ®ðµ}Á¡ªº°ª¤s©~¥Á¡A¬õ¦å²y¼Æ¥Ø¤]·|¸û¦h¡C www.blood.org.tw/Internet/main/docDetail_Content_Print.aspx?uid=6536&pid=6387&docid=23909 ¦å²G°ò¥»¤¶²Ð - ¥xÆW¦å²G°òª÷·| |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 03:47:25²Ä 2868 ½g¦^À³
|
¨È·à¤½¥¬ªº¬O ASLAN004 10mg/kg IV (ÀR¯ßª`®g)¥i§¹¥þ§í¨î29¤Ñ¥H¤W¡X¡X-2019,05,31 60¤½¤çÅ髱wªÌ¶· 60x10=600mg SC(¥Ö¤Uª`®g)¥Î¶q=600mg/87%=690mg. Y50¤½¤çÅ髱wªÌ 50x10=500mg SC¡]¥Ö¤Uª`®g)¥Î¶q=500mg/87%=575mg(600mg ¥i§¹¥þ§í¨î29¤Ñ) 52¤½¤çÅé«¥H¤U±wªÌ¬Ò¥i³Q600mg §¹¥þ§í¨î¡C29¤Ñ ¤T´Á¥Dn«ü¼Ð : 1.EASI-90 2.IGA-0/1 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 03:18:37²Ä 2867 ½g¦^À³
|
¤@¡BASLAN004 ¥H50»õ¬ü¤¸¾P°â°ªÂIªº±ÂÅv¼ÒÀÀ¤Î§é²{È (1)±ÂÅvª÷=ñ¬ùª÷¡Ïùµ{ª÷=25»õ¬ü¤¸ (2)¾P°â¤À¼í 10%~20% ¥H¤W§é²{È ¨È·à±d ³¡¥÷ ¦û25»õ¬ü¤¸¡ACSL 15»õ¬ü¤¸ , ¦Xp 40»õ¬ü¤¸.¡]2022¦~°µ§¹2bÁ{§É) ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ²{¦b¦pªG¨È·à±d¤°»ò³£¤£°µ³Q¨ÖÁʧé²{È¡A³Ì°ª¥i½Í¨ì21»õ¬ü¤¸(¦©°£2bÁ{§É4»õ¬ü¤¸ªº¨ÑÄm¡^¡A¨Ì50»õ¬ü¤¸¾P°âª÷ÃB¬°°ªÂIpºâ¡C ¦Ó2019¦~5¤ë¡A¨Ì30»õ¬ü¤¸¾P°â°ªÂI¡A¦ô10»õ¬ü¤¸§é²{È¡A¨È·à¤£·|¦P·N¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤G¡AÄvª§Àu¶Õ °²³] 1.ASLAN004 200mg/2¶g¤@°wx16¶g,¤G´ÁÁ{§É,p<0.001 200mgx8=1600mg ¡A¡X¡XASLAN004 Àøµ{°w¾¯¶q¤@¤@¤@¤@A 300mgx9=2700mg¡X¡X-dupilumab 3´ÁADÁ{§É16¶g¥Î¶q.°_©l¶q600mg¤@¤@¤@B ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- A¡þB=60% ASLAN004 ¡A¥i¥H¥Î60% DupilumabÀøµ{¦¨¥»¥h¥Ê¤À¤Î¼W¥[¥«³õ¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-¡X¡X¡X- Ó¤HÆ[¹î ¥H¤U¤è®×¥i¯à¦¨¥\: ASLAN004 °_©l¶q600mg À³¨¬¥H§í¨î90~100% 29¤Ñ¥H¤W¡A«e¥|¶g¤j´T°§CEASI¨ì60%¥ª¥k¡A«á±12¶g¥Î200mg x3°w ´N¬Û·í¤j¾÷·|¨¬°÷¡A 600mg¡Ï3x200mg=1200mg¡X¡XASLAN004 Àøµ{°w¾¯¶q, °_©l¶q600mg /¥|¶g¤@°w ,²Ä¤G¨ì¥|¶g¦U200mg¡X¡X¡XC C/B=1200mg/2700mg=45% ASLAN004 ¡A¥i¥H¥Î45% dupilumab Àøµ{¦¨¥»¡þ¥|¶g¤@°w¡A¥h¤ö¤À¤Î¼W¥[¥«³õ¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X °Æ§@¥Î: ASLAN004 µLDupilumab µ²½¤ª¢ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 12:51:44²Ä 2866 ½g¦^À³
|
¤@.ASLAN004 ¥Ø«e±ÂÅv»ùÈ 20»õ¬ü¤¸¡A¬O¥h¦~5¤ë31¤éªº¦æ±¡. 2019/6¤ë1¤é¡ã¨ì¥Ø«e·s¼W»ùÈ 1.Dupilumab «Å¥¬¾P°â°ªÂI¥Ñ¥«³õ»{¦Pªº50»õ¬ü¤¸¡A¼W¥[¨ì110»õ¬ü¤¸. ªñ¤»¤ë¨ÓÉ]ȼW300»õ¬ü¤¸¡C 2.ASLAN004 ¤w°µ§¹ 6¤Hªº¤¤««×AD¡A200mg /¨C¶g¤@°w¡A«e3¤H ¥§¡ °EASI°71%¡]4-6¶g¡^¡A¤wÀu©óDupilumab 2aÁ{§É¼Æ¾Ú¡CµLµ²½¤ª¢°Æ§@¥Î¡C ¥H¤W¨â¶µ§Q¦h¡Aµ´«D¥h¦~5¤ë©³ªº±ÂÅv¦æ±¡¥i¤ñ¬ü¡C ¦X²zªº·s±ÂÅv¦X¬ù¦ô¾P°â°ªÂI50e¬ü¤¸¡A¬°°ò¦ªº±ÂÅv¯uªº𣎴¹L¥÷¡C¦Ó«D¥h¦~30e¬ü¤¸ªº°ò¦¡C ¥H¤WÓ¤H·N¨£ ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 12:29:09²Ä 2865 ½g¦^À³
|
¦A±j½Õ¤@¦¸¡A¨È·à±d¤°»ò³£¤£¥Î°µ¡A¥Ø«e§é²{È10e¬ü ¤@.ASLAN004 ¥Ø«e±ÂÅv»ùÈ ¡]1) «eª÷+¨½µ{ª÷ 2.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. =§é²{È20»õ¬ü¤¸ ,¨È·à±d©MCSL ¦UÀò10»õ¬ü¤¸§é²{È ----°ê¤ººÙ¸¹ ±ÂÅvª÷ÃB(1)+(2)=2.5+13.1=15.6»õ¬ü¤¸ CSL Åv§Q: ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤U¤È 12:21:41²Ä 2864 ½g¦^À³
|
200mg/¨C¶g¤@°w¡A6¤H¡Ï¹ï·Ó²Õ2¤H¡A¤w°µ§¹¡C ³o¬O¤W¥«Dupiluma ¦P级(MOA) ¤G¶g¤@°w¥ÎÃĶq300mg ªº 1.44 ¿¡A 400mg /600mg ¥u¬O¦b´ú·¥¤j¤Æªº@¨ü©Ê¤Î¦w¥þ©Ê¡C¨ä¹ê¤£°µ¥çµL§«¡C¡]µL¥«³õÄvª§¤O) À³¸Ó¥i¥t´ú150mg/¤@¶g¤@°w¡C 6¡Ï2 ¤H AD¡A¤w¨¬°÷ ¶i«×Àu©óFB825 , ¤w§¹¦¨¤@¦¸±ÂÅvªºASLAN004 , ¤w¦s¦b°ê»Ú¦æ±¡»ùÈ¡C ¥Ø«e10e¬ü ¡n©¹14e¬ü©Î 25 e¬ü¡AÁÚ¶i¡C ±q²{¦b°_³sº¦30¤Ñ¡A¤£¹L7.5e¬ü¥«È¡C ¹³¦Xx º¦3.5¿x10 e ¬ü¦b¥xÆW¥i¯à¨£¤£¨ì¡A2022¦~¥h¬ü°ê¬Ý 14~25e¬ü ¥H¤W¾÷·|¤j¡C n¯d¥xÆW¶·¥[¤JÃþ¦ü¤¤x¶°¹Î¡þ´Ix¶°¹Î⋯, Àq§JÃļt¡þ²H°¨¿ü¤£·|¦P·N¦A¼W¸ê¥»ÃBÅý§Qµ¹°ê¤º¤½¥q¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X 2b Á{§É250¤H¡A¬ü°êÁ{§É©ú¦~¶}©l¡A¤~¬O«ÂI¡A¨ä¥L¬Ò¤p¨Æ¡C §Æ±æ¬ü°ê¬Ì±¡¯à¦b©ú¦~±±¨î¤U¥»¡C ¥H¤WÓ¤H·N¨£¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/7/8 ¤W¤È 11:58:41²Ä 2863 ½g¦^À³
|
1.»°§Ö«ì´_¦¬®×(¨Ó¥xÆW³]ÂI¦¬®×¤]¨Ï«Ü¦nªº¦Ò¶q),¦b2020¦~«e¥H§¹¦¨004ªº1a¸Ñª¼...§_«h¼ç¦b»ùȳ£¬O¹Ú... 2.ªÑªF·|»¡ºÉ§Ö¬ãij¤U¥««áÂàADRªº¤èªk,¤£n¦A©ì... 3.¥Í§Þ·sÃIJ£·~µo®i±ø¨Ò¦A©µ¤Q¦~¹LÃö,¤]¥i¥H¦Ò¶q¯d¦b¥xÆW¨É¦³ªº¯²µ|¦n³B.... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 09:50:01²Ä 2862 ½g¦^À³
|
×¥¿1. ----------------------------------------------------- Lebrikizumab----§¨Ó¤½¥q 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É ------------------------------------------------------- ¦PMOA ¤TÃľú¥v Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ p¹º2022¦~°µ§¹2b ´ÁADÁ{§É¦A±ÂÅv . ---¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 09:44:11²Ä 2861 ½g¦^À³
|
¦PMOA ¤TÃľú¥v Dupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- Lebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, 2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó4000¤Hªº¤T´ÁADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ ------- ASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ñ¤U¥þ²y°Ó·~¤Æ p¹º2022¦~°µ§¹2b ´ÁADÁ{§É¦A±ÂÅv . ---¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 09:08:33²Ä 2860 ½g¦^À³
|
ASLAN004 »PCSL 2019/05Q ¥þ²y°Ó·~¤Æ±ÂÅv¦X¬ù ±µªñ--¦P¯ÅMOA Lebrikizumab ,2017¦~±ÂÅv°ê»Ú¦æ±¡ ------------------------------ 2017/08/08 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. ----------------------------------- Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB. ----------------------------------- Âê©wIL13 °tÅéB.CÃ줧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà ----------------------------------------- 2017¦~¦~©³,Dermira ¶}©l°µ2b AD 280¤HÁ{§É (2019/10 ¤T´ÁÁ{§É¶}©l) 2020¦~¤¸¤ë Dermira ³Q§¨ÓÃļt11»õ¬ü¤¸¨ÖÁÊ. |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/7/8 ¤W¤È 09:03:51²Ä 2859 ½g¦^À³
|
·à¤l²×©ó¦³ÂI¹³¼Ëªº«ã§q ¸Ü»¡¡A¨ì©³¦ó®Én¤UÂdªü? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 08:48:44²Ä 2858 ½g¦^À³
|
¤@.ASLAN004 ¥Ø«e±ÂÅv»ùÈ ¡]1) «eª÷+¨½µ{ª÷ 2.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. =§é²{È20»õ¬ü¤¸ ,¦©°£¨È·à±d©MCSL ¦UÀò10»õ¬ü¤¸§é²{È ----°ê¤ººÙ¸¹ ±ÂÅvª÷ÃB(1)+(2)=2.5+13.1=15.6»õ¬ü¤¸ CSL Åv§Q: ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. ¤G.ASLAN004 2022¦~°µ§¹2b AD Á{§É»ùÈ ¡]1) «eª÷+¨½µ{ª÷ 6.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. =§é²{È24»õ¬ü¤¸ ,¦©°£CSL Àò10»õ¬ü¤¸,¨È·à±dÀò14»õ¬ü¤¸§é²{È ----°ê¤ººÙ¸¹ ±ÂÅvª÷ÃB (1)+(2)=6.5+13.1=19.6»õ¬ü¤¸ CSLÅv§Q ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. -------------------------------------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 08:27:35²Ä 2849 ½g¦^À³ 2022¦~¡A°µ§¹2b , ¤¤««×AD ,¬ù250¤H¡AÁ{§É ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥¼¨ÓY¦A±ÂÅv¡A¥i¯à±ø¥ó¡A¦p¤U ¡]1) «eª÷+¨½µ{ª÷ 6.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. ¨ä¤¤§t CSL Åv§Q¡A ¥ç§Y¨È·à±d¥t¥²¶·¤ä¥ICSL ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 08:00:41²Ä 2857 ½g¦^À³
|
¥«³õ¥D¤O ¦XxªºFBxxx±ÂÅv¡A4¤ë15¤é°_º¦ ,31.55¤¸/ªÑ 6¤ë11¤é³Ì°ª233.5 ¤¸ ¤jº¦ 200¤¸¡A¥«È¼W¥[700»õ¥x¹ô 700/30=23»õ¬ü¤¸ ¦ôp§é²{È6.66»õ¬ü¤¸ 23/6.66¡×3.5¿(ªÑ»ù/§é²{Ȥñ) ¦U¦ì¥D¤O¤j¤j ¨È·àªºÃD¤~Àu¡A §é²{È10e¬ü¤¸¡A¬OFBxxx1.5¿ ¥Ø«e0.5»õ¬ü¤¸¤£¨ì¡A Y¯à¦p ¦XxFBxxx¡C, 10ex3¿ =30e¬ü ¸êª÷³ø¹S²v¤@辈¤lÃø§ä¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 07:30:12²Ä 2856 ½g¦^À³
|
¨È·à±dASLAN004»ùÈ¡C 1.2014¦~©MCSLñ¬ù¡A¦@¦P¶}µoASLAN004¡A¨ì·§©À©ÊÁ{§É¡A¥Ñ¨È·à§ä寻¡A¥þ²y°Ó·~¤Æ¹ï¶H¨Ó±ÂÅv¡A©Ò±o§Q¯q¨â®a¤½¥q§¡¤À¡C µ²ªG2019/05,¥Ñ¨È·à±dñ¤U¥þ²y°Ó·~¤Æ¦X约¡C ¦¹¶¥¬q¨È狮¤ÎCSLÀò§Q谮¦b§é现ȦU10»õ¬ü¤¸¡C ¦Xp20»õ¬ü¤¸¡C (¾P°â°ªÂI30»õ¬ü¤¸¡A200mg/¨C¨â¶g¤@°w) 2.2019¦~10¤ë¨È·à±dpµe¡A 2022¦~°µ§¹2bÁ{§É¦A±ÂÅv¥X¥h¡A ¦¹¶¥¬q¨Ì°ê»Ú¦æ±¡¼W¥[4e¬ü¤¸¡C¡B 3.¥¼¨Ó2bÁ{§Éµ²ªG Y200mg /¨C¥|¶g¤@°w¹F¼Ð¥Bp<0.001 ¦Xp³Q¨ÖÁʲ{ª÷»ùȦô25e¬ü¤¸¡C (¦~¾P°âÃB¬D¾Ô50»õ¬ü¤¸) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/8 ¤W¤È 06:53:34²Ä 2855 ½g¦^À³
|
www.marketwatch.com/investing/stock/regn ¦h¬Ý¬Ý¤j¥xÆW60¿ªº¥Í§Þ¥«³õ¡A²ö¥u·í¤«©³¤§µì¡I REGN¡Aªñ¥b¦~¤jº¦ªñ8800»õ¥x¹ô¡C Dupilumab ´£°ª¥¼¨Ó¾P°â预测110»õ¬ü¤¸¡A¬O§Uº¦³Ì¤j¥\¦Ú¡C 2019¦~Dupilumab¾P°âÃB23»õ¬ü¤¸¡A¥þ¤½¥q¾P°âÃB约80»õ¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/7 ¤U¤È 07:59:47²Ä 2854 ½g¦^À³
|
¥Ø«e©Ò¦ôASLAN004 ³Q¨ÖÁʲ{ª÷»ùÈ¡C10e¬ü ¬O¦XxFBxxxªº1.,5¿»ùÈ¡C ¦ý¥«³õ¤W±`¨£ªº¬OªÑ»ù=§é²{²bÈx3¿ ©Ò¥H³æFBxxx=10/1.5x3 =20 e¬ü¤¸ ¡A©Ò¥H¥D¤O´±©Ô¡B¥~¸ê´±¶R¡C ¥t¥~ONxxx ,Ȧh¤Ö¡H¤£ª¾¡A¤£´±»¡¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/7 ¤W¤È 10:55:33²Ä 2853 ½g¦^À³
|
·f¦Xx±M¨® 10e¬üx30/19*10=157 ¼ç¦b¨ÖÁʲ{ª÷»ùÈ¡C ¥D¤O¤j¤j¡A²´·ú©ñ¹L¨Ó¡I 2022¦~ »ùȦA¼W4e¬ü¤¸¡C Y200mg/4¶g¤@°w¹LÃö 25e¬ü¤¸¡A²{ª÷¨ÖÁÊ谮È¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/7 ¤W¤È 07:21:04²Ä 2852 ½g¦^À³
|
¦Xx¤wº¦11¿¡C ¨È·à¥Ø«e³Q¨ÖÁʲ{ª÷»ù10»õ¬ü¤¸¡C ¦ý²{Ȥ£¨ì0.5 »ù¬üª÷¡AÄY«³Q§C¦ô¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¦X¤@FB825 ¡A¥u°µ12¦ì¤¤¤@««×ADªº¤@´Á¡A´N±ÂÅv¡A¨ä¾÷Âà¡]M〇A¡^¡A³QÅçÃÒ¡C ¨È·àASLAN004 ¡A¤w°µ6¦ì¤¤¤@««×AD¡X-200mg/¡A¤w¤½¥¬ªì¨B4¤@6¶gµ²ªG¡A¦ýªýÂ_IL4/IL13°T¸¹¶Ç»¼ªºMOA¡A¤w³Q¶W¹L18¸U¤H¡A¤T«·sÃÄ Åçµý¹LÃö¡C ASLAN004 ¥«³õ¼ç¤O¡A¨Ì±ÂÅvª÷p¹º¤ñ²v¬OFB825ªº3¿¡C ¬ù 30»õ¬ü¤¸ VS10»õ¬ü¤¸ ¨ä¤¤¨È·àÅv¯q¤ñ¦û1.5¿¡C ¦X¤@ªºFB825±ÂÅv¹ï¶HLEO ,¦~À禬¬ù10»õ¬ü¤¸¡X-2014¦~ ¨È·àªºASLAN004 ¬ãµoªÌCSL¡A¦~À禬66»õ¬ü¤¸¡X2020¦~¡A¥@¬É»sÃıƦW26¦W¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥«³õ¥D¤O ¤j¤j¬Ý²M·¡¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/7 ¤W¤È 02:21:21²Ä 2851 ½g¦^À³
|
¦XXªº¥D¤OYÁo©ú¡A¦]·í©Ô¥x¨È·à¡A³o¼ËGDR¡A¤]¦³¦nªº¤ñ»ù°ò¦!¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/6 ¤U¤È 11:42:18²Ä 2850 ½g¦^À³
|
¤Ñ©R¤j ·¤ô½ü¬yÂà¡C NBI¥Í§Þ«ü¼Æ¦A³Ð¾ú¥v·s°ª¡A¦pªG¨S¬Ý¿ù±q§Þ³N½u«¬¨Ó¬Ý¸êª÷«Ü©úÅã¬y¤J¥Í§ÞÂåÃĪѡH ¦X¤@º¦´TÅå¤H¡A·|¤£·|®i¶}¤ñ»ù®ÄÀ³¡A®É¶¡·|µ¹µª®×¡H¦³¼ç¤Oªº¥Í§ÞªÑ±`±`Åý¤H¶^¯}²´Ãè¡I¨«¼Ú¬ü±ÂÅv¤~¬O¥¿³~¡A¨È·à±dÁöµM¶^¶^¼²¼²¡A¦ý¨«¹ï¤è¦V¡A¶°¤¤¤õ¤OµoASLAN004 ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 08:27:35²Ä 2849 ½g¦^À³
|
2022¦~¡A°µ§¹2b , ¤¤««×AD ,¬ù250¤H¡AÁ{§É ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥¼¨ÓY¦A±ÂÅv¡A¥i¯à±ø¥ó¡A¦p¤U ¡]1) «eª÷+¨½µ{ª÷ 6.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. ¨ä¤¤§t CSL Åv§Q¡A ¥ç§Y¨È·à±d¥t¥²¶·¤ä¥ICSL ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ASLAN004 ¾ú¥v 2014¦~ CSL °µ§¹¦Ñ¹«¹êÅç«á±ÂÅvµ¹¨È·à±d¡C ¦X¬ù±ø¥ó¡A¥Ñ¨È·à±d°µ§¹ASLAN004 ªº·§©À©ÊÁ{§É(1b) ,µM«á´M§ä¹ï¶H¡A¦A±ÂÅv¨ä¥L¤½¥q°µ¥þ²yµo®i¡B¥Í²£¡B°Ó·~¤Æ (¤G´Á/¤T´ÁÁ{§É¤Î¥þ²y¾P°â/»s³y). ©Ò±o§Q¼í ¥ÑCSL¤Î¨È·à±d¦U¦û50%. 2019¦~5¤ë¥Ñ¨È·à±dñ¤U ASLAN004 ªº¥þ²yµo®i¡B¥Í²£¡B°Ó·~¤ÆÅv§Q¡C±ø¥ó¦p¤U ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ©Ò¥HY2019¦~5¤ëñ¤Uªº¬O²Ä¤T¤è¤½¥q¡A«h·í®É»ùÈx2 ¥i¯à¬°¡]1) «eª÷+¨½µ{ª÷ 2.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. ¦ÓCSL©M¨È·à±d¦U¤À¤@¥b¡C约¦U±o ¦X¤@FB825ñ约ª÷¡A5.3»õ¬ü¤¸ªº150%, ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 07:34:07²Ä 2848 ½g¦^À³
|
°ê»Ú·sÃıÂÅv¦X¬ù µ²ºc 1¡Añ¬ùª÷ : ñ¸p¦X¬ù«á¤ä¥I. 2¡Aùµ{ª÷ : ¦UÁ{§É§¹¦¨¡A¨úµý¡A¦U¶¥¬q¾P°âª÷ÃB¤§©â¦¨ 3¡A¾P°â¤À¼í : ¨Ì¾P°âÃB ¤@©w¤ñ¨Ò¤À¼í¡C ¥xÆW´CÅé¤W©ÒºÙ ±ÂÅvª÷ÃB¡A¦p¦X¤@FB825 ³q±`¬° 1¡Ï2 =ñ¬ùª÷¡Ïùµ{ª÷ ¦Ó°ê»Ú¤W·|®Ú¾Ú¨CºØ·sÃÄ¥¼¨Ó ¨úÃÄÃÒ ¦~¥«³õ¾P°â ¨Óñ¬ù¡C ¦p¨È·à ASLAN004 ¡A¦bCSL¤Î¨È·à¨Ì°ê»Ú¦æ±¡¤Î¥i¯à¥«³õ¦û¦³²v¡A»{¬°¦b30»õ¬ü¤¸¥ª¥k¡C ¦]¦¹ 1¡Ï2 =ñ¬ùª÷¡Ïùµ{ª÷= ¬ù¬°³Ì°ª¾P°âª÷ÃB¤@¥b :15»õ¬ü¤¸¡C 3 . ¾P°â¤À¼í ¦û³Ì°ª¾P°âª÷ÃB¥t¤@¥b : 15»õ¬ü¤¸ ©Ò¥H¦X¤@FB825 ±ÂÅvª÷5.3»õ¬ü¤¸¡A¥Nªí¦X¤@¤ÎLE〇»{¬°¡A¥¼¨Ó¾P°âª÷ÃBÂI¦b5.3X2=10.6 »õ¬ü¤¸¡C ¥H¤WÓ¤HÆ[¹î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 06:28:43²Ä 2847 ½g¦^À³
|
¨È·à¥Ø«eªº»ùÈ约¦X¤@FB825ªº150% 2022¦~°µ§¹约250¤HªºAD¡A2bÁ{§É¡A¦A¼Wñ¬ùª÷»ùÈ约4»õ¬ü¤¸¡C ³Q¨ÖÁÊ»ù14»õ¬ü¤¸¡A°_¸õ¡C¡K¡K°²³]200mg/¨C¤G¶g¤@°w¦¨¥\¡C Y200mg/¨C¥|¶g¤@针¡A¦¨¥\¡A ¨È狮³Q¨ÖÁÊ»ù¦ô¡A25»õ¬ü¤¸¡C ³o¬O°ê»Ú¦æ±¡¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 05:58:24²Ä 2846 ½g¦^À³
|
ASLAN004 ¾ú¥v 2014¦~ CSL °µ§¹¦Ñ¹«¹êÅç«á±ÂÅvµ¹¨È·à±d¡C ¦X¬ù±ø¥ó¡A¥Ñ¨È·à±d°µ§¹ASLAN004 ªº·§©À©ÊÁ{§É(1b) ,µM«á´M§ä¹ï¶H¡A¦A±ÂÅv¨ä¥L¤½¥q°µ¥þ²yµo®i¡B¥Í²£¡B°Ó·~¤Æ (¤G´Á/¤T´ÁÁ{§É¤Î¥þ²y¾P°â/»s³y). ©Ò±o§Q¼í ¥ÑCSL¤Î¨È·à±d¦U¦û50%. 2019¦~5¤ë¥Ñ¨È·à±dñ¤U ASLAN004 ªº¥þ²yµo®i¡B¥Í²£¡B°Ó·~¤ÆÅv§Q¡C±ø¥ó¦p¤U ¡]1¡^«eª÷+¨½µ{ª÷ ¦@1.25»õ¬üª÷ +¡]2)§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+¡]3) ¥[¾P°â¤À¼í5%~<= 10%. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ©Ò¥HY2019¦~5¤ëñ¤Uªº¬O²Ä¤T¤è¤½¥q¡A«h·í®É»ùÈx2 ¥i¯à¬°¡]1) «eª÷+¨½µ{ª÷ 2.5 »õ¬üª÷ +¡]2)³Ì°ª¹F 13.1 »õ¤§¾P°â¨½µ{ª÷¡Ï¡]3)¾P°â¤À¼í10%~20%. ¦ÓCSL©M¨È·à±d¦U¤À¤@¥b¡C约¦U±o ¦X¤@FB825ñ约ª÷¡A5.3»õ¬ü¤¸ªº150%, ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤U¤È 04:27:26²Ä 2845 ½g¦^À³
|
¥xÁÞ¤j, AD¼Ð¹v·sÃÄ¥þ²y°Ó·~¤Æ±ÂÅv¡A¥þ³¡µo¥Í¦b1b°µ§¹«e¡þ«á¡A ¦p ¦PMOA ,¹vÂI§@¥Î¦bIL13ªº¨âÓ·sÃÄ (1)Lerikizumab SC(¥Ö¤Uª`®g)250mg/2¶g¤@°w(2019/10¤ë, ¤T´ÁÁ{§É¶}©l) (2)Tralokinumab SC(¥Ö¤Uª`®g) 300mg/2¶g¤@°w(2019¦~©³¤T´Á¹LÃö,P=0.002/<0.001 (3)Aslan004 SC(¥Ö¤Uª`®g)200mg/¹w´Á¥|¶g¤@°w(2019/5 ,1´Á¦w¥þ©Ê¹LÃö CSL±ÂÅv) (4)FB825 IV(ÀR¯ßª`®g)/12¶g¤@°w(1b /12¤H°µ§¹¡A2a 90¤HÁ{§É°µ§¹¹F¼Ð¥æ¥I ) ¿D¬wCSL Ãļt¬O20,000¤Hªº¤jÃļt¡A¥«È1320»õ¤¸¿D¹ô(910»õ¬ü¤¸/2.7¥ü¥x¹ô, ¬O¥xÆW¥Í§Þªº2.7¿) ¬°¦ó¨È·à±d¤p¤½¥q¯àñ¤UASLAN004 ? I«á¤jªÑªFݸ³¨Æ : Àq§JÃļt¤Î·s¥[©Y²H°¨¿üªº©ÛµP¥\¤£¥i¨S. ASLAN004 AD Ãĵý¤Q®³¤QáA¥Ø«e³Q¨ÖÁʲ{ª÷»ùȦܤ֦ôp10»õ¬ü¤¸°_¸õ¡A¥¼¨Ó2020¦~°µ§¹2bÁ{§É14»õ¬ü¤¸°_¸õ¡C ¯à§_¹F25e¬ü¤¸n¬Ý¯à§_¹F¤½¥q¹w´Á¥|¶g¤@°w¡A¥B200mg/¨C°w. Ó¤H»{¬°200mg/2¶g¤@°w¡A¥i¦p´Á¹F¦¨¡A¹w«á«ü¼Ð¦PDupilumab ¤T´ÁÁ{§Éªº¤ô·Ç¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/6 ¤W¤È 10:56:09²Ä 2844 ½g¦^À³
|
¥xÁÞ¤j¡A ³oÓ¤ñ¸û¡A¤w§i¶D§ÚÌ¡A³o¨âºØÃĪºÀø®Ä·¥¡C ®t¤£¦h¡I 4.ASLAN004 ,2019/5 ¥þ²y°Ó·~¤Æ±ÂÅv¦ÛCS𠃊 7.8»õ¬ü¤¸(ªº±ÂÅvª÷¡Ïùµ{ª÷)¡Ï5%~10% ¾P°â¤À¼í (CSL©M¨È·à±d¦@¦P¶}µo¡A¨¥©ú¥þ²y°Ó·~¤Æ±ÂÅv§Q¯q¦U¥b,©Ò¥H¨È·à±d¾Ö¦³¦PCSL¬Û¦P¼ç¦b§Q¯q), ¹vÂI : IL13¨ü¾¹ , 200mg/¹w´Á¥|¶g¤@°w 1bÁ{§É¡Aªì¨B3¦ì¤¤¤@«AD±wªÌ¡A¸g4¤@6¶gªvÀø(¥¼¨Ó¨ì8¶gÀø®ÄÁÙ·|¼W¥[)¡A¨C¶g¤@°w/200mg EASI ¥§¡°´T71%( ¤T¤H°´T85%/70%/59%, ¥§¡°´T71%) ir.aslanpharma.com/static-files/ab9d6aa1-435d-41fc-af67-5b03c4b36409 p.19 ASLAN004 ¼È®ÉÀu©ó Dupilumab 2a ,n=118¤H , 300mg/¨C¶g¤@°w(°_©l¶q600mg),ªº¥§¡EASI°´T ²Ä¥|¶gEASI ¥§¡°´T¬ù61% ²Ä¤¶gEASI ¥§¡°´T¬ù67% ²Ä¤»¶gEASI ¥§¡°´T¬ù70% ²Ä4-6¶g¥§¡°´T¬ù67% ¹Ï¤@¥Øµø journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.asp |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/6 ¤W¤È 10:33:09²Ä 2843 ½g¦^À³
|
¤Ñ©R¤j Dupilumab 2Ó¤T´ÁÁ{§É¤§ ¥Dn«ü¼Ð IGA 0/1 ¦¸nÀø®Ä«ü¼ÐEASI-75 2020¦~¤U¥b¦~ªº¼Æ¾Ú¤ñ2019¦~12¤ëªº¼Æ¾ÚÂI«n¡A¼Æ¾Ú¦³¦h¦n ¹Ú·Q¤~¯à¦³¦h¤j¡A¨B¨B¬°Àç¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/5 ¤U¤È 05:37:39²Ä 2842 ½g¦^À³
|
¥xÁÞ¤j , ¥Ø«e§e²{ªº¤TÃĹw«á«ü¼Ð¡A½T¹ê¬O¼Ð¹v¹v㸃¦b¨ü¾¹Àu©ó°tÅé¡C «ÂI¬O ¦PMOA¨ä¥L¤TÃÄ ¤G/¤T´Á¥Dn«ü¼Ð ¹êÅç²ÕVS ¹ï·Ó²ÕÀø®Ä¤ñ ³£»´©ö¶W¹L2¿,¹F3~4.5 ¿¡A p=<0.002~ 0.0001 ²Îp¤W§e©úÅã®t²§¡A¥[¦w¥þ©Ê¹LÃö¡A §@¥Î¦bIL13ªº°tÅé¨ä¥L2ÃÄ¥ç ¤Q®³¤Q穏¥i®³ Ãĵý¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ASLAN004 ¹B®ð¦n¡A¯à¦b°ª³t¦¨ªø, 210»õ¬ü¤¸ ADªº¥«³õ¦û¤@®u¤§¦a¡C ¥Dn«ü¼ÐÀø®Ä: Ó¤H¹w´úÀ³¸Ó ASLAN004»PDupilumab ¬Û·í. ¦w¥þ©ÊÀu ©óDupilumab . Àøµ{§C¦¨¥»ASLAN004 ¦³¾÷·|§CDupilumab 5¦¨¤Á¤JÉ]³õ¡C 200mg/4¶g¤@°w vs 300mg/2¶g¤@°w Ãĵý¤Q®³¤QÃ¥BÄvª§¤O¤Q¨¬¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/5 ¤U¤È 01:44:02²Ä 2841 ½g¦^À³
|
ASLAN004Âê©wIL-13¨üÅé£\1¦¸³æ¦ì (IL-13R£\1) ¤§¥þ¤H·½³æ®è§ÜÅé¡A¦¹ÃĨã³Æ¦¨¬°¦P¯Å³Ì¨ÎÀøªk¤§¼ç¤O¡C ¦~³ø45¶¦³ÃöASLAN¤è±¤½¥q»{¬°¨ä±M§Q«OÅ@¥i¥H¨¾¤î¨ä¥L¥Í§Þ¤½¥q¬ãµo¦PÃþ²£«~¡A ²³æ»¡Âê©wIL-13¨üÅé£\1¦¸³æ¦ì¥u¦³¤@®a §OµL¤À¸¹¡C ¤£ª¾¹D¬O§_Âê©w¨üÅé¤ñÂê©w°tÅé±j¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/5 ¤U¤È 12:08:39²Ä 2840 ½g¦^À³
|
ªø´Á§ë¸êªÌ ½Ð¬Û«H! ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥i¥H¨ú±oÃĵýªºÁ{§É¬ì¾Çµý¾Ú ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ªvÀø¤¤¤@««×AD(²§¦ì©Ê¥Ö½§ª¢), ¬Û¦PMOA¡]¾÷Âà) : ªýÂ_IL4»PIL13 ¤§¶¡°T¸¹¶Ç»¼ªº¥|ºØ¼Ð¹vÃĪ«ÃÄ¡A ¦]¹vÂI¤£¦P¡A¦Ó¦³¤£¦P¹w«á¡®Ä¡A°Æ§@¥Î¡A¥ÎÃĶq¡A¦PÃÄÀW²v Á{§É¹w«á«ü¼Ð»P¹ï·Ó²Õ¤ñÈ¡APÈ 1.Dupilumab , ¤W¥«¤T¦~¡A¸Ó¤½¥q¤w¾P°â43»õ¤¸¬ü¤¸¡ACEO¥h¦~©³«Å¥¬¡A¥¼¨Ó¾P°â°ªÂI110»õ¬ü¤¸¡CREGN ªÑ»ù¥«È¤jº¦8000»õ¥x¹ô¡Aªñ¥b¦~¡C ¹vÂI:IL4ªº¨ü¾¹¡A300mg/¨C¤G¶g¤@°w Dupilumab 3.8~4.5 / ¹ï·Ó²Õ 1 =3.8~4.5 /1 , P< 0.0001 ( 2Ó¤T´ÁÁ{§É¤§¥Dn«ü¼Ð IGA 0/1¤ÎEASI-90) IGA 0/1 Dupilumab 38%~36% VS. ¹ï·Ó²Õ10%~8% EASI-90 Duilumab 36%~30% VS.¹ï·Ó²Õ 8%~7% www.nejm.org/doi/full/10.1056/NEJMoa1610020?cookieSet=1 °Æ§@¥Î:µ²½¤ª¢ 2. 丅ralokinumab , 2019¦~¦~©³¡A¤T´ÁÁ{§É¹LÃö¡B¥«³õ¤ÀªR®v¹w´ú2027¦~¥i¾P°â16»õ¬ü¤¸¡A¸Ó¤½¥qLEO 2016 ±ÂÅv¦Û¤W´åªü´µ§Q±d¡]LSE¡GAZN¡^¼t°Ó11.5»õ¬ü¤¸¡C ¥t©ó2020¦~¥|¤ë ñ¤U¦X¤@FB825 5.3»õ¬ü¤¸ªº±ÂÅv¡C ¹vÂI : IL13 °tÅéADÃì¡A300mg/¨C¤G¶g¤@°w. Tralokinumab 2~2.9/¹ï·Ó²Õ 1= 2.2~2.9 , P=0.002~ <0.001¡]2Ó¤T´ÁÁ{§É«ü¼ÐIGA 0/1 ¡AEASI-75) IGA0/1 15.8%~22.2%/7.1%~10.9% =2.2~2 EASI-75 25%~33.2%/12.7%~11.4%=2~2.9 www.practiceupdate.com/content/aad-2020-tralokinumab-with-and-without-topical-corticosteroids-effective-in-moderate-to-severe-atopic-dermatitis/102983/45 3. Lebrikizumab ,2019¦~10¤ë¡A¶}©l¤T´ÁÁ{§É,¸Ó¤½¥qDermira 2020¦~³Q ¬ü°ê§¨ÓÃļt11»õ¬ü¤¸¨ÖÁÊ¡C ¹vÂI : IL13°tÅéBCÃì¡A250mg/¨C¶g¤G°w¡A 𠃊ebrikizumab 2.9/¹ï·Ó²Õ 1= 2.9~ 3.9, p< 0.001 (¤G´ÁÁ{§É«ü¼Ð IGA 0/1 ,EASI-90) IGA0/1 Lebrikizumab 44.6%/ ¹ï·Ó²Õ15.3%=2.9 EASI-90 Lebrikizumab 44.7%/ ¹ï·Ó²Õ11.4.%=3.9 www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab 4.ASLAN004 ,2019/5 ¥þ²y°Ó·~¤Æ±ÂÅv¦ÛCS𠃊 7.8»õ¬ü¤¸(ªº±ÂÅvª÷¡Ïùµ{ª÷)¡Ï5%~10% ¾P°â¤À¼í (CSL©M¨È·à±d¦@¦P¶}µo¡A¨¥©ú¥þ²y°Ó·~¤Æ±ÂÅv§Q¯q¦U¥b,©Ò¥H¨È·à±d¾Ö¦³¦PCSL¬Û¦P¼ç¦b§Q¯q), ¹vÂI : IL13¨ü¾¹ , 200mg/¹w´Á¥|¶g¤@°w 1bÁ{§É¡Aªì¨B3¦ì¤¤¤@«AD±wªÌ¡A¸g4¤@6¶gªvÀø(¥¼¨Ó¨ì8¶gÀø®ÄÁÙ·|¼W¥[)¡A¨C¶g¤@°w/200mg EASI ¥§¡°´T71%( ¤T¤H°´T85%/70%/59%, ¥§¡°´T71%) ir.aslanpharma.com/static-files/ab9d6aa1-435d-41fc-af67-5b03c4b36409 p.19 ASLAN004 ¼È®ÉÀu©ó Dupilumab 2a ,n=118¤H , 300mg/¨C¶g¤@°w(°_©l¶q600mg),ªº¥§¡EASI°´T ²Ä¥|¶gEASI ¥§¡°´T¬ù61% ²Ä¤¶gEASI ¥§¡°´T¬ù67% ²Ä¤»¶gEASI ¥§¡°´T¬ù70% ²Ä4-6¶g¥§¡°´T¬ù67% ¹Ï¤@¥Øµø journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤U¤È 03:16:09²Ä 2839 ½g¦^À³
|
¥xÆW¸ê¥»¥«³õªº¨î«×,¥[ªo! §Öתk¦¨¬ü°êªÑ¥«¨î«×! finance.yahoo.com/quote/TSLA/?p=TSLA ¦¨¥ß¦Ü¤µ16¦~,EPS 没¥¿¹L.ªÑ»ù¥Ø¼Ð»ù½Õ°ª¦Ü2,000¬ü¤¸¡C ----------------------------------- ¯S´µ©Ô(TESLA)¦¨¬°¥þ²y¥«È³Ì°ªªº¨T¨®»s³y°Ó¡C ¯S´µ©Ô2¤é¤½¥¬²Ä2©u¥æ¨®¶q¡AÀu©ó¥«³õ¹w´Á¡A¦½LªÑ»ùÄ~Äò§ï¼g·s°ª¡C¤ÀªR®v¼ÖÆ[¬Ý«Ý¯S´µ©Ôªº¥¼¨Ó¡A³Ì°ª¤@¤f®ð§â¥Ø¼Ð»ù½Õ°ª¦Ü2,000¬ü¤¸¡C ¯S´µ©Ôªí¥Ü¡A²Ä2©u¦@¥æ¨®90,650½ø¡A¤ñ«e¤@©u¼W¥[2.5%¡A¨Ã°ª©ó¥«³õ¹w¦ôªº74,130½ø¡A¨ä¤¤Model S©MModel X¥æ¨®Á`p¹F10,600½ø¡C²Ä2©u²£¶q¬°82,272½ø¡A¤ñ«e¤@©u´î¤Ö20%¡C ¥t¥~¡A¸ô³z¤Þz¯S´µ©Ôºô¯¸³ø¾É¡A¸Ó¤½¥q½Õ°¤¤°êModel S©MModelXªº°_°â»ù¡AModel S±q¤H¥Á¹ô764,900¤¸°¦Ü756,900¤¸¡AModel X±q780,900¤¸°¦Ü772,900¤¸¡A¦¹Á|À³¸Ó¦³§U©ó¯S´µ©Ô¦b¤¤°ê¤j³°ªº¾P°â¡C ¯S´µ©Ô1¤é¦¬½Lº¦3.69%¡A¦Ü¨CªÑ1,119.63¬ü¤¸¡A¾Ú´^³Õ¸ê°T¦ôºâ¡A¯S´µ©Ô¥«È¦]¦Ó¹F2,077»õ¬ü¤¸¡]¬ù·s¥x¹ô6¥ü¤¸¡^¡A°ª©óÂץШT¨®ªº2,042»õ¬ü¤¸¡A¦P®É¤]¶W¶V¹D㦨¤ÀªÑ¥i¤f¥i¼Ö¡B}¤h¥§¡B¤Î®J§J´Ë¬ü§·³o¨Çª¾¦W¤j¥ø·~¡C¥Ø«e¦b¼Ð´¶500¦¨¤ÀªÑ¤¤¡A¶È19®a¥ø·~¥«È°ª©ó¯S´µ©Ô¡C ¯S´µ©Ô2¤é¦½L¤@«×º¦¬ù9.7%¡A³ø¨CªÑ1,228¬ü¤¸¡A¦¬½LY¯àºû«ù¦b¥½L¤§¤W¡A±N¬O³sÄò²Ä¤T¤Ñ§ï¼g·s°ª¬ö¿ý¡CµØº¸µó¨é°ÓWedbush¤ÀªR®v¦ã¤Ò´µ§â¯S´µ©Ôªº¥Ø¼Ð»ù±q1,250¬ü¤¸½Õ°ª¬°2,000¬ü¤¸¡A¦¨¬°FactSet³X½Õ¤ÀªR®v¤¤³Ì¬Ý¦n¸Ó¤½¥qªº¤@¦ì¡C ¦ã¤Ò´µªí¥Ü¡G¡u§Ú̬۫H¡A¦bÁÚ¤J®L©u¤§»Ú¡AModel 3¦b¤¤°ê¤j³°ªº»Ý¨D±N¤ñ¹w´ÁÁÙn±j«l¡C¼Ú¬ü³°Äò¸Ñ«Ê¡B¹q¦À§Þ³Nªº¤@¨Ç¥i¯à¡y§ïÅܧ½¶Õ¡zªºµo®i¡A¤]³£¥i¯àÅý¯S´µ©ÔªÑ²¼¦³§ó¦h¤Wº¦ªÅ¶¡¡C¡v ¦ý®Ú¾ÚFactSetªº¸ê®Æ¡AYÆ[¹î¯S´µ©Ô©MÂץЪº¤½¥q»ùÈ¡]¥]§t¶Å°È¡^¡AÂץШì3¤ë©³¬°¤î¤½¥q»ùȬ°2,900»õ¬ü¤¸¡A¯S´µ©Ô¬°2,520»õ¬ü¤¸¡C ÂץЪº«~µP«Ø¥ß¦b¤j³W¼Ò¥Í²£³Ð·s±a¨Óªº©Ê»ù¤ñ©M¥i«H¿àµ{«×¡C ¾¨ºÞ¯S´µ©ÔªÑ»ù±q¤µ¦~¨Ó¤@¸ô¨göt¡A³¡¤ÀµØº¸µó¤ÀªR®v»{¬°¡A¯S´µ©ÔªÑ»ùÁö¬O¥þ¦~Àò§Qªº300¿¦³¾l¡A«o¥¼¨ü¨ì°ò¥»±¤ä¼µ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤U¤È 01:35:14²Ä 2838 ½g¦^À³
|
Tralokinumab 2bÁ{§É ¹w«á«ü¼Ð,¥»¤ñDupilumab 2b ®t ---------------------------------------------- Phase 2b-Dupilumab-300mg/q2w/12 weeks ,n=64 (Table) 1.EASI-50 81.3%(52/64=81.3%) 2.EASI-75 54.3%(35/64=54.3%) 3.EASI-90 29.7%(19/64=29.7%) 4.IGA 0/1 25%(16/64=25%) phase2 -placebo-300mg/q2w/12 weeks n=61 1.EASI-50 29.5%(18/61=29.5%) 2.EASI-75 13.1%(8/61=13.1%) 3.EASI-90 3.3%(2/61=3.3%) 4.IGA 0/1 0%(0/61=0%) p=0.001 journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults A pooled analysis of two phase 2 clinical trials ------------------------------ Tralokinumab 2bÁ{§É, 300mg/2¶g¤@°w¡A12¶g ¤G´ÁÁ{§Éµ²ªG www.ncbi.nlm.nih.gov/m/pubmed/29906525/ n=51:51,Á{§Éµ²ªG¡A (1)IGA 26.7%¹êÅç²Õ;vs 11.8%¹ï·Ó²Õ;¡Cp¦ô=0.046 (2)EASI¥§¡¤À¼Æ®t²§ ¹êÅç²Õ;-¹ï·Ó²Õ; 4.94 ,p =0.01 (EASI adjusted mean difference, -4.94; 95% CI, -8.76 to -1.13; P = .01), |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤U¤È 01:02:00²Ä 2837 ½g¦^À³
|
§@¥Î¦bIL13°tÅéB¡BC键¡Aªº¤G´ÁÁ{§É¼Æ¾Ú Lebrikizumab IGA,0/1©M¹ï·Ó¤ñ 约3:1 Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬) (¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%** (¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%* (¤T)¹ï·Ó²ÕPlacebo EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤U¤È 12:41:28²Ä 2836 ½g¦^À³
|
¥xÁÞ¤j¡A LEOªºtralokinumab ¤T´ÁÁ{§É«ü¼Ð IGA¡A0/1¡A©M¹ï·Ó组¤ñ¤j约2:1 ¦ÓDupilumab ¤T´Á¦P«ü¼Ð3.8/4:1, ¥i¨£¦p¤½¥q©Ò»¡¡A§@¥Î¦bIL13ªº°tÅéA¡BDÃ줣¦pIL4¨üÅé¡C Ãø©ÇLEO¡A«æ§ä¦X¤@FB825±ÂÅv¡A¨Ó¸É®t²§¡C Á`¤§tralokinumab¤£¬ODupilumabªº¹ï¤â¡C Significantly greater IGA 0/1 and EASI 75 response rates at week 16 were observed with tralokinumab with and without topical corticosteroids, when compared with placebo. In ECZTRA 1, 15.8% of patients taking tralokinumab had an IGA 0/1, compared with 7.1% on placebo (P = .002), and 25.0% had an EASI 75 versus 12.7% with placebo (P < .001). In ECZTRA 2, the IGA 0/1 proportion was 22.2% versus 10.9% (P < .001), and EASI 75 proportion was 33.2% versus 11.4% (P < .001). For ECZTRA 3, the respective proportions were 38.9% versus 26.2% (P = .015) for IGA 0/1 and 68.0% versus 36.7% (P < .001) for EASI 75. For the ECZTRA 1 and 2 trials, a sensitivity analysis of nonresponders demonstrated superior outcomes among those on active therapy even in this group. Specifically, the proportion with an IGA 0/1 was 19.1% with active therapy versus 8.1% with placebo (P < .001) in ECZTRA 1 and 24.0% versus 12.4% (P < .001) in ECZTRA 2. For EASI 75, the respective proportions were 33.4% versus 17.3% (P< .01) and 37.9% versus 16.4% (P < .01). Following the maintenance treatment period, the use of tralokinumab with and without topical corticosteroids successfully preserved IGA 0/1 and EASI 75. At 52 weeks, among responders who received tralokinumab every 2 weeks during maintenance, 51.3% had an IGA 0/1 and 59.6% had an EASI 75 in ECZTRA 1. For ECZTRA 2, the respective values were 59.3% and 55.8%. At week 32 in ECZTRA 3, 89.6% of responders receiving tralokinumab every 2 weeks during maintenance had an IGA 0/1 and 92.5% EASI 75. These response rates were only significantly greater than placebo in ECZTRA 2, however. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/3 ¤U¤È 12:23:27²Ä 2835 ½g¦^À³
|
¦~³ø48¶»¡©úªº«Ü²M·¡ ´XÓÄvª§Àu¶Õ ASLAN004 §ÚÌ»{¬° ASLAN004 ¨ã³Æ¦¨¬°¦P¯Å³Ì¨ÎÀøªk¤§¼ç¤O: • ¸gÃҹꪺ¾÷Âà¡AÀø®Ä¥i±æ¤ñ¨ã¿ï¾Ü©Êªº IL-13 ©M IL-4 §í¨î¾¯¨Î¡C¨ã¿ï¾Ü©Êªº IL-13 ©M IL-4 §í¨î ¾¯¡A¦p lebrikizumab »P tralokinumab¡A¹ï¹L±Ó©Êµoª¢ªºÀø®Ä¦³¡C§ÚÌ»{¬°¯à¦P®ÉªýÂ_ IL-4 »P IL13 °T¸¹¶Ç»¼ªºÃĪ«¨ã³ÆªºÀø®Ä¸û¨Î¡CDupilumab ¦P®ÉªýÂ_ IL-4 »P IL-13 °T¸¹¶Ç»¼¡A¸gÃÒ¹ê¹ï¤¤«× ¦Ü««×²§¦ì©Ê¥Ö½§ª¢¨ã¦³Àø®Ä¡CASLAN004 Âê©wªº§@¥Î¾÷Âà»P dupilumab ¬Û¦ü¡A¤]¦P®É³z¹L¤G«¬ ¨üÅéªýÂ_ IL-4 »P IL-13 ªº°T¸¹¶Ç»¼¡C • ¥t¥~¥ÎÃÄÀW²v¥i±æ¸û§C¡A²£¥ÍÀø®Ä®É¶¡¸û§Ö ¡]½Ð°Ñ¦Ò¦~³ø48¶¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/3 ¤U¤È 12:09:02²Ä 2834 ½g¦^À³
|
¤Ñ©R¤j °£¤FASLAN004¥~¥Ø«e¦³¨âÁû²§¦ì©Ê¥Ö½§ª¢ªºÃĪ«§@¥Î©óIL-13¦b¶i¦æÁ{§É¡A°²³]¼Æ¾Ú¦³®Äªí¥Ü³oÓªv¯f¾÷¨î¥i¦æ¡A³o¹ï¨È·à±d¨Ó»¡¬O¥Rº¡¼ç¤O¡A¥u¬OASLAN004©ÒÂê©wªº¬O¦³±M§Qªº¡A¦n¹³¨S¦³¥Í§Þ¤½¥q¬ãµoªºÃĪ«»PASLAN004Âê©w¤@¼Ëªº³¡¦ì¡C www.pharmiweb.com/press-release/2020-06-15/new-phase-3-data-from-leo-pharma-s-dermatology-portfolio |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/7/3 ¤W¤È 11:54:29²Ä 2833 ½g¦^À³
|
Tralokinumab ¼Æ¾Ú¥X¨Ó¤F www.practiceupdate.com/content/aad-2020-tralokinumab-with-and-without-topical-corticosteroids-effective-in-moderate-to-severe-atopic-dermatitis/102983/45 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤W¤È 08:45:15²Ä 2832 ½g¦^À³
|
«Øij¤½¥q ¥¼¨ÓY´M¨D¨ÖÁʪº¤j¼t¡A¤Å¥²¥[REGN, REGN ¤@¨ÖÁÊASLAN004¥i¦AºÙÅQ10¦~¡AµL«áÅU¤§Àu¡C ¨ÖÁʪ÷ÃB·|¤j´T¼W¥[¡C Y¶È±ÂÅvÀq§J¤jÃļt¤´¬°º¿ï¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤W¤È 08:07:25²Ä 2831 ½g¦^À³
|
§ó¥¿ ¥þ²y»sÃÄ«e50¤j¤¤¦³16®a¦b¬ü°ê¤W¥«¡A2020¦~7¤ë/2¤êªÑ²¼¦¬½L¥«È ¦Xp¬ù 18,810»õ¬ü¤¸¡C ¬O¥xÆW¬ù330»õ¬ü¤¸¥«Èªº57¿ ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦U¦ì¤j¤j¡A½Ð±aµÛ1.88¥ü¬ü¤¸(57¥ü¥x¹ô)ªº¤ß¨Ó¬Ý¬ü°ê·sÃÄ¥«³õ¡C(¬ù¬ü°ê«e16¤j) ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤W¤È 06:41:38²Ä 2830 ½g¦^À³
|
m.youtube.com/watch?v=iocO3Tn7wp4 Åé¯×ªÕ¤Ó°ª«ç»ò¿ì¡H¸Ó¦p¦ó°Åé¯×ªÕ¡H¯×ªÕ¨x¯uªº¥i¥H°fÂà¶Ü¡H§A¬O§_¹ï´î¯×¦³³\¦hªººÃ°Ý¡A¤£ª¾¸Ó¦p¦ó¶i¦æ¡Hª÷Åa¶E©Ò´î«Âå®v¡Ð¿½±¶°·¡A¦b5¦~¨Ó¤w¸gÀ°«È¤á´î±¼¤F5¸U¤½¤ç¥H¤WªºÅé«¡A¤µ¤Ñ¥L´N¨ÓÀ°¤j®a¸Ñµª¡AÃö©ó´î¯×ªº¦UºØºÃ°Ý¡I ·Q´î«ªº¤j¤j¡A½Ð°Ñ¦Ò ¥H¤Wªº«Øij |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 06:22:54²Ä 2829 ½g¦^À³
|
«D°sºë©Ê¯×ªÕ©Ê¨x¯f¡]NAFLD¡^¡ANASH(«D°sºë©Ê¯×ªÕ¨xª¢) 专®a点评 S«Ø°ª±Ð±Â¡G«D°sºë©Ê¯×ªÕ©Ê¨x¯f¡]NAFLD¡^ªº¯e¯f谱¥]¬A单纯©Ê¯×ªÕ¨x¡BNASH¤Î¨ä¬Û关¨x纤维¤Æ©M¨xµw¤Æ¡C单纯©Ê¯×ªÕ¨x³q±`仅»Ý§ï变¥Í¬¡¤è¦¡ªº«D药ª«ªv疗¡Aú£¤ÖÊ^«5%¦}¨¾ªv¦Ù¤Ö¯g´N¥i¥H¨Ï¯×ªÕ¨x°f转¡F¨x¬¡检证实ªºNASH¡A¤×¨ä¬O¦X¦}显µÛ¨x纤维¤Æ¡]F2,F3,F4,¡^©M进®i´Á¨x纤维¤Æ¡]F3¡AF4¡^¬Æ¦Ü¨xµw¤Æ¡]F4¡^ªº±wªÌ¥H¤Î临§ÉºÃ¦üNASH©M进®i´Á¨x纤维¤ÆªºNAFLD±wªÌ¡A尽ºÞú£¤Ö10%¥H¤WªºÊ^«¦Pý©¥i¥H显µÛ§ïµ½¯×ªÕ©Ê¨xª¢©M纤维¤Æ¦ñ¨x酶«ìÎ`¦Ü¥¿±`S围¡A¦ý¬OüL¤Æ§ï变¥Í¬¡¤è¦¡ªº临§É试验显¥Ü1¦~内¤£¨ì10%¯àû{ú£«10%¥B¨ä¦ZÊ^«还会¤Ï弹¡C为¦¹¡A°£«Dªv疗¦}¦sªº2«¬¿}§¿¯fªº药ª«¦P时¨ã¦³显µÛú£ªÎ¥\¯à¡A¦bNASH¯S别¬O¦X¦}显µÛ¨x纤维¤Æ时»Ýn应¥Î针对¨x脏损伤ªº药ª«ªv疗¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 06:17:52²Ä 2828 ½g¦^À³
|
«¢«¢ ¦¤W¦n! ³Qµo²{§Úªº¤pªL§Ó¬ÂÅo¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤W¤È 06:12:32²Ä 2827 ½g¦^À³
|
ROGER¥S¦, ¯×ªÕ¨xÃĤS¤jÁÈ¡A¯u¼F®`¡I ¡X¡X¡X¡X¡X¡X ¥þ²y»sÃÄ«e50¤j¤¤¦³16®a¦b¬ü°ê¤W¥«¡A2020¦~7¤ë/2¤êªÑ²¼¦¬½L¥«È ¦Xp¬ù 18,810»õ¬ü¤¸¡C¬O¥xÆW¬ù33»õ¬ü¤¸¥«Èªº570¿¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦U¦ì¤j¤j¡A½Ð±aµÛ1.88¥ü¬ü¤¸(570¥ü¥x¹ô)ªº¤ß¨Ó¬Ý¬ü°ê·sÃÄ¥«³õ¡C(¬ù¬ü°ê«e16¤j) ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- 2020¦~«×¥þ²y»sÃÄ¥ø·~50±j±Æ¦æº] ±Æ¦W ¤½¥q Á`³¡©Ò¦b¦a ³B¤èÃľP°âÃB/¬ãµo§ë¤J//¬ü°êªÑ²¼¥«È(»õ¬ü¤¸/e) (¼Æ¾Ú¥H2020¦~³B¤èÃľP°âÃBpºâ) 1.½÷·ç(Pfizer) ¬ü°ê 459.06»õ¬ü¤¸/78.41»õ¬ü¤¸¡þ¡þ1916e 2.¿ÕµØ(Novartis) ·ç¤h 415.54»õ¬ü¤¸/79.16»õ¬ü¤¸ 3.ù¤ó(Roche) ·ç¤h 395.52»õ¬ü¤¸/87.17»õ¬ü¤¸ 4.Àq§J(Merck & Co.¡AÀq¨FªF) ¬ü°ê 355.63»õ¬ü¤¸/97.60»õ¬ü¤¸¡þ¡þ1988e 5.ÁÉ¿Õµá(Sanofi) ªk°ê 341.74»õ¬ü¤¸/57.22»õ¬ü¤¸ 6.±j¥Í(Johnson & Johnson) ¬ü°ê 316.71»õ¬ü¤¸/69.67»õ¬ü¤¸¡þ¡þ3713e 7.¦N§Q¼w¬ì¾Ç(Gilead Science) ¬ü°ê 299.92»õ¬ü¤¸/39.25»õ¬ü¤¸¡þ¡þ957e 8.¸¯Äõ¯À¥v§J(GlaxoSmithKline) ^°ê 277.75»õ¬ü¤¸/46.97»õ¬ü¤¸ 9.¦ã§Bºû(AbbVie) ¬ü°ê 252.99»õ¬ü¤¸/41.50»õ¬ü¤¸¡þ¡þ1742e 10.¦w¶i(Amgen) ¬ü°ê 218.92»õ¬ü¤¸/37.55»õ¬ü¤¸¡þ¡þ1519e 11.ªü´µ§Q±d(AstraZeneca) ^°ê 209.67»õ¬ü¤¸/56.31»õ¬ü¤¸ 12.¦ãº¸«Ø(Allergan) ¬ü°ê 185.97»õ¬ü¤¸/28.45»õ¬ü¤¸//636e 13.±è¥Ë(Teva Pharmaceutical Industries) ¥H¦â¦C 184.62»õ¬ü¤¸/21.11»õ¬ü¤¸ 14.¦Ê®É¬ü¬I¶QÄ_(Bristol-Myers Squibb) ¬ü°ê 181.63»õ¬ü¤¸/44.05»õ¬ü¤¸//1338e 15.§¨Ó(Eli Lilly) ¬ü°ê 171.73»õ¬ü¤¸/49.28»õ¬ü¤¸//1568e 16.«ô¦Õ(Bayer) ¼w°ê 168.86»õ¬ü¤¸/30.83»õ¬ü¤¸ 17.¿Õ©M¿Õ¼w(Novo Nordisk) ¤¦³Á 166.10»õ¬ü¤¸/21.64»õ¬ü¤¸ 18.«kªL®æ®ï®æ¿«(Boehringer-Ingelheim) ¼w°ê 133.16»õ¬ü¤¸/31.75»õ¬ü¤¸ 19.ªZ¥Ð(Takeda) ¤é¥» 127.73»õ¬ü¤¸/29.24»õ¬ü¤¸ 20.·s°ò(Celgene) ¬ü°ê 111.14»õ¬ü¤¸/27.62»õ¬ü¤¸//(³QMyers Squibb Co¨ÖÁÊ,¦ô333e) 21.¦w´µ®õ¨Ó(Astellas Pharma) ¤é¥» 111.09»õ¬ü¤¸/19.85»õ¬ü¤¸ 22.®Lº¸(Shire) ·Rº¸Äõ 108/86»õ¬ü¤¸/12.87»õ¬ü¤¸ 23.ÁÚÄõ(Mylan) ¬ü°ê 108.39»õ¬ü¤¸/7.06»õ¬ü¤¸//82e 24.¦Ê°·(Biogen) ¬ü°ê 98.18»õ¬ü¤¸/19.73»õ¬ü¤¸//432e 25.²Ä¤@¤T¦@(Daiichi Sankyo) ¤é¥» 75.35»õ¬ü¤¸/18.56»õ¬ü¤¸ 26.CSL ¿D¤j§Q¨È 66.74»õ¬ü¤¸/6.28»õ¬ü¤¸ 27.Àq§J(Merck KGaA) ¼w°ê 66.33»õ¬ü¤¸/16.55»õ¬ü¤¸ 28.¤Z§Q¨ÈÃÄ«~°ê»Ú(Valeant Pharmaceuticals International) ¥[®³¤j 61.83»õ¬ü¤¸/4.21»õ¬ü¤¸ 29.¤jà(Otsuka Holdings) ¤é¥» 53.89»õ¬ü¤¸/14.70»õ¬ü¤¸ 30.¤Ó¶§»sÃÄ(Sun Pharma Industries) ¦L«× 48.04»õ¬ü¤¸/4.02»õ¬ü¤¸ 31.½Ã§÷ÃÄ·~(Eisai) ¤é¥» 43.01»õ¬ü¤¸/10.78»õ¬ü¤¸ 32.¬Iºû¶®(LES LABORATOIRES SERVIER) ªk°ê 41.67»õ¬ü¤¸/10.04»õ¬ü¤¸ 33.»·Ãðê»Ú(Endo International) ·Rº¸Äõ 40.10»õ¬ü¤¸/1.75»õ¬ü¤¸ 34.Àu®É¤ñ(UCB) ¤ñ§Q®É 40.05»õ¬ü¤¸/11.29»õ¬ü¤¸ 35.¶®°ö(Abbott Laboratories) ¬ü°ê 38.59»õ¬ü¤¸/1.37»õ¬ü¤¸//1639e 36.¶O´Ë¤×´µ(Fresenius) ¼w°ê 37.53»õ¬ü¤¸/4.03»õ¬ü¤¸ 37.¤¤¥~»sÃÄ(Chugai Pharmaceutical) ¤é¥» 36.99»õ¬ü¤¸/7.61»õ¬ü¤¸ 38.»\¥ß´_(Grifols) ¦è¯Z¤ú 35.72»õ¬ü¤¸/2.19»õ¬ü¤¸ 39.¦A¥Í¤¸(Regeneron) ¬ü°ê 33.38»õ¬ü¤¸/20.52»õ¬ü¤¸//637e 40.¦í¤Í»sÃÄ(Sumitomo Dainippon Pharma) ¤é¥» 31.97»õ¬ü¤¸/7.49»õ¬ü¤¸ 41.¨È¤O¥S»sÃÄ(Alexion Pharmaceuticals) ¬ü°ê 30.82»õ¬ü¤¸/7.47»õ¬ü¤¸//247e 42.°¨ªL§Jù(Mallinckrodt) ·Rº¸Äõ 29.18»õ¬ü¤¸/2.62»õ¬ü¤¸ 43.¬ü¯Ç¨½¥§(Menarini) ¸q¤j§Q 29.16»õ¬ü¤¸/¡X¡X 44.¥ÐÃä¤TµÙ»sÃÄ(Mitsubishi Tanabe Pharma) ¤é¥» 26.96»õ¬ü¤¸/6.14»õ¬ü¤¸ 45.¾|»«(Lupin) ¦L«× 24.90»õ¬ü¤¸/3.27»õ¬ü¤¸ 46.·R¥i®õ¶©(Actelion) ·ç¤h 24.48»õ¬ü¤¸/5.38»õ¬ü¤¸ 47.¦ã°·(Aspen Pharmacare) «n«D 24.03»õ¬ü¤¸/¡X¡X 48.¨ó©Mµo»ÃÄQÅï(Kyowa Hakko Kirin) ¤é¥» 22.28»õ¬ü¤¸/4.96»õ¬ü¤¸ 49.¤p³¥ÃÄ«~¤u·~(One Pharmaceutical) ¤é¥» 21.53»õ¬ü¤¸/5.19»õ¬ü¤¸ 50.½÷âÂåÃÄ(Ferring Pharmaceuticals) ¬ü°ê 21.34»õ¬ü¤¸/3.09»õ¬ü¤¸//¡]¦ô63e) 2020¦~«×¥þ²y»sÃÄ¥ø·~50±j±Æ¦æº] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 06:05:34²Ä 2826 ½g¦^À³
|
¨S¦³¥hªÑªF·|¡A¦ý¤ÏÂкݸԤѩR¥S6/30«¶K¤½§i¡A¤ß»â¯«·|! ............................................................................................. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/30 ¤U¤È 09:01:51²Ä 2813 ½g¦^À³ ¥xÆW/¬ü°ê¬Ò¦b6¤ë15¤é¤½§i [¤½§i] ¨È·à±d-KY:¥»¤½¥q¸³¨Æ·|»¡©ú¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤§¼ç¦b¥i¯à¤Î¬ÛÃö·ÀI¦]À³¨Æ¶µ ¤½¶}¸ê°TÆ[´ú¯¸ (2020-06-15 14:43:32) ²Ä53´Ú ............................................................................................. ·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2020/6/29 ¤U¤È 02:21:08²Ä 2811 ½g¦^À³ ½Ð°Ý¦³·à¤Í¯à¤À¨É©Î·§z¤µ¤ÑªÑªF·|¤º®e¶Ü¡H .................... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/3 ¤W¤È 03:52:13²Ä 2825 ½g¦^À³
|
finance.yahoo.com/quote/REGN/ REGN ¥«È640»õ¬ü¤¸¡A约2¥ü¥x¹ô¡A¬O¥xÆW¥Í§Þ¥«³õªÑ»ù¥« ¥«È1¥ü¥x¹ôªº2¿¡A¥Lªº¥@¬É±Æ¦W¡A¤~²Ä39¦W¡C ¦Ó¨È·àªºASLAN004 ¥¼¨Ó±N¾Ù°ÊREGNªºAD(约80»õ¬ü¤¸)¦Ü¤Ö¤@¥b¥«Ô·¡C ¥xÆWªk¥O¸ò¤£¤W¬ü°ê¡Aµw§â¨È狮±d6497 (Àq§J¶°¹Î/²H马¿ü-¦Xp12¥ü¥x¹ô¥«Èªº¤jªÑªFݸ³¨Æ)»°¦^¬ü°ê¥«³õASLN¥æ©ö¡C ¥xÆW¬F©²¥[ªo¡I¤p^Á`²Î¥[ªo¡I ªk¥O¤£§ï¡A¯u¥¿¦³¹ê¤Oªº·sÃĤ½¥q¡A¯d¤£¤U¨Ó¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤U¤È 05:34:03²Ä 2824 ½g¦^À³
|
www.marketwatch.com/investing/stock/asln/analystestimates ¦³¤TÓ¬ü°ê¤ÀªR®vµû¦ôASLN ADR³ø§i(³Ìªñ¤@Ó¤ë), ¦p¤W 2020¦~12¤ë, ¥§¡¥Ø¼Ð»ù 5.5¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤U¤È 04:49:50²Ä 2823 ½g¦^À³
|
¬ü国¤ÀªR®v给¨È·àªº¥Ø¼Ð»ù 5-8¬ü¤¸/¥«È2.2e¬ü¤¸~4e¬ü¤¸¡K¡K°µ§¹1b ADÁ{§É ¡K¡K¡K¡K¡K¡K¡K¡K Ó¤H¦ôp 2022¦~°µ§¹ 2b Á{§É¤@ (¤@)Y200mg/¥|¶g¤@°w¡AP<0.001¡A»ùÈ«D±`°ª¡C (¤G)Y¥u¦³200mg/2¶g¤@°w©Î400mg/¥|¶g¤@针¡AP<0.001 ³Q¨ÖÁÊ»ùÈ14e¬ü¤¸°_¸õ¡C ³Q¨ÖÁÊ»ùÈ14-25e¬ü¤¸¡AºÝ¬Ý2bÁ{§É结ªG¦p¦ó¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤U¤È 04:25:40²Ä 2822 ½g¦^À³
|
¬ü°ê¥Í§ÞªÑ²¼¥«³õ¤j¡A¾iªº°_¤@¸s¦~Á~2000-3000¸U¥x¹ô¡A ¥¿统¥Í§Þ¤À§é®v¡C ¥xÆW®£©Æ¡I ¥D¤O¤O¶q¤Ó¤j¡I¥@¬É¼F®`¡I 没¦³¥¿±`©uÀ禬¥Í§ÞªÑ¡A¤£©ö¤ä¼µ°ªªÑ»ù¡C¡C¤p¤ß¡I¤p¤ß¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤U¤È 02:41:08²Ä 2821 ½g¦^À³
|
¨È·àªºADR / ASLN ´N¦b¬ü°êNasdaq ªÑ¥«(¥þ¥@¬É³Ì¤jªº¥Í§ÞªÑ²¼¥«³õ.) ¥xªÑ6497 ¨È·à±d ´« ADR ASLN ,¥Ø«e·¸»ù¬ù12/4.85=247% ¥¼¨ÓµLº¦³l´T¨î. ------------------------------- »´äªkªv»P¦Û¥Ñ¨â¥¢ ¦ÑÁ¤OÆ~¡G¥xÆW©Ó±µ¤U¤@ÓÁ×·´ä¨¤¦â¡I 2020/07/02 08:42 ¡e§Y®É·s»D¡þºî¦X³ø¾É¡f»´äª©°ê¦wªk¤W¸ô¡A¬ü¡B^µ¥°ê¹ï»´ä´£«¤jª÷¿Ä¨îµô¡A¥¼¨Ó»´ä°ê»Úª÷¿Ä¤¤¤ß¦a¦ì±N¤£«O¡A¦Ó½Ö¯à±µÄò»´äª÷¿Ä¦a¦ì¡H°]«H¶Ç´C¸³¨ÆªøÁª÷ªe´N«ü¥X¡A¹L¥h¦Ê¾l¦~¡A»´äÁcºa¾aªº¬Oªkªv»P¦Û¥Ñ¡A¦p¤µ³o¨â¼Ë¤¸¯ÀÑ¥¢¡A¥xÆW±N§ó¦³Ävª§¤O¡A¥¿¬O¥´³y¥xÆW¦¨¬°¨È¬wÄw¸ê¤¤¤ßªº¦n®É¾÷¡A«Øijª÷ºÞ·|¥i¥H¿n·¥«ä¦Ò¥xÆW¦p¦ó©Ó±µ¤U¤@ÓÁ×·´ä¨¤¦â¡I Áª÷ªe¦bÁy®Ñ¤W¤ÀªR¡A»´äªÑ¥«¡u¦b´äª©°ê¦wªk½ÄÀ»¤Uªº»´äªÑ¥«¡A¥b¦~¤U¶^3762.66¡A¶^´T13.34%¡A¾¨ºÞ¦³ÄË°T¡A¬ü¹Î¤Îªü¨½¡Aºô©ö¡A¨ÊªF¦^´ä¼µ¦í¤j§½¡A¦ý»´ä¸êª÷¬y¥¢À£¤O¤£»´¡A»´ä«í¥Í«ü¼Æ¦b¥þ²yªºªí²{¤´ÄÝ¥½¬q¯Z¡C²`¦`¦³¬ì§ÞªÑ¼µ¤j§½¡Aªí²{Àu©ó¤W®ü¡C¥xªÑ«h¬O¤º¸ê³Ó¹L¥~¸ê¡A¬ü°ê«h¬O·s¸gÀÙ¥ø·~±¾«Ó¡C¡v Áª÷ªe«ü¥X¡A¡u¹L¥h¦Ê¾l¦~¡A»´äÁcºa¾aªº¬Oªkªv»P¦Û¥Ñ¡A¦p¤µ³o¨â¼Ë¤¸¯ÀÑ¥¢¡A¾¨ºÞ¤¤°ê¬F©²¤@©w¤O®¼»´ä¡A¦ý»´äªº¨ý¹D·|³vº¥§ïÅÜ¡C¥¼¨Ó±q»´ä¥X¨Óªº¸êª÷¡A¹³¬O©T©w¦¬¯qªº°]´IºÞ²z¡A·|¥H·s¥[©Y¬°«¤ß¡A·ÀI©Ê¸ê²£§ë¸ê¡A¥xÆW·|§ó¦³Ävª§¤O¡A¦n¦n¥´³y¥xÆW¦¨¬°¨È¬wÄw¸ê¤¤¤ß¡A¦¹®É¥¿¬O¦n®É¾÷¡C¡v ¥L«Øij¡A¥xÆWª÷ºÞ·|¥i¥H¦Ò¼{¥[±j°ê»ÚªO¡B¦Ò¼{¸òNasdaq¦X§@¡A©µ¦ù¦¨¬°¬ü°ê¬ì§ÞªÑ¡B¥Í§Þ²£·~ªº²Ä¤G¥«³õ¡A¹ï¥xÆW·|§ó¦³§U¤O¡C Áª÷ªe§ó»{¬°¡A¹L¥h¨p¶Ò°òª÷·~ªÌªº¥Dn®Ú¾Ú¦a¬O¦b»´ä¡A¦p¤µ¡A¥xÆW¥i¥H±j¤Æµo®i¨p¶Ò°òª÷¥¥x¡A¥H±µ´À³o¼Ëªº®Ú¾Ú¦a¡A¨Ã²`¤Æ³oÓ·~°È¡A¥H¥Ø«e¸êª÷¥R¨K¡A¥xÆWªºETF°Ê»³¶Ò¨ì¦Ê»õ¥H¤W¸êª÷¡A¥i¥H¦Ò¼{¶}©ñ§ó¦h¨p¶Ò°òª÷¦b¥xÆWµo®i¡F¬Æ¦Ü¦Ò¼{Åý¥xÆWÃÒ¥æ©Ò¤½¶}¤W¥«¡A¥H±j¤Æ¸ê¥»É]³õ®Ä²v¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤W¤È 08:31:27²Ä 2820 ½g¦^À³
|
ADÃĵý¤Q®³¤QáA¤S¦³§C¦¨¥»ªºÄvª§¤O¡C ¨ÖÁʵ¥¦P¨Ö¤@ºZ¾P·sÃÄ¡C ¤jÃļt´N¬O¾a¨ÖÁʨӧ§¤j¦Û¤vªº¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤W¤È 07:13:35²Ä 2819 ½g¦^À³
|
Àq§J¶°¹Î¬ãµo费¥Î¦Xp¡A2020¦~¦@114»õ¬ü¤¸¡C¥@¬É²Ä¤@¡C n¨Ó¶R°µ§¹¤G´ÁADÁ{§ÉªºASLAN004, 14-25»õ¬ü¤¸¡A¬O²³æ¥B¦Xºâ¤§¨Æ¡C ¡K¡K 4.Àq§J(Merck & Co.¡AÀq¨FªF) ¬ü°ê 355.63»õ¬ü¤¸/97.60»õ¬ü¤¸ 27.Àq§J(Merck KGaA) ¼w°ê 66.33»õ¬ü¤¸/16.55»õ¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤W¤È 05:42:55²Ä 2818 ½g¦^À³
|
4.Àq§J(Merck & Co.¡AÀq¨FªF) ¬ü°ê 355.63»õ¬ü¤¸/97.60»õ¬ü¤¸ 27.Àq§J(Merck KGaA) ¼w°ê 66.33»õ¬ü¤¸/16.55»õ¬ü¤¸ Àq§J¶°¹Î¡A«e2®a¤½¥q¡A ¾P°â¦Xp422»õ¬ü¤¸¡A¥@¬É²Ä¤G¡C Y¥¼¨Ó¥[ASLAN004¡A30-60»õ¬ü¤¸销°â¡A将ª§¥@¬É²Ä¤@¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/2 ¤W¤È 05:24:53²Ä 2817 ½g¦^À³
|
¨È·à¤jªÑªF¤Î¸³¨Æ¡AÀq§J¥þ²y±Æ¦W²Ä¥|¦W¡C ±ÂÅvASLAN004给¨È狮ªºCSL¡A±Æ¦W²Ä26¦W¡C Dupilumabªº¤½¥qREGN¡A±Æ¦W²Ä39¦W¡C ¡K¡K¡K¡K¡K¡K¡K¡K ¡K¡K¡K¡K¡K¡K¡K¡K 2020¦~«×¥þ²y»sÃÄ¥ø·~50±j±Æ¦æº] ±Æ¦W ¤½¥q Á`³¡©Ò¦b¦a ³B¤èÃľP°âÃB/¬ãµo§ë¤J (¼Æ¾Ú¥H2020¦~³B¤èÃľP°âÃBpºâ) 1.½÷·ç(Pfizer) ¬ü°ê 459.06»õ¬ü¤¸/78.41»õ¬ü¤¸ 2.¿ÕµØ(Novartis) ·ç¤h 415.54»õ¬ü¤¸/79.16»õ¬ü¤¸ 3.ù¤ó(Roche) ·ç¤h 395.52»õ¬ü¤¸/87.17»õ¬ü¤¸ 4.Àq§J(Merck & Co.¡AÀq¨FªF) ¬ü°ê 355.63»õ¬ü¤¸/97.60»õ¬ü¤¸ 5.ÁÉ¿Õµá(Sanofi) ªk°ê 341.74»õ¬ü¤¸/57.22»õ¬ü¤¸ 6.±j¥Í(Johnson & Johnson) ¬ü°ê 316.71»õ¬ü¤¸/69.67»õ¬ü¤¸ 7.¦N§Q¼w¬ì¾Ç(Gilead Science) ¬ü°ê 299.92»õ¬ü¤¸/39.25»õ¬ü¤¸ 8.¸¯Äõ¯À¥v§J(GlaxoSmithKline) ^°ê 277.75»õ¬ü¤¸/46.97»õ¬ü¤¸ 9.¦ã§Bºû(AbbVie) ¬ü°ê 252.99»õ¬ü¤¸/41.50»õ¬ü¤¸ 10.¦w¶i(Amgen) ¬ü°ê 218.92»õ¬ü¤¸/37.55»õ¬ü¤¸ 11.ªü´µ§Q±d(AstraZeneca) ^°ê 209.67»õ¬ü¤¸/56.31»õ¬ü¤¸ 12.¦ãº¸«Ø(Allergan) ¬ü°ê 185.97»õ¬ü¤¸/28.45»õ¬ü¤¸ 13.±è¥Ë(Teva Pharmaceutical Industries) ¥H¦â¦C 184.62»õ¬ü¤¸/21.11»õ¬ü¤¸ 14.¦Ê®É¬ü¬I¶QÄ_(Bristol-Myers Squibb) ¬ü°ê 181.63»õ¬ü¤¸/44.05»õ¬ü¤¸ 15.§¨Ó(Eli Lilly) ¬ü°ê 171.73»õ¬ü¤¸/49.28»õ¬ü¤¸ 16.«ô¦Õ(Bayer) ¼w°ê 168.86»õ¬ü¤¸/30.83»õ¬ü¤¸ 17.¿Õ©M¿Õ¼w(Novo Nordisk) ¤¦³Á 166.10»õ¬ü¤¸/21.64»õ¬ü¤¸ 18.«kªL®æ®ï®æ¿«(Boehringer-Ingelheim) ¼w°ê 133.16»õ¬ü¤¸/31.75»õ¬ü¤¸ 19.ªZ¥Ð(Takeda) ¤é¥» 127.73»õ¬ü¤¸/29.24»õ¬ü¤¸ 20.·s°ò(Celgene) ¬ü°ê 111.14»õ¬ü¤¸/27.62»õ¬ü¤¸ 21.¦w´µ®õ¨Ó(Astellas Pharma) ¤é¥» 111.09»õ¬ü¤¸/19.85»õ¬ü¤¸ 22.®Lº¸(Shire) ·Rº¸Äõ 108/86»õ¬ü¤¸/12.87»õ¬ü¤¸ 23.ÁÚÄõ(Mylan) ¬ü°ê 108.39»õ¬ü¤¸/7.06»õ¬ü¤¸ 24.¦Ê°·(Biogen) ¬ü°ê 98.18»õ¬ü¤¸/19.73»õ¬ü¤¸ 25.²Ä¤@¤T¦@(Daiichi Sankyo) ¤é¥» 75.35»õ¬ü¤¸/18.56»õ¬ü¤¸ 26.CSL ¿D¤j§Q¨È 66.74»õ¬ü¤¸/6.28»õ¬ü¤¸ 27.Àq§J(Merck KGaA) ¼w°ê 66.33»õ¬ü¤¸/16.55»õ¬ü¤¸ 28.¤Z§Q¨ÈÃÄ«~°ê»Ú(Valeant Pharmaceuticals International) ¥[®³¤j 61.83»õ¬ü¤¸/4.21»õ¬ü¤¸ 29.¤jà(Otsuka Holdings) ¤é¥» 53.89»õ¬ü¤¸/14.70»õ¬ü¤¸ 30.¤Ó¶§»sÃÄ(Sun Pharma Industries) ¦L«× 48.04»õ¬ü¤¸/4.02»õ¬ü¤¸ 31.½Ã§÷ÃÄ·~(Eisai) ¤é¥» 43.01»õ¬ü¤¸/10.78»õ¬ü¤¸ 32.¬Iºû¶®(LES LABORATOIRES SERVIER) ªk°ê 41.67»õ¬ü¤¸/10.04»õ¬ü¤¸ 33.»·Ãðê»Ú(Endo International) ·Rº¸Äõ 40.10»õ¬ü¤¸/1.75»õ¬ü¤¸ 34.Àu®É¤ñ(UCB) ¤ñ§Q®É 40.05»õ¬ü¤¸/11.29»õ¬ü¤¸ 35.¶®°ö(Abbott Laboratories) ¬ü°ê 38.59»õ¬ü¤¸/1.37»õ¬ü¤¸ 36.¶O´Ë¤×´µ(Fresenius) ¼w°ê 37.53»õ¬ü¤¸/4.03»õ¬ü¤¸ 37.¤¤¥~»sÃÄ(Chugai Pharmaceutical) ¤é¥» 36.99»õ¬ü¤¸/7.61»õ¬ü¤¸ 38.»\¥ß´_(Grifols) ¦è¯Z¤ú 35.72»õ¬ü¤¸/2.19»õ¬ü¤¸ 39.¦A¥Í¤¸(Regeneron) ¬ü°ê 33.38»õ¬ü¤¸/20.52»õ¬ü¤¸ 40.¦í¤Í»sÃÄ(Sumitomo Dainippon Pharma) ¤é¥» 31.97»õ¬ü¤¸/7.49»õ¬ü¤¸ 41.¨È¤O¥S»sÃÄ(Alexion Pharmaceuticals) ¬ü°ê 30.82»õ¬ü¤¸/7.47»õ¬ü¤¸ 42.°¨ªL§Jù(Mallinckrodt) ·Rº¸Äõ 29.18»õ¬ü¤¸/2.62»õ¬ü¤¸ 43.¬ü¯Ç¨½¥§(Menarini) ¸q¤j§Q 29.16»õ¬ü¤¸/¡X¡X 44.¥ÐÃä¤TµÙ»sÃÄ(Mitsubishi Tanabe Pharma) ¤é¥» 26.96»õ¬ü¤¸/6.14»õ¬ü¤¸ 45.¾|»«(Lupin) ¦L«× 24.90»õ¬ü¤¸/3.27»õ¬ü¤¸ 46.·R¥i®õ¶©(Actelion) ·ç¤h 24.48»õ¬ü¤¸/5.38»õ¬ü¤¸ 47.¦ã°·(Aspen Pharmacare) «n«D 24.03»õ¬ü¤¸/¡X¡X 48.¨ó©Mµo»ÃÄQÅï(Kyowa Hakko Kirin) ¤é¥» 22.28»õ¬ü¤¸/4.96»õ¬ü¤¸ 49.¤p³¥ÃÄ«~¤u·~(One Pharmaceutical) ¤é¥» 21.53»õ¬ü¤¸/5.19»õ¬ü¤¸ 50.½÷âÂåÃÄ(Ferring Pharmaceuticals) ¬ü°ê 21.34»õ¬ü¤¸/3.09»õ¬ü¤¸ 2020¦~«×¥þ²y»sÃÄ¥ø·~50±j±Æ¦æº] ¬ü°ê¡m»sÃĸg²z¤H¡n(Pharm Exec)Âø»x¤½¥¬2020¦~«×°ò©ó³B¤èÃľP°âªº2020¦~«×¥þ²y»sÃÄ¥ø·~50±j±Æ¦æº]¡C¥»¦¸±Æ¦W°ò©ó¦U¤jÃļt2020¦~ªº¾P°â¼Æ¾Ú¡A³B¤èÃľP°âÃB½÷·ç¨Ì±ƦW²Ä¤@¡A¬ü°êÀq§J(Àq¨FªF)¤½¥qªº¬ãµo¤ä¥X¦W¦C²Ä¤@¦ì¡C ¡m»sÃĸg²z¤H¡n¨C¦~ªºº]³æ¼Æ¾Ú¨Ó¦Û¥þ²yÂåÃÄ¥«³õ¬ã¨s¾÷ºcEvaluate¡A³oÓº]³æ±Mª`¥þ²y»sÃÄ¥ø·~ªº³B¤èÃľP°â¡A©Ò¥H¤@ª½³Q¥ø·~¦~«×Á`µ²¤ÎÂåÀø¾÷ºc©Ò«µø¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/7/1 ¤W¤È 07:15:53²Ä 2816 ½g¦^À³
|
¤T´ÁADÁ{§Éªº¥Dn«ü¼Ð¬° EASI -90 ¤Î IGA0/1 Dupilumab /¹ï·Ó²Õ(,2Ó¤T´ÁÁ{§É¤ñ) 1A/1C 36%/8%=450% 30%7%=428% 2B/2D 38%/10%=380% 36%/8%=450% ¥Ñ¤Wz¬Ý¨âÁ{§Éªº¨âÀø®Ä¬Û¤ñÈ380%~450%, ¤@¯ë¤T´ÁÁ{§É¨CÓÁ{§ÉN=400¤H ªºª¬ªp¤U¡AÀø®Ä ¤ñÈ ¡Ö 150% , PÈ¡Õ5% ,´N¥i¥H¹LÃö¡A ¥[¤W¦w¥þ©Ê¨S°ÝÃD¡AÃĵý´N¤Q®³¤QÃ. ASLAN004 MOA ªýÂ_IL4/IL13 °T¸¹¶Ç»¼ ©MDupilumab ¬Û¦P¡AÀø®ÄÀ³¬Û·í¡C ¥B¬Ò¥iÀu©ó¹ï·Ó²Õ¡]«D¼Ð¹vÃĪ«¡^Àø®Ä3.8~4.5¿¡CP¡Õ 0.0001 ¦Ó¦w¥þ©Ê¤è±¡AASLAN004 Àu©óDupilumab ,¨S¦³µ²½¤ª¢°ÝÃD¡C ¬GºÙASLAN004 ¤¤-««×ADªºÃĵý¤Q®³¤QáC ¡X¡X¡X¡X¡X¡X¡X¡X¡X ¡X-¦X¤@ ªºON101 »O/¤¤¤T´ÁÁ{§É ¥Dn«ü¼Ð 62.2%/34.7%=179% ,p=0.001 ¡X¡X¡X 1)¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: A.¥þ¤ÀªR¼Æ¾Ú¶°(FAS)¤§¼Æ¾ÚÅã¥Ü¡AON101²Õ62.2%¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡A¹ï·Ó²Õ (Aquacel)34.7% ¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡F¨â²Õ¶Ë¤f§¹¥þ¡¦X²v®t²§27.5%¡A¹F ¨ì²Îp¤WÅãµÛ®t²§(p=0.0001¡Õ0.03476 £\¬ÉÈ)¡C ¡i¥þ¤ÀªR¼Æ¾Ú¶°(FAS)¡G³QÀH¾÷¤À¬£¤§¨ü¸ÕªÌ¡A¤£½×¦³µL±µ¨ü¸ÕÅçÃĪ«¡A¬Ò·|³Q¯Ç ¤J¥Dnµû¦ô«ü¼Ðªº¤ÀªR¡j B.×¥¿«¬·N¹ÏªvÀø(mITT)¤ÀªR±Ú¸s¼Æ¾ÚÅã¥Ü¡AON101²Õ63.6%¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X ¡A¹ï·Ó²Õ(Aquacel)33.3% ¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡F¨â²Õ¶Ë¤f§¹¥þ¡¦X²v®t²§30.3% ¡A¹F¨ì²Îp¤WÅãµÛ®t²§(p<0.0001)¡C ¡i×¥¿«¬·N¹ÏªvÀø(mITT)±Ú¸s¡G³QÀH¾÷¤À¬£¤§¨ü¸ÕªÌ¡A¤£½×¦³µL±µ¨ü¸ÕÅçÃĪ«¡A ¨ä¥Ø¼Ð¶Ë¤f¬Ò²Å¦Xpµe®Ñ±ø¥óªÌ¡A©l±o¯Ç¤J¥Dnµû¦ô«ü¼Ðªº¤ÀªR¡j ¡X¡X¡X¡X ¡X¡X¡X¡X¡X¡X¡X- Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬) (¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30%¡X¡X¥Dn«ü¼Ð1A IGA0/1 38%/36%¡X¡X¥Dn«ü¼Ð2B (¤T)¹ï·Ó²ÕPlacebo EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7%¡X¡X¥Dn«ü¼Ð1¡XC IGA0/1 10%/8%¡X¡X¥Dn«ü¼Ð2¡XD www.nejm.org/doi/full/10.1056/NEJMoa1610020?cookieSet=1 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/30 ¤U¤È 10:20:15²Ä 2815 ½g¦^À³
|
¥xÁÞ¤j¡A ASLAN004 ADªºÃĵý10®³10áA¥¼¨Ó¤W¥«¦PMOAªº Dupilumab ¥«³õ»{¦P¥i¾P°â110»õ¬ü¤¸¡C ¦ÓÄvª§¤O¡AASLAN004 VS Dupilumab ,¥i¹w¨£Àu¶Õ¯S¦â¡AYÀq§JÃļt¨Óµo®i¤T´Á¡A¤Î¾P°â¡A¹ïDupilumab ¥«³õ¥Ê¤À¥i¯à¬Û·í¤j¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/30 ¤U¤È 09:52:38²Ä 2814 ½g¦^À³
|
¤Ñ©R¤j ¦~³ø48¶³Ì«n (´XÓÄvª§Àu¶Õ) (1) ASLAN004 §ÚÌ»{¬° ASLAN004 ¨ã³Æ¦¨¬°¦P¯Å³Ì¨ÎÀøªk¤§¼ç¤O: • ¸gÃҹꪺ¾÷Âà¡AÀø®Ä¥i±æ¤ñ¨ã¿ï¾Ü©Êªº IL-13 ©M IL-4 §í¨î¾¯¨Î¡C¨ã¿ï¾Ü©Êªº IL-13 ©M IL-4 §í¨î ¾¯¡A¦p lebrikizumab »P tralokinumab¡A¹ï¹L±Ó©Êµoª¢ªºÀø®Ä¦³¡C§ÚÌ»{¬°¯à¦P®ÉªýÂ_ IL-4 »P IL13 °T¸¹¶Ç»¼ªºÃĪ«¨ã³ÆªºÀø®Ä¸û¨Î¡CDupilumab ¦P®ÉªýÂ_ IL-4 »P IL-13 °T¸¹¶Ç»¼¡A¸gÃÒ¹ê¹ï¤¤«× ¦Ü««×²§¦ì©Ê¥Ö½§ª¢¨ã¦³Àø®Ä¡CASLAN004 Âê©wªº§@¥Î¾÷Âà»P dupilumab ¬Û¦ü¡A¤]¦P®É³z¹L¤G«¬ ¨üÅéªýÂ_ IL-4 »P IL-13 ªº°T¸¹¶Ç»¼¡C • ¥ÎÃÄÀW²v¥i±æ¸û§C¡C¤ñ°_ ASLAN004¡ADupilumab »Ýn°ª¥X³\¦hªºÃºA¿@«×¤~¯à¹F¨ì§¹¥þ§í¨î¡A ¦]¦¹ ASLAN004 ªº¥ÎÃÄÀW²v¥i±æ¸û§C¡CDupilumab ªº§ëÃĬ°¨â¶g¤@¦¸ 2mL ªº¥Ö¤Uª`®g¡A¦ý°ò©ó ASLAN004 ªº¯SÂI¡A§ÚÌ¥i±æ´£¨Ñ¯f±w¨C¤ë¤@¦¸ªºªvÀø¤è¦¡¡A¥ÎÃÄÀW²v¸û§Cªºµ¹ÃĤ覡¥i¤j´T´î ¤Ö¯f±wªºt¾á¡C • §ó§Ö°_Àø®Äªº¼ç¤O¡C¦bÁ{§É¸ÕÅ礤Åã¥Ü¥X¡A³z¹LÀR¯ß¥ÎÃĪº ASLAN004 ¦b¥ÎÃÄ«á¤@¤p®É¤º°_®Ä¨³ ³t¡A¨ä§¹¥þ¦û¾Ú¨üÅé¨Ã§í¨î IL-13 ©M IL-4 °T¸¹¶Ç»¼ªºÃöÁä©Ê¤U´å¥Íª«¼Ð»x(downstream biomarker) ¦]¤l STAT6¡A±K¤Á¦a¤Ï¬M¤F§Ú̱q¹ÃÉônµU¨¤WÀò±oªº¼Æ¾Ú¡C • ¦w¥þ©Ê¥i±æÀu©ó²{¦³ÃĪ«¡AASLAN004 Âê©wªýÂ_ IL-13R£\1 ¦¸³æ¦ì¡A¦Ó dupilumab Âê©wªº¬O IL4R£\¡C¦]¦¹¡Adupilumab »P ASLAN004 ¬Ò¥iªýÂ_¤G«¬¨üÅé¡A¦ý dupilumab ¤]·|ªýÂ_ 1 «¬¨üÅé¡A1 «¬ ¨üÅé§t IL-4R£\¡A¤£§t IL-13R£\1¡A¥i¨£©óªì©l T ²ÓM»P B ²ÓM¡C¦b¤wµoªíªº²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç µ²ªG¤¤¡A¨Ï¥Î dupilumab ªº¨ü¸ÕªÌ¦³ 5-28%¥X²{ÄY«¡B«ùÄò©Êªºµ²½¤ª¢¡A»Ýn¨Ï¥Î tacrolimus ©Î Ãþ©T¾Jµ¥¥~¥Î²´³¡ÃĪ«ªvÀø¡C¬Û¤ñ¤§¤U¡Alebrikizumab ¶È³z¹L¤G«¬¨üÅéÂê©w IL-13 °tÅé¡A²§¦ì©Ê ¥Ö½§ª¢¨ü¸Õ¯f±w¥X²{µ²½¤ª¢ªºµo¥Í²v»·§C©ó dupilumab¡AÅã¥Ü§í¨î¤@«¬¨üÅé¦Ó«D¤G«¬¨üÅé¬O¤Þµo µ²½¤ª¢ªºì¦]¤§¤@¡C • ª`®g³¡¤À¥X²{¸û¤Ö¤£¨}¤ÏÀ³¡C¨Ï¥Î dupilumab ªº±wªÌ¬ù¦³ 10%¥X²{ª`®g³¡¦ì¤£¨}¤ÏÀ³¡A¨Ò¦p¥Ö ½§µo¬õ¤Î¯kµh¡C¬Û¸û¤§¤U¡AºI¦Ü¥Ø«e¬°¤î¥u¦³¤T¦ì±wªÌ¥X²{»´·Lª`®g³¡¦ì¤£¨}¤ÏÀ³¡A¦ý¸Ó¤ÏÀ³ «Ü¨³³t¦a®ø¥¢¡A¥B¦b«½Æ¥ÎÃÄ«á¤]¥¼´_µo¡C • ¼W¥[ÃĪ«Ã©w©Êªº¼ç¤O¡CDupilumab ¦b·Å«× 2¢XC ©Î 77¢XF ¤U³Ì¦h¥i¥H«O¦s 14 ¤Ñ¡A¥BµLªk¦b°ª©ó¦¹ ·Å«×ªºÀô¹Ò¤U«O¦s¡A¥Ñ©ó¸ÓÃĪ«¥i¥H¦Û¦æ¥ÎÃÄ¡A¦]¦¹¦b®È¦æ®É¥i¯à»Ýn¯S®í«O¦s¤è¦¡¤Î³B²z¡C ¬Û¤ñ¤§¤U¡AASLAN004 ¨ã¦³§ó¤jªº«O¦sÆF¬¡©Ê¡A¦b¦¹·Å«×¤U¨ã¦³¶W¹L 9 Ӥ몺éw©Ê¡C www.eduhk.hk/has/phys/units/convert/temp.htm µØ¤ó77«× = Äá¤ó25«× ¡@ Dupilumab¡G¡@À³¸m©ñ¦b즳¯È²°¨ÃÀx¦s©ó¦B½c2¢XC- 8¢XC ¥HÁקK¥ú·Ó¡C ¥²n®É¡A¹w¶ñª`®g¾¹¥i¸m©ó«Ç·Å¤U¤£¶W¹L25¢XC³Ì¦h¹F14¤Ñ¡C¤£¥iÀx¦s°ª©ó25¢XC¡C±q¦B½c¨ú¥X«á¡ADUPIXENT¥²¶·¦b14¤Ñ¤º¨Ï¥Î¡A§_«hÀ³¤©¥H¥á±ó file:///C:/Users/User/Downloads/tbDrug001%20(1).pdf ¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C to develop a comprehensive conversion plan, by which the Company would facilitate the ability of itsshareholders, at their option, to convert its ordinary shares into ADSs listed on Nasdaq over a 6-12 month time frame. ±q^¤åª©¨Ó¬Ý time frame ¬O«ü¤@©w®É¶¡¤º¿ì²zÂà, °²³]¤½§i¶}©lÂà´«®É¶¡, ¦³ªÑªF¤â¸}§Ö¥i¯à«Ü§Ö´N§¹¦¨Âà´«¤âÄò ¦ý¬O³ÌºC¤£¯à¶W¹L12Ó¤ë (¥H¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¬°·Ç) ³o´N¦n¹³¬F©²µoªºX¿ú³¤@¼Ë¦~©³«e¦³®Ä Âà´«¬°¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U¾ÌÃҮɶ¡ªº§ÖºC»PªÑªFÓ¤Hªº°Ê§@§ÖºC¦³Ãö ¥H¤W¬OÓ¤H¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/30 ¤U¤È 09:01:51²Ä 2813 ½g¦^À³
|
¥xÆW/¬ü°ê¬Ò¦b6¤ë15¤é¤½§i [¤½§i] ¨È·à±d-KY:¥»¤½¥q¸³¨Æ·|»¡©ú¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤§¼ç¦b¥i¯à¤Î¬ÛÃö·ÀI¦]À³¨Æ¶µ ¤½¶}¸ê°TÆ[´ú¯¸ (2020-06-15 14:43:32) ²Ä53´Ú 1.¨Æ¹êµo¥Í¤é:109/06/15 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q¸³¨Æ·|©ó109¦~6¤ë15¤é¥l¶}·|ij°Q½×¨Ã«Å¥¬¥i¯à©ó°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi ¶R½æ¤¤¤ß²×¤î¦³»ùÃÒ¨é¶R½æ¤§¼ç¦b¼vÅT¡A¨Ã¦P¨B©ó¬ü°êÃÒ¨é¥DºÞ¾÷Ãö«ü©wºô¯¸¤½§G¬Û Ãö·ÀI¨Æ¶µ¡C ¥»¤½¥q¸³¨Æ·|¤wª¾±x®Ú¾Ú°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ßÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³ »ùÃÒ¨é·~°È³W«h(¥H¤UºÙ¡§·~°È³W«h¡¨)²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú³W©w¡A¥»¤½¥q¨ÌÃÒ¨é¥æ ©öªk²Ä36±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼Æ¡A¤Î·~°È³W«h²Ä7´Ú³W©w ¡A¤½¥qÀç¹B¥þ±°±¹y¹O¤»Ó¤ë©Î³sÄò¤»Ó¤ë¤½§i¤§Àç·~¦¬¤J¬°¹s©Ît¼Æ¡A°]¹Îªk¤H¤¤ µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß±o¨Ì¬ÛÃö³W©w¤½§i²×¤î¥»¤½¥q¦³»ùÃÒ¨éÂdÂi¶R½æ¡A¨Ã³ø½Ð¥D ºÞ¾÷Ãö³Æ¬d¡C±©¤Wz¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤@¨Æ¨Ã¤£¼vÅT¥»¤½¥q¤§¬ü°ê¦s°U¾ÌÃÒ (American Depositary Shares, or ADS)«ùÄò©ó¬ü°ê¨º´µ¹F§J¥«³õ¤W¥«¤Î¥æ©ö¡C 6.¦]À³±¹¬I: ¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ¦p¥»¤½¥q¦³»ùÃÒ¨é²×¤î¶R½æ«á¡A±N¾ÉP¨ä¥L©Ò¦³¥xÆW±¾µPªk«ß¡]¥]¬A³W«h¡^³v¨B¤£ ¾A¥Î©ó¥»¤½¥q¡C¥»¤½¥q¸³¨Æ·|¤wª¾±x¦¹¶µ¾Aªk©ÊÅÜ°Ê¥B¦P·N¦¹¶µÅܰʱN¦³§Q©ó¥»¤½¥q ¥R¤À¾A¥Î¬ü°ê¦h¤¸Äw¸ê¤u¨ã¡B´£¤É¥»¤½¥q¶Ò¶°¸êª÷¯à¤O¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: «e¤©Ê³¯z ¥»«¤j°T®§¥]§t¦U¶µ«e¤©Ê³¯z¡C¤Wz³¯z¨Æ¶µ«Y¥»¤½¥q°ò©ó¥Ø«e²z©À¡B¹w´Á©Ò§@¥X ¤§Án©ú¡C¤Wz«e¤©Ê³¯z¥]¬A¦ý¤£©ó¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¡F¥»¤½¥q¨îq¨Ã ¹ê¬I¥þ±Âà´«pµe¤§¯à¤O¡F²×¤îÂdÂi¶R½æ«á¤§¼ç¦b§U¯q©ÎÄw¸ê¯à¤O¡F¤Î¥»¤½¥q·~°Èµ¦ ²¤¡C ¥»¤½¥q¤§«e¤©Ê³¯z«Y°ò©óºÞ²z¶¥¼h¥Ø«e¹ï¥¼¨Ó¨Æ¥ó©MÁͶժº·í«e°²³]©M¹w´Á¡A³o¨Ç ¥i¯à¼vÅT¤½¥q·~°È¡Bµ¦²¤¡B¹BÀç©Î°]°ÈÁZ®Ä¡A¨Ã¥B¥ý¤Ñ©Ê¯A¤Î«¤j¤wª¾©M¥¼ª¾ªº·ÀI »P¤£½T©w©Ê¡C°ò©ó³o¨Ç·ÀI©M¤£½T©w©Ê¥i¯à¾ÉP¹ê»Úµ²ªG©Î¨Æ¥ó»P¹w´Á«¤j¤£¦P¡C ³o¨Ç¤£½T©w©Ê¥]§t¦ý¤£©ó¥»¤½¥q©ó¬ü°êÃÒ¨é¥æ©ö©eû·| (U.S. Securities and Exchange Commission)¥Ó³ø¤§¤å¥ó (Commission File No. 001-38475)¡B¥]§t¥»¤½¥q©ó2020¦~4¤ë16¤é´£¥æ¤§20-Fªí®æ¡C °£¾ú¥v©Ê¨Æ¹ê³¯z¥~¡A¨ä¥L©Ò¦³³¯z§¡¬°«e¤©Ê³¯z¡A¬ÛÃö¥Î»y½Ñ¦p¡¨¬Û«H¡¨¡A ¡¨¥i¥H¡¨¡A¡§¥i¯à¡¨¡A¡§±N¡¨¡A¡§¥Ø¼Ð¡¨¡A¡§¦ôp¡¨¡A¡§«ùÄò/Ä~Äò¡¨¡A¡§¹w´Á¡¨¡A ¡§¥´ºâ¡¨¡A¡§´Á±æ¡¨¡A¡§p¹º¡¨µ¥¡A¤Î¨ä¥LÃþ¦ü·N¸qªº§_©wµü»y¨ÓÃѧO³o¨Ç«e¤©ÊÁn ©ú¡C ¥»¤½¥q¹ï¤Wz¦ôp¡B¹w´ú¡B¤Î©Ò¦³«e¤©ÊÁn©úªþ¦³§K³d«OÅ@¡A¤£©Ó¾á§ó·s©Î¼f¾\¥ô¦ó «e¤©Ê³¯z¤§¸q°È¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/30 ¤U¤È 08:55:18²Ä 2812 ½g¦^À³
|
¤½¥q¤»¤ë15¤é¤½§i¡A·í¤é¦P¨B¦b¬ü°êµýºÞ·|¤½§i ir.aslanpharma.com/financial-information/sec-filings Board of Directors¡¦ Meeting to consider next steps after advice from Taipei Exchange (¡§TPEx¡¨) on possible delisting of ASLAN Pharmaceuticals Limited from TPEx As previously reported on Form 6-K dated June 9, 2020, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) disclosed that as a result of irregular trading of its ordinary shares, TPEx had requested the Company publish certain regulatory and financial information on TPEx¡¦s Market Observation Post System (¡§MOPS¡¨). Such MOPS notice identified that as a result of the Company¡¦s anticipated negative net worth and lack of operating revenue for the six months ending June 30, 2020, the Company anticipated that TPEx would delist the Company¡¦s ordinary shares from trading on TPEx (the ¡§TPEx Delisting¡¨). As previously reported, the Company also confirmed that in the event of the TPEx Delisting, the listing of the Company¡¦s ADSs on the Nasdaq Global Market (¡§Nasdaq¡¨) in the United States would be unaffected, and ADS would continue to trade on Nasdaq. On June 15, 2020, the Company announced that the Board of Directors of the Company (the ¡§Board¡¨) held a meeting to discuss the potential impact of a TPEx Delisting. Among other things, the Board confirmed that in order to help achieve and preserve value for its shareholders if a TPEx Delisting occurs, it was authorizing and directing the Company to develop a comprehensive conversion plan, by which the Company would facilitate the ability of its shareholders, at their option, to convert its ordinary shares into ADSs listed on Nasdaq over a 6-12 month time frame. The Company intends to update its shareholders as to details of such plan once formalized and approved by the Board. The Company also confirmed that a TPEx Delisting would have the effect that all Taiwan and TPEx laws, regulations and rules regarding its securities would cease to apply to the Company. It was noted by the Board that this change could potentially benefit the Company¡¦s ability to raise capital through the sale of its securities in ways that are currently prohibited or not feasible under TPEx rules and Taiwanese laws. Forward-looking statements This Form 6-K contains forward-looking |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2020/6/29 ¤U¤È 02:21:08²Ä 2811 ½g¦^À³
|
½Ð°Ý¦³·à¤Í¯à¤À¨É©Î·§z¤µ¤ÑªÑªF·|¤º®e¶Ü¡H |
|
|
·|û¡Gonly10135877 µoªí®É¶¡:2020/6/28 ¤U¤È 11:47:41²Ä 2810 ½g¦^À³
|
Âà´«ªº®É¶¡¦³ÂIªø,Y¦³¶¶§Ç,§Æ±æ´²¤áªÑªF̯ધ¨ú¨ì²Ä¤@§åÂà´«adr |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/28 ¤U¤È 10:46:31²Ä 2809 ½g¦^À³
|
¥un¯àÂà´«ADRÁÙ·T¨S»ù®t? ¥S§ÌÌ¡A©ú¤Ñ·Ç³Æ¦n°Ñ¥[ªÑªF·|¤F¶Ü? |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2020/6/28 ¤U¤È 06:09:06²Ä 2808 ½g¦^À³
|
±q°ªÂI ¤S¦^¸¨22% ¦^¨ì1.98 ¨Ó¥h¤@³õªÅ |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/6/26 ¤U¤È 01:23:39²Ä 2807 ½g¦^À³
|
§Ú¦³´¤ªù²¼ µ¥¬Ý³Ì²×³¹ ¥u¬O©µ±`Áɦ³ÂIªø ¤Sn²§¦a¥[ÁÉ ¬ü°ê¤H¶Ì¥J §Ú¤£»{¬° ¦pªG¤£¼vÅT¥Í¬¡ªº±ø¥ó¤U ¯dµÛ·íÓ¨£ÃÒ ÁÙ¬O»{¬°¨È·à±d¬O®a³z©ú¤Æ ¨î«×¤Æªº¦n¤½¥q §Ú¬O¨È·à±dªÑªF §Æ±æ¯à¬°¨È·à±d¦¨¥\³yºÖ¤HÃþ°µ¨£ÃÒ Ó¤HÆ[ÂI ¥[ªo¨È·à±d ¨¯W¤F¦U¦ì¨È·à±dªºªÑªF |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/26 ¤W¤È 08:57:08²Ä 2806 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/1/1 ¤W¤È 09:30:52²Ä 904 ½g¦^À³ GILDILD§Y±N±Á{leronlimab(PRO140)½ÄÀ»!? 565¦W±wªÌPRO140[³æÃÄ]ªvÀøªñ¤@¦~... CytoDyn In the Running as Trump¡¦s PrEP Replacement Plan Gilead Maintains Dominance - But for How Long? Samsung Biologics ready to provide them with up to $1.0 billion of inventory ¦³¶R¬üªÑªÌnÃöª`Cytodyn¤@¤U! .......................................................................................... ¦b¤¤¸ÎªÅª©±ÀÂ˦aCytodyn PR-140¤@¼Ë¸ò[¦X¤@]³Q»Ä¦an¦º! µ²ªG±q0.35¤¸¨ì¬Q¤é¦A³Ð·s°ª6.65¦¬6.15! ´Nºâ¶R¦b3/31¤é¤]¬O½¿ÁÈ! ·|û¡GROGER588910148151 µoªí®É¶¡:2020/3/31 ¤W¤È 05:26:58²Ä 915 ½g¦^À³ cytodyne¬Q¤é¦A³Ð·s°ª3.5¦¬½L2.61(+90.51%)¦³¤j¨Æ? ²´¥ú¿W¨ì¡A¨ä¾l´N¥u¯à¬Ý¦Ñ¤Ñ·Ý(¤j´I¥Ñ¤Ñ)»P®É¶¡ÅçÃÒ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/26 ¤W¤È 08:44:38²Ä 2805 ½g¦^À³
|
¯×ªÕ¨x¬O¥i°f¨S¿ù¡AÃöÁ䪼ÂI¦b¨ºùØn¦Û¤v¬}±xÅo! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/26 ¤W¤È 08:26:14²Ä 2804 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/30 ¤W¤È 08:35:06²Ä 1701 ½g¦^À³ ¤@Â಴«D³h§Y´I! 6¤Ñ±q0.35¨ì°ª7.07(20¿)news.futunn.com/post/4493229 ¨s³ºI«á¯u¹êì¦]¬O¬Æ??? ............................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/29 ¤U¤È 10:47:30²Ä 1688 ½g¦^À³ °¨¿Í,³Q½L¤¤°ª7.07À~¿ô!!!«¥12¤¸³o»ò§Ö´N¸Ñ®M¤F?ªÅ¥S±z¦aÁÙ¦b¶Ü? [·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/11/11 ¤U¤È 06:01:16²Ä 1510 ½g¦^À³ ¥´©µªøÁɪº·§©À¶Ü¡Hªù²¼¦¤wÁʶR´N¦A§¤¤@·|°fÂà³Ó¦A¨£¥þÂS¥´] ............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/28 ¤W¤È 09:43:04²Ä 1658 ½g¦^À³ °l·¥S¦pªG±z¶R¤J»ù¦b3.86¨º°÷µR§Q¤F!«¥Ã¨µ¥3¥H¤U¥[½X¤@¨Ç¦a.... ............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/25 ¤W¤È 09:07:36²Ä 1618 ½g¦^À³ °l¥S±z«õ§|,§O±À«¥¤U§|°Ú! «¥ì¨Ó¥u»{©w¥Í¦º¥æ±µ¦b004,¤£´¿·Q¨ì¦¹®É¦¹¨è´N¦h¶}¤F1±ø003¥Í¸ô. [·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/11 ¤U¤È 04:33:19²Ä 1500 ½g¦^À³ ¥¢±Ñ¨Ã¤£¥i©È¡A¤ßºA¨M©w¤F§ÚÌ·|¦p¦ó¦^À³!§ë¸êµJÂI»P§ë¤J»ù¦ì¤£¦P¡A©Ò¯à©Ó¨üÀ£¤O´N¤£¤@P¡C «¥10¶ôªì§ë¤J¡A¬OÀ£µ¥«½SÃĪ«ASLAN004½µP!©ó«¥¨Ó»¡¡A©ú¦~¤~¬O¨£¯u³¹Â_¥Í¦º®É¨è¡C] .............................................................................................. ¾ú¥vÁ`¬OÅå¤Hªº¬Û¦ü! ³o¦¸«¥µ¥ªº¬O[Áp¥Í¤U¥«]«ºt¾÷·|!!! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/26 ¤W¤È 05:15:47²Ä 2803 ½g¦^À³
|
Roger ¥S finance.yahoo.com/quote/ASLN/ ¦¬½L2.2¬ü¤¸¡A§é¦X¥xªÑ¨È·à¬°13.2¤¸¡C ½L¤¤2.5¬ü¤¸¡A¦^¨ì¥h¦~12¤ëªº¼W资»ù¡C ±z±b±¤W¤S¤jÁÈ¡C ¦b¯×ªÕ¨xÃĤW¡A ªk»¡·|资®Æ ¡A¥§¡ªº¨â项¨x«ü¼Æµ´¹ï°´T¶q¡A¦ü¥G¤ñ´î«8%ªº¤H©Ò±o§ïÅÜÁÙ¤Ö¡C ®Ú¾Ú¼Æ¾ÚÅã¥Ü¡A°ê¤H¦³¯×ªÕ¨x°ÝÃDªº¤ñ¨Ò°ª±o¡uÀ~À~¥s¡v¡A¾ÚÂå®vÁ{§ÉÆ[¹î¡A¥§¡¨C2Ó°µ¸¡³¡¶WµªiÀˬdªº¥Á²³¡A´N¦³1¤H³Qµo²{¦³»´·L¯×ªÕ¨x¡AµM¦Ó³o¥u¬O°w¹ï¦³°µÀˬdªº¤H¦Ó¤w¡C ¾a¡u´îªÎ¤@Ó¤ë¡v¡A¨x«ü¼Æ170¡÷40 ¡m¨C¤é°·±d¡nºî¦X¤F´CÅé³ø¾É¡Aµo²{¤@¶µ«¤jºÖµ¡I¥Ø«e¦b½Ã¥ÍºÖ§Q³¡¹ü¤ÆÂå°|¾á¥ôÂåÀË®vªº¸â¤¯¤h¡A75KGªº¼Ð·ÇÅé«¡A¦ý¡u¨x¥\¯à«ü¼Æ¡vªø¦~¤@ª½¦b170¥ª¥k(¼Ð·ÇȬO40)¡AªA¥Î«O¨xÃĪ«¤]µL¥Î¡C¦Ó«á¸g¨ä¥LÂå®v¹ªÀy¡A©êµÛ¡utry try¬Ý¡vªº¤ß¥h°Ñ¥[Âå°|¬°û¤u¶}¿ìªº¡u´îªÎ¯Z¡v¡C ¤@Ó¤ë«á¡A¨{¤l¤j®ø·¡AÁy¤]¡u«Ó¦y¤F¡v¡AÅé«ÅÜ69KG(´î6KG)¡A¯×ªÕ¨x¤]¡u¸°¡v¬°¥¿±`ªº40¡C ¹ï¦¹¡A¸â¤¯¤h»¡¡A´î«¯Z¦³¶¼¹¦Ñ®v«ü¾É°·±d¶¼¹¤è¦¡¡AÁ|¨Ò¡G¤@©P¦Ü¤Ö1¤Ñ½¹¡A¦Yªº¶¶§Ç¬O³J¥Õ½è¡÷½µæ¡÷¾ý¯»Ãþ¡A±q쥻ªº¡u¦Y¶º°tµæ¡vÅܦ¨¡u¦Yµæ°t¶º¡v¡A¦Y¥XÀç¾i°·±d¨ú¥N¦Y¹¡µ¥ì«h¡A¤èªk¤£½ÆÂø¥B¤£»Ýªá¤j¿ú¡A¡u¦Ó¥B¦³¦P¦ñ¤¬¬Û¹ªÀy¡A´îªÎ´N§ó¥[²³æ¤F¡C¡v ¨§÷¸ûDªÌ³q±`¦³¯×ªÕ¨x¡A¤]±`¦ñÀH¨x¥\¯à«ü¼Æ²§±` ¦Ó¹ü¤ÆÂå°|¨xÁx¸zG¬ì¥D¥ô³¯¸Ö¨åªí¥Ü¡A«Ü¦h¤H°·À˵o²{±w¦³¯×ªÕ¨x¦X¨Ö¨xª¢¡A¤ÏÀ³³£¬O¡u¨SÅܦ¨Àù¯g´N¦n¡v¡A¤£¦A«áÄò°lÂÜ¡CµM¡u¯×ªÕ¨xª¢±wªÌ¡v¤´¦³ºtÅܦ¨¡u¨xµw¤Æ¡v©Î¡u¨xÀù¡vªº¾÷·|¡A¥B¦³°ª¤ñ¨Ò¦X¨Ö¤T°ª¤Î¤ß¦åºÞ¯e¯f¡A·í¤ß¡I ³¯¸Ö¨åÂå®vªí¥Ü¡A¡u¨§÷¸ûDªÌ³q±`¦³¯×ªÕ¨x¡A¤]±`¦ñÀH¨x¥\¯à«ü¼Æ²§±`¡C¡v³o±Ú¸sªº¤HY¯à¦³®Ä´î«5%~7%¡A¹ï©ó¯×ªÕ¨x¦³¤@©wªº®ÄªG¡CYÄÝÄY«ªÎD¡A¥i¦bÂå®v«ü¾É¤U¨Ï¥Î¦Xªk¦w¥þªº´î«ÃĪ«¡A¹F¦¨¥Ø¼Ð¡A§ä¦^°·±d¡C °£¤F´î«¡A§A¤]¥²¶·... ¨Ì¾Ú¡mÄ«ªG¤é³ø¡n³ø¾É¡A°£´îªÎ¤§¥~¡A¸q¤jÂå°|G¸z¨xÁx¬ì¥DªvÂå®v¤ý¤åÛ«h¤]«Øij¡A¯×ªÕ¨x±wªÌÀ³ÁקK³Ü°s¡A´î¤Öªo¯×¡B¿}¤ÀÄá¨ú¡A¨C¤Ñ°µ¬y¦½¹B°Ê¦Ü¤Ö30¤ÀÄÁ¡A§¡¦³§U©ó®ø°£¯×ªÕ¨x¡C ¯×ªÕ¨x¥i³z¹L¶WµªiÀˬdµo²{¡A¦pÄݪÎD¡B°ª¦å¯×¡B50·³¥H¤W¡B¥þ¨Â«åªÌµ¥°ª¦MÀI¸s¡A³£À³±µ¨ü¸¡³¡¶WµªiÀˬd¡AYµo²{¦³¯×ªÕ¨x¡AÀ³¨C¥b¦~°lÂܤ@¦¸¡A¨Ã©â¦åÀËÅç¨x«ü¼Æ¡A½T©w¨xŦ¦³µLµoª¢¡C www.google.com.tw/amp/s/amp.healthylives.tw/article/48motDCtE62.html |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/25 ¤W¤È 07:33:31²Ä 2802 ½g¦^À³
|
¦X¤@FB825±ÂÅvª÷5.3»õ¬ü¤¸À³¸Ó«Ü§Ö¤S·|³Q¨ê·s!?(¥H«á¦³¾÷·|¦A¸É¤W) ¬Q¤é¬üªÑ¶^710.16(2.72%) ¥Í§Þ«ü¼Æ NASDAQ Biotechnology(NBI)-83.19713 (-1.91%) ¨È·à°f¶Õ¤Wº¦¦¬2.1200+0.1700 (+8.72%) /½L«á2.1700 +0.05 (2.36%) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/23 ¤U¤È 12:40:23²Ä 2801 ½g¦^À³
|
¦X¤@ ON101 ¥xÆW/¤j³° 210¦ì,ªá7¦~¤~§¹¦¨. ¥¼¨Ó¯à½æ¦h¤Ö¤H¡H À³¸Ó°Ý¤½¥q, ¼Ú¡B¬üÁ{§É¸ÕÅç¡An¦¬¦h¤Ö¤H¡A¦ôp¦h¤[? ³o¨Ç°Ý²M¦¡Aªø´Á§ë¸ê¤~¯à«O¥¦w¡C µu½u¤j¤j̫ܼF®`¡I¦Û¤v§PÂ_¡C |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2020/6/23 ¤U¤È 12:25:17²Ä 2800 ½g¦^À³
|
¦X¤@·sÃıÂÅv¡AÁÙ¦³¤U¤@ªimoney.udn.com/money/story/10161/4653619 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/23 ¤W¤È 10:56:35²Ä 2799 ½g¦^À³
|
2020¦~6¤ë23¤é¬P´Á¤G ·s¥[©Y¥¸¤d»õµo®i³Ð·s¶µ¥Ø®¶¸gÀÙ ¡i©ú³ø±M°T¡j´^³ÕªÀ³ø¹Dªí¥Ü¡A·s¥[©Y±N¦b·s«a¯f¬rªÍª¢¬Ì±¡«á¥¸¥¨¸êµo®i³Ð·s¶µ¥Ø¡A¨Ã¦³±æ¨ó§U·s¥[©Y¸gÀÙ±q¿½±ø¤¤¤Ï¼u¡C·s¥[©Y°ÆÁ`²zÝ°]¬F³¡ªø¤ý·çªN¡] Heng Swee Keat¡^¦b³ø¹D¤¤ºÙ¡A·s¥[©Y¬F©²±N¼·¥X¶W¹L200»õ©Y¤¸¡]¬ù1112»õ´ä¤¸¡^¥Î©ó¤ä«ù¡u°ª¼vÅT¤O»â°ì¡]high impact areas¡^¡vªº¬ãµo¡A·í¤¤¥]¬A°·±d¡B¥Íª«Âå¾Ç¡B®ðÔÂàÅÜ¥H¤Î¤H¤u´¼¯àµ¥¡A¸Óp¹º¥Ø«e³B©ó³Ì²×½T©wªº¶¥¬q¡C 1112»õ¤ä«ù¥Íª«Âå¾Ç¤H¤u´¼¯à ¤ý·çªN¤Sªí¥Ü¡A¦b·s«aªÍª¢¬Ì±¡ªº¼vÅT¤U¡A¥]¬A·s¥[©Y¥H¤ºªº©Ò¦³°ê®a³£¦³´£¨Ñ§Y®Éªº¨ó§U¥H§@½w½Ä¡A¦ý·s¥[©Y¬F©²¤ñ¨ä¥L°ê®a°µ±o§ó¦h¡A·|¬°©Ò¦³¤H´£¨Ñ¸õªO¡]springboard¡^¡AÅý¥L̯à°÷¦^´_¥H«eªº¤ô¥¡A¬Æ¦Ü¤Ï¼u±o§ó°ª¡C¤ý·çªNªí¥Ü¡A·s¥[©Y¬F©²ºÉ¤O¥O¥i¦æªº¥ø·~Ä~Äò¹B§@¡A¨Ã¯d¦í¤u¤H¥Hºû«ù¨ä¥Íp¡C¥L±j½Õ¡A³o¦¸¬O¬F©²º¦¸¦V¦Û¹µ¤u¤H´£¨Ñ²{ª÷¸ê§U¡A¦Ó¬F©²§OµL¿ï¾Ü¡A¦]¬°·s¥[©Y¬O¥@¬É¨ä¤¤¤@ӳ̨̿à¥X¤fªº¸gÀÙÅé¡AY¥X¤f¥ø·~˳¬¡A·s¥[©Y¥ç·|±Á{µ~¹Ò¡C¤ý·çªNªí¥Ü¡A·s¥[©Y²Ä¤@©uªº´N·~¤H¼Æ³Ð¤U¦³¥v¥H¨Ó³Ì¤jªº¤U¶^¡A¦]¦¹¬F©²³Ì¹G¤Áªº¥ô°È«K¬On³Ð³y¤j¶q´N·~¾÷·|¡A¦Ó¥LºÙ¬F©²©xû¤w¸g©Ó¿Õ³Ð³y10¸UÓ¤u§@¤Î°ö°V¾÷·|¡A¥H¨ó§U·~¬É¨Ã´î»´¬Ì±¡ªº¥´À»¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/23 ¤W¤È 10:52:50²Ä 2798 ½g¦^À³
|
¥xÆW¦A«×®½ÃØ·s¥[©Y110¸U¤ù¤f¸n¨¾¬Ì 2020-06-22 15:12¤¤¥¡ªÀ °OªÌ¶À¦Û±j·s¥[©Y22¤é±M¹q ¾n¬P¥Nªí±ç°ê·s¤µ¤Ñ¥Nªí¥xÆW®½ÃØ100¸U¤ùÂåÀø¯Å¤f¸n»P10¸U¤ùN95¤f¸nµ¹·s¥[©Y°ê®aºÖ§Q²z¨Æ·|¡A¤À°tµ¹¤½³]¾i¦Ñ°|¨ü·ÓÅUªÌ¤Îû¤u¨Ï¥Î¡C³o¤]¬O¥xÆW²Ä¤G«×´©ÃØ·s¥[©Y¤f¸n¡C ¾n·s¥[©Y¥x¥_¥Nªí³B¤µ¤Ñ¤W¤ÈÁ|¦æ®½ÃØ»ö¦¡¡A¥Ñ²z¨Æ·|Á`µô³¯ÄR¬À¡]Tan Li San¡^¥Nªí±µ¨ü¡C ³¯ÄR¬À¦b®½ÃØ»ö¦¡¤¤·PÁÂ¥xÆWºB´n®½ÃØ¡A¤]·PÁ¾n·s¥[©Y¥x¥_¥Nªí³B©~¶¡Ápô¡A³o§å¤f¸n±N¤À°tµ¹¤½³]¾i¦Ñ°|¨ü·ÓÅUªÌ»Pû¤u¨Ï¥Î¡C ±ç°ê·sPµüªí¥Ü¡A¥~¥æ³¡¤µ¦~4¤ë²ÎÄw³W¹º¹ï¦U°ê¤H¹D´©§U¨Ã®½ÃØ1000¸UÓ¤f¸n¡A¨ä¤¤¤]®½ÃØ·s¥[©Y10¸UÓÂåÀø¯Å¤f¸n¡A·í®É®½Ãؤf¸nªº¼Æ¶qÁöµM¤£¦h¡A¦ý¥Nªí¤¤µØ¥Á°ê¬F©²»P¤H¥Áªºµ½·N©M¤Í½Ë¡C ¥L«ü¥X¡A·s¥[©Y¦p¤µ¶i¤JªýÂ_±¹¬I¡]CircuitBreaker¡^¤À¶¥¬qÃP¸jªº²Ä2¶¥¬q¡A¨¾¬Ì¦¨®ÄÁö¦³¥Ø¦@¸@¡A¦ý¦Ò¶q¥x¬P¤§¶¡ªº°í¹ê¤Í½Ë¡A¨¾¬Ì¤§¸ôÀ³¬Û¤¬§ß«ù¡A¥~¥æ³¡¦]¦¹¨M©w¦A«×®½ÃØ100¸U¤ùÂåÀø¯Å¤f¸n¤Î10¸U¤ùN95¤f¸nµ¹·s¥[©Y¡C ±ç°ê·sPµü®É¤]·PÁ·s¥[©Y°ê®aºÖ§Q²z¨Æ·|¦w±Æ¡AÅý¥xÆW©Ò®½Ãتº¤f¸n¯à¥Î©ó¾i¦Ñ¾÷ºcû¤u¡B¥H¤Î³Ì»Ýn«OÅ@ªº»È¾v±Ú¸s¡A§Æ±æ¬Ì±¡¾¨§Ö¹L¥h¡A¤H¥Á¥Í¬¡¦^Âk¥¿±`¡AÂù¤è¥Á²³¦Û¥Ñ¤¬³X¡A«ì´_©¹¨ÓÀWÁc²±ªp¡C ¥L±j½Õ¡A¥x¬PÂù¤èÃö«Y·½»·¬yªø¡A¬F©²¤Î¥Á¶¡¥æ¬y±K¤Á¡AÂù¤è§¡¬Ã±¤³o¥÷¯S®í¤Í½Ë¡C¨â°ê¬F©²±N°ò©óªø¤[±¡½Ë¡A¦@¦P§V¤O²`¤ÆÃö«Y¼W¶i°ê¥ÁºÖ¬ç¡C ·s¥[©Y¤µ¦~4¤ë¶¡¬Ì±¡¦Yºò¡AÄY®æ°õ¦æ¨¾¤î¬Ì±¡ÂX´²ªºªýÂ_±¹¬I¡A¥xÆW¤]ºò«æ´©ÃØ10¸U¤ùÂåÀø¯Å¤f¸nµ¹·s¥[©Y¬õ¤Q¦r·|¡A¥æ¥Ñ·s¥[©Y¬õ¤Q¦r·|ªº²Ä¤@½uªA°È¤Hû¡B§Ó¤u¡B¦~ªøªÌ¥H¤Î²¾¤uµ¥®z¶Õ±Ú¸s¨Ï¥Î¡Aµo´§¨¾¬ÌµL°ê¬Éªº¤j·Rºë¯«¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/22 ¤U¤È 01:42:33²Ä 2797 ½g¦^À³
|
¿D¬w¸Ñ«Ê¤¤ë¹s°â¾P°âº¦´T³Ð38¦~·s°ª ²§¦ì©Ê¥Ö½§ª¢¦h¾¯¶q´¤É»P±Ú¸sÂX¼W¸ÕÅç ¿D¬w¦³¥[¶}¼ÆÓ¦¬®×Âå°|¡A½Ð¤½¥q¥[§Ö¸}¨B°t¦X·s¥[©YÁ{§É¸ÕÅç¦aÂI¡A¥[³t¦¬®×¡C www.google.com/amp/s/ec.ltn.com.tw/amp/article/breakingnews/3203222 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/22 ¤U¤È 12:54:59²Ä 2796 ½g¦^À³
|
¥xÁÞ¤j¡A ¼¯®Ú¤j³q¡A6¸U±i¡A¬O¨â¦¸µo¦æADRªº«H°U°ò¦¡C ¤½¥q¤w¤½§i¡A ªí¥Ü¨ä¥L13¸U±i¡A¥i´«ADR¡C ¸Ô²Ónµ¥Âà´«¿ìªk¤½§G¡C ADRÁÙ¦b¡A Y8¤ë¤UÂd¡A ¥¼Âà´«ADR«e¡A·Q¥æ©ö¡A «Øij´N¨ì¥²´Iºô¨Ó¥æ©ö¡C 19¸U±i¡A¨C¤@±iªÑªFÅv§Q¬Û¦P¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/22 ¤U¤È 12:44:51²Ä 2795 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¤w¸g¦³6¸U±iÂà´«¦¨¬üªÑADR ¥¼¨Ó¬O§_n¦AÂà´«13¸U±i¥xªÑ¡H ªÑªF¤j·|¸ê®Æ¬°¦ó¼¯®Ú¤j³q«ùªÑ¼W¥[¨ìªñ6¸UªÑ¡H ¤pªÑªF¥i¥H¦V¤½¥qª§¨úºÉ¦Âà´«ADR¥H¹üÅ㤽¥q·ÓÅUªø´Á¤ä«ù¤½¥qªº¤pªÑªF¡A³o¨Ç¤pªÑªF¸g±`³z¹L¥²´Iºô¤À¨É¸ê°T¡A¹ï¤½¥q´£¨Ñ«Ø¨¥,¤£Â÷¤£±ó§óÀ³¸Ó¬O¤½¥q·ÓÅUªºÀu¥ý¹ï¶H¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/22 ¤U¤È 12:26:45²Ä 2794 ½g¦^À³
|
¦Ñ·à¦b¥x¤WÂd,¤@¦A¸Ñª¼¤@¦A¥¢±Ñ,·Q¤UÂdÂà¾ÔADR,¹ï¥xÆWªÑªF¶È¯à´Á¬ßªº¬O¯u¯à¦p´ÁÂনADR,©Ò¥H«Øij¤j®a¤@©wn¥h°Ñ¥[6/29ªÑªF·|¥hª§¨ú¦Û¤vªºÅv¯q....¥[ªo.·à¤ÍÌ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/22 ¤W¤È 12:19:46²Ä 2793 ½g¦^À³
|
§ó¥¿¸É¥R ¬ü°êNBI¥ÍÂå«ü¼Æ¦A«×³Ð¤U¾ú¥v·s°ª¡A¥xªÑ¥ÍÂå«ü¼Æ¶q¤£Â_ÂX¼W¡AÂåÃĪѬ¡¼â¶Ã¸õ¡A³o¸êª÷¶°¤¤¦b¥ÍÂåªÑªºÁͶÕèè¼ö¨¤£¤[¡AÀHµÛ¦X¤@¤jº¦¶W¹L¤Q¤G¿«á¡A¥¼¨Ó¤@¤G¦~ÁÙ¬O¥ÍÂåªÑªº¤Ñ¤U¡A´x´¤ÁͶմx´¤°]´I¡A¥¼¨Ó¸Ó¥Ñ¯E¹©¡A¨È·à±d¡A¤ß®®¡A¥_·¥¬P¡A°ê¹©¡AÁÞ°ò¡A¤Ó´º¡A¤¤¸Îµ¥ÂåÃĬãµo¤½¥q¨Óªí²{¡A³o¨Ç¤½¥q¤]¬ãµo¤@¬q®É¶¡¤F¡A¤]¸Óªí²{ªí²{¡A´£¥X¦nªº¼Æ¾ÚÅý¤H¦Õ¥Ø¤@·s¡Aªí²{¤@¤U¥xÆWªº¥Í§Þ¬ãµo¯à¶q¡A¨Ã²£¥Í¨}©Ê´`Àôªº¿R줧¶Õ¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/22 ¤W¤È 12:04:43²Ä 2792 ½g¦^À³
|
¬ü°êNBI¥ÍÂå«ü¼Æ¦A«×³Ð¤U¾ú¥v·s°ª¡A¥xªÑ¥ÍÂå«ü¼Æ¶q¤£Â_ÂX¼W¡AÂåÃĪѬ¡¼â¶Ã¸õ¡A³o¸êª÷¶°¤¤¦b¥ÍÂåªÑªºÁͶÕèè¼ö¨¤£¤[¡AÀHµÛ¦X¤@¤jº¦¶W¹L¤Q¤G¿«á¡A¥¼¨Ó¤@¤G¦~ÁÙ¬O¥ÍÂåªÑªº¤Ñ¤U¡A´x´¤ÁͶմx´¤°]´I¡A¥¼¨Ó¸Ó¥Ñ¯E¹©¡A¨È·à±d¡A¤ß®®¡A¥_·¥¬P¨Óªí²{¤@¤U ¤~¦³¿R줧¶Õ¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/21 ¤U¤È 10:04:59²Ä 2791 ½g¦^À³
|
·PÁ¤ѩR¤j¹d²ÓÃû¿òªº¸É¥R¾ã²z ¥h¦~¤»¤ë³o«h«°TÅã¥Ü¥ÎÃij̧C¾¯¶q¤ñ¨ä¥LÃĪ«§C¤@Ӽƶq¯Å¡A¤@Ӽƶq¯Å´N¬O®t¤Q¿ ³o¤]Åã¥Ü¥|¶g¥´¤@°wªº¥i¯à©Ê°ª¡A¦bÀø®Ä±µªñªº±¡ªp¤U¦³»ù®æÄvª§¤OªºÀu¶Õ www.google.com/amp/s/tw.stock.yahoo.com/amphtml/%25E5%2580%258B%25E8%2582%25A1-%25E4%25BA%259E%25E7%258D%2585%25E5%25BA%25B7-ky-6497-%25E5%25AE%25A3%25E5%25B8%2583%25E5%25AE%258C%25E6%2588%2590aslan004%25E7%2595%25B0%25E4%25BD%258D%25E6%2580%25A7%25E7%259A%25AE%25E8%2586%259A%25E7%2582%258E-233053270.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/21 ¤U¤È 08:12:54²Ä 2790 ½g¦^À³
|
1.¦PMOA ¥|ÃĪº³¡¤À¬OªýÂ_IL4»PIL13 ¤§¶¡ªº°T¸¹¶Ç»¼¡C ------------------------------ ³oÓMOA½T«O¦U¹w«á«ü¼ÐªºÀø®Ä¬Ûªñ,°ª¹ï·Ó²Õ2-4¿---- ----½T«O¥i¤Q®³¤QÃADÃĵý.----- 2.¥|ÃĹvÂI¤£¦P: ¦]¦¹¥H¤U¾¯¶q¡B¥ÎÃÄÀW²v¡B°Æ§@¥Î¡B¦w©w©Ê¦³®t²§, ASLAN004 ¬Ò¦P·¥³Ì¨Î.¦ôp§C©óDupilumab50%Àøµ{¦¨¥»¤§Ävª§¤O. A.¾¯¶q : ASLAN004 200mg Lebrikizumab 250mg Dupilumab/Tralokinumab 300mg B.¥ÎÃÄÀW²v:2¶g¤@¦¸/4¶g¤@¦¸ 2¶g¤@¦¸ :Lebrikizumab /Dupilumab/Tralokinumab 300mg 4¶g¤@¦¸: ASLAN004 ¹w´Á C.°Æ§@¥Î: Dupliumab 25~50% ·|¦³²´·úµ²½¤ª¢.ª`®g³¡¦ì¦³©úÅã¤ÏÀ³ ASLAN004 : µLµ²½¤ª¢,0%, ª`®g³¡¦ì¨´¤µ¨ÃµL©úÅã¤ÏÀ³ D.¦w©w©Ê Dupliumab 25«×c ¥H¤U ASLAN004:Äá¤ó25⁰C¥H¤U¥i¦s©ñ9Ó¤ë¥H¤W Àx¦s¤Î¹B°e±ø¥ó¼u©Ê¸û¤j 3. ¬ü°ê¤½/¨p¥ß«OÀI¤½¥q³W©w:°²³]Àø®Ä¦P¯Å,¨Ì«K©yªºÃÄ¥ý¥Î. ¦ôp¦³§C©óDupilumab50%Àøµ{¦¨¥»¤§Ävª§¤O. ----------------------------------- ¡X¡X¡X¡X¡X¡X¡X¡X ¦P¾÷Âà¹B(MOA)¥|ÃÄ ¼Ð¹v¤@½u ªvÀø¤¤-««×AD ---------------------- 1.Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-4R£\(IL4¨üÅé)§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 »P IL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡C 300mg/2QW(¨â¶g¤@°w),¹s°â»ù 3200¬ü¤¸/¤ë , 2017¦~Q3¶}©l¾P°â,¨ì2020¦~Q1,²Öp¥þ²y¾P°â43»õ¬ü¤¸¡C(180,000¤H¦~¥Î¹L ,¤¤¡Ð««×AD¥«³õº¯³z²v <1.8%) ¥¼¨Ó¾P°â°ªÂI110»õ¬ü¤¸/¦~¡A¤µ¦~REGNªºªÑ»ù¥«È¤jº¦6000»õ¥x¹ô(200»õ¬ü¤¸) 2.Tralokinumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 ªº A ¤Î D Á³±Û(IL13°tÅé)ªº§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 »P IL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡CªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 300mg/2QW(¨â¶g¤@°w),LEO (¦P¦X¤@FB825ªº±ÂÅv¤½¥q)ªº¤T´ÁÁ{§É ¤¤««×AD2019¦~12¤ë¤w¹LÃö. 3.Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 ¦b B¡BC Á³±Û(IL13 °tÅé)¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 250mg/2QW¡]¨â¶g¤@°w) 2019¦~10¤ë¶}©l800¤Hªº¤T´ÁÁ{§É www.tsim.org.tw/journal/jour29-6/02.PDF 4.ASLAN004 ¬O¤H·½§ÜÅé¡A ¾÷Âà(MOA) : ÂÇ¥Ñ »P IL-13 R£\1 (IL13¨üÅé) §Üìªí¦ìµ²¦X ¡AªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 200mg/400mg/600mg / ¨C4¶g¤@°w?? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/21 ¤U¤È 04:14:38²Ä 2789 ½g¦^À³
|
¥xÁÞ¤j¡A ¥|ÃĹvÂI¤£¦P¡A ¦ý¦PMOA ªº³¡¤À¬OªýÂ_IL4»PIL13 ¤§¶¡ªº°T¸¹¶Ç»¼¡C ¡X¡X¡X¡X¡X¡X¡X- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/5/20 ¤W¤È 08:53:44²Ä 39 ½g¦^À³ ¨È·àªºASLAN004 ¦P¯Å(¦P¾÷Âà:¦PMOA) ³ÌÀu(¥ÎÃĶq³Ì¤Ö /¥ÎÃÄÀW²v³Ì¤Ö) SLAN004 ¸g°·±d¤Hªº44¤HÁ{§É¸ÕÅç¡A1mg/L ´N¥i¹ïpSTART6§¹¥þ§í¨î ,¬O¦P¯Å(Dupilumab) 1/10. 2019/12¤½¥qªk説·|) ¨âªÌ®t70¿¡C ©Ò¥H»¡ASLAN004 200mg ªº§C¶q¨¬¥H§¹¥þ§í¨î(¨â¶g¤@°w), ASLAN004 ¾÷Âà(MOA)©M¤U¦C¤TºØÃĬۦP; ªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É. ASLAN004 ¬O¤H·½§ÜÅé¡A ¾÷Âà(MOA) : ÂÇ¥Ñ »P IL-13 R£\1 (IL13¨üÅé) §Üìªí¦ìµ²¦X ¡AªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 200mg/400mg/600mg / ¨C4¶g¤@°w?? ¡X¡X¡X¡X¡X¡X¡X¡X ¨ä¥L¤TÃľ÷Âà 1.Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-4R£\(IL4¨üÅé)§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 »P IL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡C 300mg/2QW(¨â¶g¤@°w),¹s°â»ù 3200¬ü¤¸/¤ë , 2017¦~Q3¶}©l¾P°â,¨ì2020¦~Q1,²Öp¥þ²y¾P°â43»õ¬ü¤¸¡C(180,000¤H¦~¥Î¹L ,¤¤¡Ð««×AD¥«³õº¯³z²v <1.8%) ¥¼¨Ó¾P°â°ªÂI110»õ¬ü¤¸/¦~¡A¤µ¦~REGNªºªÑ»ù¥«È¤jº¦6000»õ¥x¹ô(200»õ¬ü¤¸) 2.Tralokinumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 ªº A ¤Î D Á³±Û(IL13°tÅé)ªº§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 »P IL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡CªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 300mg/2QW(¨â¶g¤@°w),LEO (¦P¦X¤@FB825ªº±ÂÅv¤½¥q)ªº¤T´ÁÁ{§É ¤¤««×AD2019¦~12¤ë¤w¹LÃö. 3.Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 ¦b B¡BC Á³±Û(IL13 °tÅé)¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_ IL-4R£\ »P IL-13R£\1 °T®§¶Ç¾É 250mg/2QW¡]¨â¶g¤@°w) 2019¦~10¤ë¶}©l800¤Hªº¤T´ÁÁ{§É www.tsim.org.tw/journal/jour29-6/02.PDF |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/21 ¤U¤È 03:54:42²Ä 2788 ½g¦^À³
|
·PÁ¤ѩR¤jªñ¦~¨Ó´£¨Ñ¥«³õ±Á{§ÉÀø®Ä±ªºÂ×´I¸ê°T¡ALerikizumab»PASLAN004¦P¦PÄݳæ§ÜÃĪ«¡A¦³¬Û¦P¹vÂI»PªvÀø¾÷¨î¡A¨È·àn«÷ªº¬Oµ¥¦P©Î§ó¦nªºÀø®Ä¡A§ó¤Öªº¾¯¶q»P¦w¥þ©Ê¡AÁÙ¦³ÃĪ«Àx¦sªº¤è«K©Ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/21 ¤U¤È 12:00:32²Ä 2787 ½g¦^À³
|
¥xÁÞ¤j, ¦pªG¬Ý¨ìREGN ªºªÑ»ùªñ5¤ë¤jº¦8000»õ¥x¹ô,¥«³õ¥R¥÷¬Û«H ÁɿյẮu°õ¦æ©x«Où¡P«¢¼w´Ë¡]Paul Hudson¡^ªí¥Ü¡A¦~¾P°âÃB¥i¯à¶W¹L111»õ¬ü¤¸¡C ©Î³\Dermira ³Q¨ÖÁÊ»ù 15»õ¦Ü20»õ¬ü¤¸ªº»ù®æ±N¥i¦¨. ¦Ó¤£¬O6Ó¤ë«eªº11»õ¬ü¤¸. ¥u¯à»¡Â§¨Ó¤½¥q¨ÖÁÊDermira ¨Ö±oº}«G! --------------------------- §¨Ó°ªºÞªí¥Ü¡A³oµ§11»õ¬ü¤¸ªº¥þ²{ª÷¥æ©ö¬O¤½¥ªº¡A¦ý¬ODermiraªºªÑ»ùªí©ú§ë¸êªÌ´Á±æ§ó¦h ¤ÀªR®v¸ô©öµ·¡P³¯¡]Louise Chen¡^»¡¡G¡§§Ú»{¬°¥LÌ»{¬°³o¤@»ù®æ¤Ó§C¤F¡C¡¨( ¡§§Ú»{¬°¥LÌ¥¿¦b§V¤O«O¯d¤ñ²{¦b§ó¦hªºªF¦è¡C¡¨ Chen»¡¡A»P¦o¥æ½Íªº§ë¸êªÌ¥¿¦b¬°Dermira´M¨D15»õ¦Ü20»õ¬ü¤¸ªº»ù®æ¡C¦ý¬O§¨Ó¤½¥q°í«ù¤F³oÓ´£Ä³¡C ------------------------------------------------------------------------------------------ www.nasdaq.com/articles/eli-lilly-made-a-deal-for-dermira.-the-biotechs-stock-price-shows-investors-expect-more. -------------------------- §¨Ó°ªºÞªí¥Ü¡A³oµ§11»õ¬ü¤¸ªº¥þ²{ª÷¥æ©ö¬O¤½¥ªº¡A¦ý¬ODermiraªºªÑ»ùªí©ú§ë¸êªÌ´Á±æ§ó¦h¡C §¨Ó¤½¥qªº¤@¦ì°ªºÞ»¡¡A³oµ§11»õ¬ü¤¸ªº¥þ²{ª÷¥æ©ö¬O¤½¥ªº¡A¦ýªÑ»ùªí©ú§ë¸êªÌ´Á±æ§ó°ªªº¦ôÈ¡C ¦b»sÃÄ·~¥¨ÀY§¨Ó¤½¥q«Å¥¬¥H11»õ¬ü¤¸¥þ²{ª÷¦¬Áʤp«¬¥Íª«§Þ³N¤½¥qDermira¤§«áªº´XÓ¤p®É¡A§ë¸êªÌ¦ü¥G«ü±æ·|¦³§ó¦nªºµo®i¡C¦ý¬O§¨Ó¤½¥qªº¤@¦ì°ªºÞªí¥Ü¡A¥L̪º³ø»ù¬O¤½¥ªº¡C ¶g¤¤U¤È¡ADermira¡]ªÑ²¼¥N½X¡GDERM¡^³ø¦¬©ó19.16¬ü¤¸¡A¸û§¨Ó¤½¥q¦«eªí¥Ü¤w¦P·N¤ä¥I¸Ó¤½¥qªÑ²¼ªº¨CªÑ18.75¬ü¤¸°ª2.1¢H¡C §¢¦«¡Pµá¯ýªN©Ô¼w¡]Cantor Fitzgerald¡^¤ÀªR®v¸ô©öµ·¡P³¯¡]Louise Chen¡^»¡¡G¡§§Ú»{¬°¥LÌ»{¬°³o¤@»ù®æ¤Ó§C¤F¡C¡¨ ¡§§Ú»{¬°¥LÌ¥¿¦b§V¤O«O¯d¤ñ²{¦b§ó¦hªºªF¦è¡C¡¨ Chen»¡¡A»P¦o¥æ½Íªº§ë¸êªÌ¥¿¦b¬°Dermira´M¨D15»õ¦Ü20»õ¬ü¤¸ªº»ù®æ¡C¦ý¬O§¨Ó¤½¥q°í«ù¤F³oÓ´£Ä³¡C §¨Ó¤½¥q°ª¯Å°ÆÁ`µô©¬¯S¨½§J¡Pã´Ë¡]Lilly Bio-Medicines¡^Á`µô¦b©P¤¤U¤Èªº¤@¦¸±Ä³X¤¤»¡¡A»ù®æ¦X²z¡C ¥L»¡¡G¡§§Ú̹ïDermira¶i¦æ¤F«D±`¹ý©³ªºµû¦ô¡A§ÚÌ°í«H»ù®æ½T¹ê¥Nªí¤FDermiraªº¤½¥»ùÈ©M¥þ³¡»ùÈ¡C¡¨ ¡§¦pªG¬Ý¤@¤U60¤Ñ¦¨¥æ¶q¥[Åv¥§¡ªÑ»ù¡A§Ú̪º»ù®æ´X¥G·¸»ù90¢H¡C¡¨ ¹ïDermiraªº¿³½ì¬O¥Ñ¸Ó¤½¥qªº¦³»ù¸ê²£±À°Êªº¡A¸Ó¸ê²£¬O¤@ºØ¦³«e³~ªºÃĪ«¡AºÙ¬°lebrikizumab¡A¸ÓÃĪ«¥¿³B©ó°w¹ï¤@ºØÀã¯lªº¯SÀ³©Ê¥Öª¢ªº3´ÁÁ{§É¸ÕÅ礤¡C¸ÓÃĪ«¬OºÙ¬°¥Õ¤¶¯À§í»s¾¯ªº¤@Ãþ¼öªù³æ§J¶©§ÜÅéÃĪ«ªº¤@³¡¤À¡C¤@ºØÃþ¦üªºÃĪ«¡A¦A¥Í¤¸¡]REGN¡^©MÁÉ¿Õµá¡]SNY¡^Dupixent¡A¥¿´ÂµÛ¥¨«¬¬µ¼uªº¤è¦Vµo®i¡CÁɿյẮu°õ¦æ©x«Où¡P«¢¼w´Ë¡]Paul Hudson¡^ªí¥Ü¡A¦~¾P°âÃB¥i¯à¶W¹L111»õ¬ü¤¸¡C Chen»¡¡A¹ï©ó§Æ±æÁʶR¹³Dermira¡¦s³o¼ËªºÃĪ«ªº¤j«¬»sÃĤ½¥q¡A«á´ÁÁ{§É¶}µo¨S¦³¤Ó¦h¿ï¾Ü¡C¦Ó¥BDermiraªºlebrikizumab¦³¾÷·|¦¨¬°¦PÃþ¤¤³Ì¦nªº¡C ¡§±z¤w¸g¬Ý¨ì¥L̪ºÄvª§¹ï¤âµo¥¬¤F¼Æ¾Ú¡A¡¨ Chen»¡¡C ¡§¦³¨¬°÷ªºÃÒ¾Úªí©úDermiraªº²£«~¦b¦PÃþ²£«~¤¤¥i¯à¬O³Ì¦nªº¡A§Ú»{¬°³o¦b³o¸Ì¯uªº«Ü«n¡C¡¨ §¨Ó¤½¥q¡]Lilly¡^ªº¸â´Ë¡]Jonsson¡^»¡¡A¥Lªº¤½¥q»{¬°¯SÀ³©Ê¥Öª¢¦³¤j¶q¥¼º¡¨¬ªº»Ý¨D¡C¥L»¡¡G¡§¦pªG§Ú̧ä¨ì¤@ºØ¯à°÷¯u¥¿§ïµ½¤HÌæ±ÄoÅéÅ窺¸ê²£¡A§ÚÌ¥i¯à·|¹ïºÎ¯v»Ùê©M¥Í¬¡½è¶q²£¥Í«¤j¼vÅT¡C¡¨ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/21 ¤W¤È 11:11:15²Ä 2786 ½g¦^À³
|
www.nasdaq.com/articles/eli-lilly-made-a-deal-for-dermira.-the-biotechs-stock-price-shows-investors-expect-more. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/21 ¤W¤È 10:54:33²Ä 2785 ½g¦^À³
|
6/29-ªÑªF·|¬ÛÃö¸ê®Æ¥H¤U¡A§Æ±æ¤j®a³£¥h°Ñ¥[~ doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=6497&year=109&mtype=F& |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤U¤È 09:00:41²Ä 2784 ½g¦^À³
|
¦X¤@ªº FB825 ¥²¶·°µ§¹90¤HªºAD ,2a Á{§É¡A¤~¥æµ¹LEO°µ2b . ³o´N¬OASLAN004 ªºÀu¶Õ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤U¤È 08:54:32²Ä 2783 ½g¦^À³
|
¦P¤@ÓMOA Dupilumab 18¸U¤H¦~¡A¤wÅçÃÒ¡C Tralokinumab ¤d¤H¡A¤wÅçµý (2019/12 ¤T´ÁÁ{§É¹LÃö) Lerikizumab , 2b Á{§É¡A¤wÅçÃÒ¡A(2019/10¤ë, ¤T´ÁÁ{§É¶}©l), §¨ÓÃļt³sDermira ¤½¥q³£¨ÖÁʱ¼¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/20 ¤U¤È 08:15:42²Ä 2782 ½g¦^À³
|
¤Ñ©R¤j «ç»ò¦³¨º»ò¦n±dªº¨Æ¡A§O®a¥Í§Þ¤½¥qÀ°¦£°µ§¹¤F¡A·à¤l¬Ù¤U«Ü¦h®É¶¡»P¶O¥Î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤U¤È 07:29:39²Ä 2781 ½g¦^À³
|
¥xÁÞ¤j, MOA ¦PIL4/IL13 °T¸¹ªýÂ_ªº¨ä¥L¤TÃÄ,ªº¤T´ÁÁ{§É Lerikizumab 250mg/2¶g¤@°w(2019/10¤ë, ¤T´ÁÁ{§É¶}©l) Duilpumab 300mg/2¶g¤@°w(2017¦~3¤ë¤W¥«,,²Ä¤@Ӽйv¤W¥«) Tralokinumab 300mg/2¶g¤@°w(2019/12 ¤T´ÁÁ{§É¹LÃö) ª½±µ°µ2b 200mg/2¶g¤@°w¡A400mg/4¶g¤@°w ,³o¬O¥²¶·¥B°ò¥»ªºÄvª§Àu¶Õ¡C 200mg/4¶g¤@°w¡A¤~¯à©Ô¤j»P¨ä¥L¤TÃĪºÄvª§®t²§¤Æ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤U¤È 07:17:48²Ä 2780 ½g¦^À³
|
¥xÁÞ¤j¡A 2a Á{§É ,Dupilumab ¤wÀ°¦PMOA ªº¨ä¥L¤TÃÄ°µ§¹¤F¡C ³o¦³ÂI¹³±M§Q¨ì´Áªº¥é¥ÍÃÄ¡A¤H®a¤G´Á®Ú¥»¤£¥Î°µ¡C¤@´ÁÁ{§¹¡Aª½±µ°µ¤T´ÁÁ{§É¡C ¥H¤W¬OÓ¤HªºÆ[¹î¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/20 ¤U¤È 07:02:06²Ä 2779 ½g¦^À³
|
¤Ñ©R¤j ·Q¤£³q¬°¦ó¤@´Á¾¯¶q´¤É¤TºØ¾¯¶q24¤H»PÂX¼W±Ú¸s18¤H«á´Nª½±µ¶i¤J¤GB´ÁÁ{§É¡A¬°¦ó¨S¦³¤GA´ÁÁ{§É¸ÕÅç¡H ·|¤£·|18¤HªºÂX¼W±Ú¸s´N¬O¤GA´ÁÁ{§É¸ÕÅç¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤W¤È 10:28:41²Ä 2778 ½g¦^À³
|
ASLAN004 1b,¤T²ÕªºEASI°´T±N±µªñ¡A¦]¬°¿@«×200mg/¨C¶g¤@°w¤w¨¬°÷¡C 600mg>=400mg>=200mg -------- ®Ú¾Ú¤½¥q²³ø, ASLAN004 °·±d¤HÁ{§É/6¤H 600mg IV(ÀR¯ßª`®g) ,¥i§¹¥þ§í¨î,29¤Ñ. ------------------------------------- 600mg IV(ÀR¯ßª`®g)/87% =690mg BC(¥Ö¤Uª`®g) ASLAN004 1b 200mg/¨C¶g¤@°w*4¶g=800mg > 690mg ------ µ²½× ®Ú¾ÚÁ{§É¾¯¶qpºâ, ¦ôp 690mg BC(¥Ö¤Uª`®g) ,¥i§¹¥þ§í¨î29¤Ñ. ©Ò¥H®Ú¾Ú¤Wz200mg/¨C¶g¤@°w*4¶g=800mg ,¥i§¹¥þ¥i§í¨î. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤W¤È 09:04:28²Ä 2777 ½g¦^À³
|
¥xÁÞ¤j¡A ASLAN004¤¤««×ADÃĵý¡A¤Q®³¤QáC ¦³¦h¤jªº»ùÈ¡A¬Ý2bÁ{§Éµ²ªG¡C ¦ý2bÁ{§É¶}©l¡A´N¤j约¥i²q¥X. ¥i¯àªº³]p¡AÓ¤H²q´ú¡A¦p¤U 1.200mg,¨C¤G¶g¤@°wx16¶g 2.200mg,¨C¥|¶g¤@°wx16¶g 3.400mg,¨C¥|¶g¤@°wx16¶g ¥H¤W¬Ò¥iºÙ¡A¦P级³ÌÀu¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/20 ¤W¤È 07:20:02²Ä 2776 ½g¦^À³
|
¥xÁÞ¤j¡A ASLAN004 200mg /¨C¶g¤@°w, ¥¼¸Ñª¼«e3¤HªºEASI, ¥±`°´T71%(4~6¶g), ¤w¶W¶V Dupliumab 300mg/¨C¶g¤@°w¡A°_©l¶q2a Á{§Éªº EASI ¥§¡°´T¡]4-6¶g) n=118 ²Ä¥|¶gEASI ¥§¡°´T¬ù61% ²Ä¤¶gEASI ¥§¡°´T¬ù67% ²Ä¤»¶gEASI ¥§¡°´T¬ù70% ¹Ï¤@¥Øµø ¦Ó²Ä¤»¶gªºEASI ¥§¡°´T¬ù70% ¡A¤w±µªñ12¶gªºÀø®Ä¡CEASI ¥§¡°´T 73.6% ¹Ï¤@¡C journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx ©Ò¥HÓ¤H§PÂ_¡AASLAN004 200mg , 6¤Hªº 1bÁ{§ÉEASI¡AÀ³¸Ó¥i°Ñ¦ÒDupilumab 2a ,12¶gªº¹w«á«ü¼Ð¦p¤Uªí-3 pooled-dupilumab-300mg/qw/12 weeks/ 1.EASI-50 83.9%(99/118=83.9%) 2.EASI-75 59.3%(70/118=59.3%) 3.EASI-90 34.7%(41/118=34.7%) 4.IGA 0/1 36.4%(43/118=36.4%) pooled-placebo-300mg/qw/12 weeks 1.EASI-50 28.7%(33/115=28.7%) 2.EASI-75 13.9%(16/115=13.9%) 3.EASI-90 6.1%(7/115=6.1%) 4.IGA 0/1 4.7%(4/115=4.7%) journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults A pooled analysis of two phase 2 clinical trials ASLAN004 1b,¤T²ÕªºEASI°´T±N±µªñ¡A¦]¬°¿@«×200mg/¨C¶g¤@°w¤w¨¬°÷¡C 600mg>=400mg>=200mg |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/19 ¤U¤È 10:35:33²Ä 2775 ½g¦^À³
|
¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ±q¥H¤W¤½¥q¤½§iªº«°T¬Ý°_¨ÓÓ¤H»{¬°Âà´«¶O¥ÎÀ³¸Ó¬O¤½¥qnt¾áªº¡H ¹ï©ó·QÂà´«¨ìADRªº¤H¨Ó»¡·QÂà´«ªºªÑªF¶V¦h¥xªÑ»ù®æ´N·|¶V°ª¡AÓ¤H»{¬°Âà´«¨ìADR¸Ñ®M¾÷²v°ª¤]¸û¦³§Q¡A¦p¤Ñ©R¤jµû¦ô6.7¬ü¤¸µ¥¦P¥xªÑ40¤¸¡A¥h¦~12¤ë¤½§iASLAN004¤TÓ¤Hªº¼Æ¾Ú¥¿±ADR´¿º¦¨ì8¶ô¦h¬ü¤¸¡A¤µ¦~¤U¥b¦~¬O¤½§i24¤Hªº´Á¤¤¼Æ¾Ú¦pªG¤]¬O¥¿±ADRªÑ»ù´N«ÜÃø¹w¦ô·|º¦¨ì¦h¤Ö¬ü¤¸? ¦pªG§ë¸ê¤£¶¶¡A¤W¤Ñ¤@©w¥t¦³¦w±Æ¡A ¦@«j¤§¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/19 ¤U¤È 09:59:31²Ä 2774 ½g¦^À³
|
§Úı±o¦pªG³Ì«á¯uªº¯àÂà´«ADR À³¸Ó¬O¥i¥H¥Î®ü¥~¨é°Ó¤áÀY¡A¤£¤@©wn¥Î½Æ©e°U ¤âÄò¶O¥i¥H¬Ù¤£¤Ö |
|
|
·|û¡Gellelin10138869 µoªí®É¶¡:2020/6/19 ¤U¤È 05:38:22²Ä 2773 ½g¦^À³
|
¤µ¤Ñ¬Ý¨ìÁÙ¨S10ÂI¦¨¥æ¶q´N600¦h±i¡Aı±o¦³°¡A »°§Ö±¾ªÑ²¼n°l»ù¡K¡KµL©`®Ú¥»¨Ó¤£¤Î¡I ¥»¨Ó¥H¬°¬Q¤Ñªº©e½æ¶qÁÙn¦A¶^°±Ó2¤Ñ¡A³Ì±ß©ú¤Ñn¨Ó°l¡A §Ú¥u¯à»¡¡A§ÚÌ·Q¨ìªº¡A¤j¤á³£ª¾¹D¡K¡K ¥t¥~¡A§Ú«æ©Ê¤lÓ©Ê¡A³o´X¤Ñ¤w¸g¸òì¨é°Ó¶}¤F½Æ©e°U¡A¥xªÑÂà´«ADRªº¤âÄò¶O¶¶«KÀ°¤j®a°Ý¤F¤@¤U¡Aµ¹¤j®a°Ñ¦Ò¡I ¡]¨C¶¡¨é°ÓÂà´«¤âÄò¶OÀ³³£¤£¦P¡A¦ýÀ³¤j¦P¤p²§¡^ ¨CÂà´«500ªÑADRn25¬üª÷ ©Ò¥H¡AY«ù¦³100±i¨È·à±d¥xªÑ ³Ì«á¸³¨Æ·|¥H5:1Âà´«¡A¨º»ò 100*1000/5=2¸UªÑADR 20000/500*25=1000¬üª÷ ¤âÄò¶O¦nÅå¤H¡I ²¦³º²{¦b¥xªÑ¶R½æ¬O¦b¥xÆW¨é°Ó¡An¨é°Ó´£¨Ñ±N¥xªÑÂনADR«á¦A¶×¼·¦Ü°ê¥~¨é°Ó¡AÀ³¸Ó¤£¦Xªk³W¡AÁÙ¬Oµ¥½T»{¥xªÑ¤U¥««á¡AÀÀ©w¿ìªk¥XÄl«á¦A¸Ô°Ý¡I ¥t¥~¡A§Ú¤]¦³¥´µ¹¨È·à±d©Ó¿ì¤p©j¡AY¥xªÑ¤U¥«¡A¤½¥q·|±H³qª¾®Ñµ¹ªÑªF¡A½Ð«ù¦³ªºªÑªF¤£¥Îºò±i³á¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/19 ¤U¤È 04:50:44²Ä 2772 ½g¦^À³
|
2019¦~©³¡A¨È狮¤½¥q¡A员¤uÁ`¤H¼Æ¡A¦@23¤H¡C 2018¦~©³¡A¦³56¤H¡C ¦@ºë²60%¡C ¤½¥q´XӪѪF·|ªk³W¡A¬Ò¦bסA±ÂÅv¡A¨ÖÁʪº¬ÛÃöªk³W¡C ¤½¥q©ñ±ó¥xÆW¤WÂd¡A¤£¶Ã¼W¥[ªÑ¥»¡Cµ¦²¤¬O¹ïªº¡C ¥H¤W¨Ó¦Û¤½¶}资°T¯¸ ªÑªF·|¤â册¡A16¤é/6¤ë¡C ¸òµÛ¸³¨Æ·|¨«¡A´N¹ï¡I ¾Ö¦³ASLAN004¡A°µ§¹¤G´Á¡A±ÂÅv¥X¥h¡A²Mºâ¡A©Î¨ÖÁÊ¥X¥h¡C ¬Ò¬O¦n¤è®×¡C 30»õ谮¦b¥«³õ¡A¨È狮²bȦô14»õ¬ü¤¸¡C 50»õ谮¦b¥«Ô·¡A¨È狮²bȦô25»õ¬ü¤¸ ·íñ¨ì¼Ö³z¡A¦Ó§â¥¦丢±¼¡C ¦p4¤ë15¤é«e¡A30¤¸¥H¤U½æ¥X¦X¤@¥Í§Þ¡C ©Î¥h¦~8¤ë¾Ö¦³FB825ªº¬u²±³Q18¤¸¦X¤@¨Ö±¼¡A ¦Ñ¤Ñ给ªº¡A须²`¤J²£«~°ò¥»¬ã¨s¡AM0A¡A¥«³õ¬ã¨s ¤~¯à©êªº¦í¡C ¨È狮¸³¨Æ¨â¤j¦¨员¡A¦U6¥ü¥x¹ô¡A¥«È/²bÈ ¤½¥qªv²z¯à¤O¡A¬O¤@¬yªº¡C ¯à³Ð³yªÑªF³Ì°ªªº»ùÈ¡A´N¬O¤@¬y¤½¥qªv²z¡C ¤pªº·sÃĤ½¥q¡A³Q¨ÖÁʦb¬ü°ê«Ü¥¿±`¡C 14-25e¬ü¤¸²bÈ¡A25»õªÑ¥» ¨CªÑ诤È166-300¤¸ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/19 ¤W¤È 11:54:20²Ä 2771 ½g¦^À³
|
¼@¥»¸Ó¤£·|¦p§Ú©Ò®Æ «Ü¦h¤HÅ¥¨ìn¤UÂd´N¤£ºÞ¤T¤C¤G¤Q¤@¥ý½æ¦A»¡ ±þÓ´X¤Ñ¤j¤á¶i³õ§C±µ µM«á¶}©l¦^º¦¦¬ÀÄ»PADR»ù®t |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/19 ¤W¤È 10:34:50²Ä 2770 ½g¦^À³
|
²z©Ê¥«³õ«ì´_ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 10:14:23²Ä 2769 ½g¦^À³
|
¦ôp¥xªÑ¤UÂd»Oªº¤é´Á:¦b 2020¦~8¤ë16~23¤é¶¡¡C Âà´«ADR¤§¤é´Á³Ì§Ö 2021¦~2¤ë ¤¤¦¯¥ª¥k¡ã2021¦~8¤ë¤¤¦¯. ¤½¥q´±¤½¥¬®Éµ{¡A´Nªí¥Ü¦³²Å¦X¬ü°êªÑ¥«ªºÂà´«ªk«ß¡A (¦]¬°¤½¥qªÑ¥»¨SÅÜ¡A¥u¬O¼W¥[ADRªºµo¦æ¶q¡A«H°U°ò¦±q¥xªÑÂà´«¦¨¥À¤½¥q:¶}°Ò¨È®v±d ¤§«e¤½Ãö³¡ªù©Ò¦^µª¡A²Å¦X¬ü°êªÑ¥«ªk³W) ³oÓ¥i¥HªÑªF·|¤¤¸Ô°Ý¡C 2021¦~ 8¤ëÂà´«§¹²¦¡AAS𠃊AN004 ¤~è¶}©l°µ2b Á{§É¡A ¦Ó§¹¦¨2bÁ{§Éªº®É¶¡¡A¬ù¦b2022¦~7~8¤ë. 2022¦~©³ªº±ÂÅv/¨ÖÁʤjÀ¸¡AªÑ²¼»ùȤ~¥i¯à¬O³Ì¨Î¡C ¡X¡X¡X¡X- ¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C |
|
|
·|û¡Gonly10135877 µoªí®É¶¡:2020/6/18 ¤U¤È 09:34:06²Ä 2768 ½g¦^À³
|
³z¹L¸ÓÂà´«pµe½á¤©¥»¤½¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸` ===================== §Úı±o¤Wzªº ¨Ì§Ç´N¦³ÂIºÃ°Ý,¬O¨Ì·ÓªÑªF§Ç¸¹¶Ü? ÁÙ¬OªÑ¥÷«ù¦³¼Æ¥Ø¤j¤p? Y¨È·à±dn¥þ±Âনadr ¤£ª¾ ¬O§_¦X¥Gªk³W?©În¬üÃÒºÞ·|¦P·N?¥þ±¤@¦¸Âà´«¥i¯à©Ê®£©È¤£°ª?,ªÑªFnÂনADR ®£©Èn¨C¥b¦~©Î¨C¤@¦~¤@¦¸ ¤À§åÂà,¤pªÑªF®£©È¤£ª¾nµ¥¤W¦n´X¦~¤~¯àÂন ADR, ©Ò¥HªÑªF·|¤j®a¹Îµ²n¤Oª§ ¤pªÑªF¬O²Ä¤@§åÀu¥ýÂ઺ ¬°ªÑªF·|ªº«ÂI |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 07:22:17²Ä 2767 ½g¦^À³
|
¨È·àªºASLAN004»ùȱNÀH¥«³õ»{¦Pdupilumab¾P°â¼ç¤O©Ô°ª¨ì110»õ¬ü¤¸(2019¦~12¤ë«e¦ô50»õ¬ü¤¸) ¦Ó¤ôº¦²î°ª.ASLAN004¾P°â¼ç¤O¥i¯à¦³¾÷·|©Ô°ª50-60»õ¬ü¤¸ 2019¦~5¤ëñ¬ù¨È·àñ¤UASLAN004 ªº¥þ²y°Ó·~¤Æij»ù°ò¦¬ù30»õ¬ü¤¸¾P°â¼ç¤O. ----°Ñ¦Ò®Éªºdupilumab¾P°â¼ç¤O,¶È³Q»{¦P50»õ¬ü¤¸, ¦Ó2022¦~±N¥Hdupilumab¾P°â¼ç¤O,³Q»{¦P110»õ¬ü¤¸ ¬°Ä³»ù°ò¦ °µ§¹aslan004 2b ±ÂÅv¥X,¥þ²y°Ó·~¤Æij»ù°ò¦¬ù©Ô°ª¨ì50-60»õ¬ü¤¸¾P°â¼ç¤O¬O«Ü¦³¥i¯à. ¦Ó¦h¥X¨Óªº·¸»ùÄÝ©ó¨È·à±d,¤£¥Î¤ÀCSL. --------- 2014¦~CSL ±ÂÅvASLAN004 °µ§¹1b·§©À©ÊÁ{§É,¨Ã§ä¹ï¶H±ÂÅv¥X¥þ²y°Ó·~¤Æ¹ï¶H,§Q¯q¦U¥b. 2019/05/31 ¨È·à±dñ¤UASLAN004¥þ²y°Ó·~¤Æ (µ¹CSL±ø¥ó=¨È·à±d¾Ö¦³¦Pµ¥»ùÈ) ±ø¥ó a.«eª÷0.3»õ¬ü¤¸(¤T´ÁÁ{§É¶}©l®É¤ä¥I)+b.¨½µ{ª÷ 0.925»õ¬üª÷(¨úÃĵý®É¤ä¥I) +c.³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷+ d.¥[¾P°â¤À¼í5%~10%.(¦ôp30»õ¬ü¤¸¾P°â¼ç¤O) 2020~2022¦~,±N§¹2b(¦ô250¤H) AD Á{§É 2022¦~p¹º±ÂÅv ¥XASLAN004 µ¹¤jÃļt,¼ç¦bªº±ÂÅv¹ï¶H¤w°Ñ»P2b AD Á{§É³W¤Æ. ---------------------------- Dupiumab ¥«³õ¾P°â¹w¦ôvs.REGNªÑ»ù 2012~2014¦~ ¥«³õ¤ÀªR®v¦ô¾P°â°ªÂI7»õ¬ü¤¸ 2017¦~3¤ë¤W¥« ¥«³õ¤ÀªR®v¦ô¾P°â°ªÂI50»õ¬ü¤¸/¤W¥«3Ӥ륪¥kREGNªÑ²¼¥«Èº¦140»õ¬ü¤¸ 2019¦~12¤ë ,CEO «ÅºÙ¦ô¾P°â°ªÂI110»õ¬ü¤¸/ªñ5¤ëREGN ªÑ²¼¥«Èº¦8000»õ¥x¹ô CSL Limited ªÑ²¼¥«È¬ù1300»õ¿D¹ô(894»õ¬ü/2.68¥ü¥x¹ô) www.google.com/search?sxsrf=ALeKk002HynNOX-tG76zwwnfr6enqcVWeA%3A1592478266169&source=hp&ei=OkrrXoiOCITdmAWI5oHQBQ&q=csl+share+price&oq=CSL+SHARE&gs_lcp=CgZwc3ktYWIQARgAMgoIABDLARBGEPoBMgUIABDLATIFCAAQywEyBQgAEMsBMgUIABDLATIFCAAQywEyBQgAEMsBMgUIABDLATIFCAAQywEyBQgAEMsBOgcIIxDqAhAnOgQIIxAnOgQIABBDOgUIABCxAzoFCAAQgwE6BwgAELEDEEM6AggAUPwKWOglYOg1aAFwAHgAgAE2iAG0A5IBATmYAQCgAQGqAQdnd3Mtd2l6sAEK&sclient=psy-ab#spf=1592478272674 Ävª§Àu¶Õ: (1)¦PMOA:Àø®Ä¬Û·í©Îµ¥©ó/Àu©ódupilumab (2)ASLAN004 ADÀøµ{¦¨¥»¦³50%§C©ódupilumab ªº¼ç¤O. ASLAN004 200mg/¨â¶g¤@°w©Î¥|¶g¤@°w Dupilumab 300mg/¨â¶g¤@°w(°_©l¶q600mg) (3)°Æ§@¥Î§C ------ ±ÂÅv¼ç¦b¹ï¶H,³Ì¦³¥i¯à¦~À禬430»õ¬ü¤¸/ªÑ²¼¥«È2000»õ¬ü¤¸ªº, ¤jªÑªF&¸³¨Æ(Àq§JÃļt). |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 04:24:48²Ä 2766 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/5/11 ¤U¤È 06:01:10²Ä 37 ½g¦^À³ nª¾¹D¥¼¨ÓASLAN004 1b 200mg/400mg/600mg--¨C¶g¤@°w*8¶g¦U«ü¼Ð ! ½Ð°Ñ¦Ò ©³¤U dupilumab 2a ,¨C¶g¤@°w/12¶g ASLAN004 600mg>=400mg>=200mg --- ----没·N¥~aslan004/200mg ´N¥i¹Fdupilumab ¤ô·Ç. **¤½¥qºÙ¦P¯Å³ÌÀu ªí-3 pooled-dupilumab-300mg/qw/12 weeks/ 1.EASI-50 83.9%(99/118=83.9%) 2.EASI-75 59.3%(70/118=59.3%) 3.EASI-90 34.7%(41/118=34.7%) 4.IGA 0/1 36.4%(43/118=36.4%) pooled-placebo-300mg/qw/12 weeks 1.EASI-50 28.7%(33/115=28.7%) 2.EASI-75 13.9%(16/115=13.9%) 3.EASI-90 6.1%(7/115=6.1%) 4.IGA 0/1 4.7%(4/115=4.7%) journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults A pooled analysis of two phase 2 clinical trials |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 04:16:26²Ä 2765 ½g¦^À³
|
¬ü°ê¥«³õ¬Ý·sÃĤ½¥q ¬O¬Ý·sÃÄ¥¼¨Ó¾P°â§é²{»ùÈ. ------ ¨È·à13¸U±i¥xªÑ¶·´«ADR, ¥þ³¡´«ADR¹L¥h, ¦@2.6¸U¤dªÑ ¥[¤W즳1.2¸U¤dªÑ ¦Xp 3.8¸U±i--¤dªÑ. Y©ú¦~ASLN ADR 3.8¸U¤dªÑ.¥[¼W¸ê6000±i(¤dªÑ) ¦Xp 4.4 ¸U(±i)¤dªÑ ªÑ»ù5-8¬ü¤¸/ªÑ,¥«È¤£¹L 2.2~3.5»õ¬ü¤¸ ¤p¤½¥q, (¦X¤@¤§«eFB825±ÂÅv,¥i¤@¤f®ð¤jº¦20»õ¬ü¤¸. ) ---------------------------------- §O¤p¬Ý2000»õ¬ü¤¸¥«È²ö§J¤jÃļt ²ö§J¤jÃļt Y¨ÖÁÊASLAN004, ¥¼¨Ó¾P°âY30 »õ¬ü¤¸,¥i³Ð³y90»õªºªÑ²¼¥«È. ADÀøµ{¦¨¥»¦³50%§C©ódupilumab ªº¼ç¤O, ¥i¯à¥´¤U¥«³õ¦³¾÷·|¨ì50»õ¬ü¤¸.¥i³Ð³y150ªÑ²¼¥«È. -------- Timchan ¤j, ¬O²z©Ê§ë¸ê¤H ----- ·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/18 ¤U¤È 04:02:19²Ä 2764 ½g¦^À³ ¥Ø«e¨È·à±d³sÄò¶^°±¦³®t¶Ü ³£¤w¸gn¤U¥«Âà´«adr ©Ò¥HªÑ»ù¤w¸g¨S¦³°Ñ¦Ò©Ê¥B¤]¤£«n ©Ò¥H«ù¦³6497ªº§ë¸êªÌÁÙ¬OÃöª`aslnªÑ»ù´N¦n¤F ´Nºâ6497º¦¨ì8¶ô§A¤]¬O¤£·|½æ±¼¤£¬O¶Ü ´N©ñÓ¤@¦~¥H¤W§a ¦pªG¤@´Á¼Æ¾Ú¤£¿ù ¨º³o´X¤Ñ½æ±¼ªº¤H¤~·|¦R¦å§a |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/18 ¤U¤È 04:02:19²Ä 2764 ½g¦^À³
|
¥Ø«e¨È·à±d³sÄò¶^°±¦³®t¶Ü ³£¤w¸gn¤U¥«Âà´«adr ©Ò¥HªÑ»ù¤w¸g¨S¦³°Ñ¦Ò©Ê¥B¤]¤£«n ©Ò¥H«ù¦³6497ªº§ë¸êªÌÁÙ¬OÃöª`aslnªÑ»ù´N¦n¤F ´Nºâ6497º¦¨ì8¶ô§A¤]¬O¤£·|½æ±¼¤£¬O¶Ü ´N©ñÓ¤@¦~¥H¤W§a ¦pªG¤@´Á¼Æ¾Ú¤£¿ù ¨º³o´X¤Ñ½æ±¼ªº¤H¤~·|¦R¦å§a |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/18 ¤U¤È 03:59:22²Ä 2763 ½g¦^À³
|
¸¤H¤j¤µ¦~ÁÙ·|°Ñ¥[ªÑªF·|¶Ü? ¤j¹Ù·Ç³Æ´X½cÂû³Jµ¹±z±a¥h °È¥²½Ð¤½¥q¥Õ¯È¶Â¦r»¡©ú²M·¡Âà´«ADRªº³W«h |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 03:17:50²Ä 2762 ½g¦^À³
|
¤½¥q¤½§i ¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ¥H¤W须¥Iªk«ß责¥ô¡C Y¦]¤½¥q¤è±ì¦]¦Ó¨ÏªÑªF¤£¯àÂà´«ADR¡A¨È·àn负ªk«ß«h¥ô¡C ¸òµÛ¤jªÑªF¨«¡A ²ö§J¤jÃļt¡AÀ禬430»õ¬ü¤¸¡A ¨ÖÁʦX¤@ªºLEO¡A¦~À禬¶È79»õ(DKK)¡A2014¦~ us$=6.6DKK |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/6/18 ¤U¤È 03:03:05²Ä 2761 ½g¦^À³
|
§Ú·Q¦A´X®Ú¶^°±¡A¤½¥qÀ³¸Ó´N·|¥X¨Ó»¡©ú¤F§a¡AªÑªFÀ³¸Ó³£µ¥¤£¤Î·Qn±Ð°V³o¨Ç¦Ñ¥~¤F§a¡A¤½¥q·d¦¨³o¼Ë¡A¯uªº¦³°÷¸Ø±iªº¡A¥H¤µ¤Ñ©Òªº±i¼Æ¨Ó¬Ý¡A¥i¯àÁÙn¦A¶^¤T¥|®Ú¶^°±¡AªÑ»ù¥i¯à·|¯}«e§C! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 03:01:26²Ä 2760 ½g¦^À³
|
ADR¤U¥«¡A¦³¬ü°êªk«ß¨Ì¾Ú¡C ¨È·à¾Ö¦³·í红2¦Ê»õ¬ü¤¸¡AAD¼Ð¹v¥«³õ¡C ¦P级REGNªºduoilumab ¥«Ô·给©ó¶W¹L300»õ¬ü¤¸¥«È¡C ¦P级³ÌÀu¡C 2022¦~¡A°µ§¹2b ADÁ{§É±ÂÅv»ùȧ󰪡C ¤jªÑªF ²ö§J¤jÃļt2019¦~430»õ¬ü¤¸销°â¡C REGN 2019¦~¡AÁ`销约80»õ¬ü¤¸¡C ²{¦b´«ADR¤£¹L2¬ü¤¸¡C §Ú̬ݪº¬O10-15¿ªº2¦~«á¨ÖÁÊ»ùÈ¡C n²`¤J°ò¥»±¡A¤è¯àÁA¸ÑASLAN004»ùÈ¡C ¥@¬É«e¤¤jÃļt¡A¦³2-3¦ì§ä¦X¤@¥X»ù¡C ¤½¥q¯dCEO¤Î°Ó°Èªø¡Aªk«ßÅU°Ý¡A°]°È°ÆÁ`µô¡C ´N¬O±ÂÅv¹Î¶¤¡C 2b ADÁ{§É¡A预p2020¦~1H¶}©l |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/18 ¤U¤È 02:28:33²Ä 2759 ½g¦^À³
|
ADRÀ³¸Ó¤£¥i¯à¤U¥«§a ¬Ý°I¤]¤£¥Î¤Ó¹LÀY ¦ý¬OªÑªF·|n¤½¥q»¡©ú²M·¡¦p¦óÂà´«¤~¬O¥²nªº ¤½¥q¬O§_¦³¸Û«H´N¬Ý¯à§_°µ¨ì³o¤@¨B |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/18 ¤U¤È 02:04:12²Ä 2758 ½g¦^À³
|
û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/17 ¤W¤È 08:56:39²Ä 2753 ½g¦^À³ ADR=5ªÑ¥xªÑ¨È·à±d¡C ¦Xp¡A¦@µo¦æªñ19¸U±i¥xÆW¨È·à±d¡C ¨ä¤¤®³6¸U±i¥hµo¦æ12,000±i(1000ªÑ)ªºADR¡C 19¸U±i¡A¨C¤@±iªºªÑªFÅv§Q¬Ò¬Û¦P¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/18 ¤U¤È 01:18:36²Ä 2757 ½g¦^À³
|
«Øij¤j®a·Q¤F¸Ñ©Î¬O·Q·FÃ×(¤×¨ä¬O¦Ñ·à¤Í,§A̪º¼vÅT³Ì¤j),³£¥hªÑªF·|,³o¼Ë¤j®a¥¼¨Ón²Õ´¦Û±Ï®É¤]¤ñ¸û®e©ö..... |
|
|
·|û¡Gjones10146258 µoªí®É¶¡:2020/6/18 ¤U¤È 12:42:24²Ä 2756 ½g¦^À³
|
¨È·à±d¨â¦ìÂå¾Ç/¬ãµo¤À§O°h¥ð¡AÂ÷¾¡C ¥¼¨Ó谮¦b³Q±ÂÅvªÌ(¥@¬É¤jÃļt)¤w¤¶¤J¥¼¨ÓÁ{§É³]p¡C ASLAN004 ¤§«á¡A¤wµL¤jÃÄ¡C ¬GÓ¤H§PÂ_¡A¤½¥q³Q¨ÖÁʾ÷²v°ª¡C => ±z¦Û¤v³£»¡¬ãµoÂå¾Ç¥DºÞ³£Â÷¾¡A¥Nªí¤½¥q¤wµL¬ãµo¯à¶q¡A½Ð°Ý¬°¦ó¨ä¥L¤½¥qn¨Ö¤@Ó©ìªo²~¦A¾i³o¨Ç°ª¶¥¸g²z¤H? n¤]¬O¥u¬Ý¤¤004¡A¨º³æ¿W½Í004±ÂÅv´N¦n¤£¥Î¨ÖÁʪü¡]¦ý¬Ý¨ì¤Ñ»ùªº¨½µ{ª÷À³¸ÓC«o¨B¤F¡^ ¥t¡AÁÙ±¾µP®É³£Âण¹L¥h¢Ï¢Ò¢à¤F¡A¤U¥«¤Ï¦Ó·|Â઺¹L¥h¡H±zı±o¦X²z¶Ü¡H¡]¦s°U¨óij¥h¬Ý²M·¡§a¡^¡@6-12¤ë¤º"¨ó§UÂà´«"¡A¨º¨SÂন©O¡H¡@¤£¬O¤@¼Ë©ç©ç§¾ªÑ¨«¤H¶Ü¡H¡@ Ó¤Hı±o¤£¥i¯à¦³Âà´«ªº¨º¤Ñ¡A¬Æ¦Ü¢Ï¢Ò¢à¤U¥«¤]¬O¦±ßªº¨Æ..... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/18 ¤W¤È 08:31:35²Ä 2755 ½g¦^À³
|
¥Õ®ö·Ê·Ê§Ú¤£©È;´I¶Q¥»¬OÀI¤¤¨D. ........................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/5/8 ¤W¤È 10:41:11²Ä 2532 ½g¦^À³ Ãø«O³oÓ¦ÑÁ󤣷|¤]¥X¤U¥«³oºØ¶ø¨B? ´¦¶}³¯®õ»Ê±N°ê¥¨¤U¥«¤º¹õ¡þ¤j¦ÑÁ󪺳¥ÆZª÷¿ú¹CÀ¸ stock.pchome.com.tw/magazine/report/po/businesstoday/4299/130262400027479004001.htm ............................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/4/20 ¤W¤È 08:24:11²Ä 2469 ½g¦^À³ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/20 ¤W¤È 07:34:49²Ä 2468 ½g¦^À³ ¥xÆW¤U¥«¤£¥NªíASLAN004 ´N¬OªÅ¡C .......................................................................... ¨S¿ù+1 2018Áp¥Ín¤U¥«,¤½¥q¬£25¤¸¦¬,¶^¨ì20¤¸¤§¤U,²V¤ô¤¤«¥ºN¤F´X±ø³½! ¤£¹L¦b2019-04/18Áp¥ÍÃĪvÀø·R´þ¯f§ÜÅé·sÃÄUB-421Á{§ÉII´Á¸ÕÅçµ²ªG ºaÀò¥Zµn©ó·s^®æÄõÂå¾Ç´Á¥Z«á, «¥·P¨ì«á®¬¤Ï¦ÓnÄ~Äò«ù¦³! www.unitedbiopharma.com/tw/news_detail.php?id=251 ¥tÃþ«ä¦Ò: ´¦¶}³¯®õ»Ê±N°ê¥¨¤U¥«¤º¹õ¡þ¤j¦ÑÁ󪺳¥ÆZª÷¿ú¹CÀ¸ stock.pchome.com.tw/magazine/report/po/businesstoday/4299/130262400027479004001.htm .......................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/5/8 ¤W¤È 10:52:39²Ä 2533 ½g¦^À³ ¯à²q³z¦ÑÁ󪺫äºû? 2019-12-03 05:30 ¤O´¹¶°¹Î¸³¨Æªø¶À±R¤¯¡]¥k¡^¹wp©ú¦~¥H¤O¿n¹q¤§¦W¥Ó½Ðµn¿ý¿³Âd¡A³W¹º«·s¤W¥« ¡C ec.ltn.com.tw/article/paper/1336373 ....... ¤O´¹2012¦~´¿¤j´T´î¸ê¡A¤@¨Ç´î¸ê«á¥H§C»ù¤j¶R¤O´¹ªº¤pªÑªF¡A¤£¥F«ù¦³¤W¸U©Î´X¤d±i¡Aªñ´X¦~»â¨ìªºªÑ§Q§¡¤Q¤ÀÅå¤H¡C¤£¹L¡A¤]¦³¤U¥««e©Î´î¸ê«e«ù¦³ªº¤pªÑªF¡AºG½ß¦Ü¤µ¡A´Á±æ¤O´¹¥H¤O¿n¹q¤§¦W¦¤é«ªð¤W¥«¤§¸ô¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/17 ¤U¤È 01:16:35²Ä 2754 ½g¦^À³
|
®³001©Î004¥h¸ò·s«a¯f¬r¤@°_co-culture»¡¤£©w¤]¦³§Ü¯f¬rªº®ÄªG...¦Ñ·àºÞ²z¶¥¼h§Ö¥h¦w±ÆÁ{§É |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/17 ¤W¤È 08:56:39²Ä 2753 ½g¦^À³
|
ADR=5ªÑ¥xªÑ¨È·à±d¡C ¦Xp¡A¦@µo¦æªñ19¸U±i¥xÆW¨È·à±d¡C ¨ä¤¤®³6¸U±i¥hµo¦æ12,000±i(1000ªÑ)ªºADR¡C 19¸U±i¡A¨C¤@±iªºªÑªFÅv§Q¬Ò¬Û¦P¡C °²³]2022¦~¡A³Q¨ÖÁÊ¡A14»õ¬ü¤¸(420»õ¥x¹ô)¦Ó·í®ÉªÑ¥»¡A¼Wªø¨ì¤F25»õ¤¸(250,000±i)¡A¨È狮±d(¶}°Ò)¡C 420/25¡Ñ10=166¤¸/ªÑ ³o¬O²bÈ¡C ¨È·à±d¨â¦ìÂå¾Ç/¬ãµo¤À§O°h¥ð¡AÂ÷¾¡C ¥¼¨Ó谮¦b³Q±ÂÅvªÌ(¥@¬É¤jÃļt)¤w¤¶¤J¥¼¨ÓÁ{§É³]p¡C ASLAN004 ¤§«á¡A¤wµL¤jÃÄ¡C ¬GÓ¤H§PÂ_¡A¤½¥q³Q¨ÖÁʾ÷²v°ª¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/17 ¤W¤È 08:40:42²Ä 2752 ½g¦^À³
|
¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡]¤j®aµ¥²Ó¸`¤½§G¤j®a´Nª¾¹D¤F¡A¤½¥qÀ³¸Ó·|¨ó§UªÑªF¦p¦óÂà´«¡A¨S¦³·Q¹³¤¤¨º»òÃø¡A©ñªø½u³¨¤j³½¡A»¡¤£©w¶V±ß´«¬ù¦n¡^ ¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/17 ¤W¤È 05:27:44²Ä 2751 ½g¦^À³
|
¥æ¥N²M·¡¡I ¤@¤Á¦³¬°ªk¦p¹Ú¤Ûªw¼v¡A¦pÅS¡A¥ç¦p¹q¡AÀ³°µ¦p¬OÆ[¡C |
|
|
·|û¡GªY½à¼Æ¦r¬ü10147157 µoªí®É¶¡:2020/6/17 ¤W¤È 01:57:11²Ä 2750 ½g¦^À³
|
¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«? ¶W¹L®É¶¡´N¤£¯àÂà¤F¶Ü? ¦Û¤v¶R¤FªÑ²¼n¸ò®a¤H¥æ¥N²M·¡¡A¥¼¤W¥«ªÑ²¼¦hªº¬O¶R¤F®a¤H³£¤£ª¾¹D n¬O¥Í¯f¾ÉP¥Í¬¡µLªk¦Û²z©ÎªÌ¦³¸U¤@..... ®a¤H³£¤£ª¾¹D¨S¤HÀ°¦£Âà´«¡B©Î¿ò²£ªÈ¯É¤@¦~¥b¸üµLªkµ½¤Fªº¨S¦b®É¤ºÂà´«.... ¯uªº·|Åܦ¨¾À¯È¤F? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 11:13:08²Ä 2749 ½g¦^À³
|
¸òµÛ80,000±i¤jªÑªF(24¤H«ùªÑ¤¤¦³²H°¨¿ü,¦³Àq§JÃļt)¨«´N¹ï¤F, ¥Ļó¬O±M·~. |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/6/16 ¤U¤È 10:56:50²Ä 2748 ½g¦^À³
|
¥xÆW¨S¦³¤W¥«Âd¤U¥«¤F¡AÁÙÂàADRªº¨Ò¤l¡C ÁöµM«Ü´Á«Ý¨È·à±d¬Oº¨Ò¡A¦ý¤£ª¾¹D¬°Ô£¤º¤ßÁÙ¬O©È©Èªº¡C ²¦³º¨S¦³¥Õ¯È¶Â¦r¡A«Ü©È³Ì«á¤@³õªÅ!!! |
|
|
·|û¡Gellelin10138869 µoªí®É¶¡:2020/6/16 ¤U¤È 10:37:48²Ä 2747 ½g¦^À³
|
·Q½Ð±Ð¦U¦ì¤j¤j¡A¦³¨S¦³¥i¯à¡A¥xªÑÁÙ¦³§Æ±æ¤£¤U¥«©O¡H EX:¬ðµM¨ÓÓ«°T¡A¨p¶Ò¸êª÷¨ì¦ì¡AÐäȦ^¨ì¥¿¼Æ¡A©ÎªÌ¡AÃÒ¥æ©Ò¦]¬°¤½¥q´£¨Ñªº¸ê®Æ¡A¯S§O¿Ä³q©O¡H ·Pı°Ý¤FӤѤè©]ÃÓªº°ÝÃD¡A¦ýÁÙ¬O·Qťť¦U¦ì¤j¤j¦³¨ä¥L¤£¦Pªº·Qªk©O¡H ²¦³º²{¦b©|¥¼¦¨©w§½¡A·d¤£¦n¦³¥i¯à®p°j¸ôÂà©O¡I ÁöµM¬Ý¨ì©M¬üªÑªº»ù®t¡A«D±`§Æ±æ¥xªÑ¤U¥«ÂনADR¡K¡KXD ¦A®z®z¤@°Ý¡A¦³¤H·Q¸ò§Ú¤@¼Ë¡AY©ú«á¤Ñ¶^°±¦AÄ~Äò¶R¶iªº¶Ü¡H |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/6/16 ¤U¤È 09:46:14²Ä 2746 ½g¦^À³
|
ADR2.18 ¥[ªo |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2020/6/16 ¤U¤È 09:25:06²Ä 2745 ½g¦^À³
|
¸É¥R¤@¤U ¦pªG¬O¹Å«H²z°]ªº¸Ü °O±o¤£n¤£¤p¤ß¦V»´ä¤À¤½¥qªº±b¤á »´ä¤À¤½¥q¸ò¬ü°êÁ`¤½¥q¶}¤áªº¸Ü¦L¶H¤¤ ¦³®t²§..... |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2020/6/16 ¤U¤È 09:19:13²Ä 2744 ½g¦^À³
|
¦pªG¥¼¨ÓÂà´«¦¨ADR·Qn¥æ©ö¬üªÑªº¸Ü ¥i¥H¤À¬°¶}®ü¥~¨é°Ó¸ò½Æ©e°U¨â±ø¸ô ®ü¥~¨é°Ó°ê¤º¦h¼Æ¤H¶}ªº¤¤¤å¤¶±¸ò«ÈªAÁÙ¤£¿ùªº¦³ firsttrade: ÀuÂI:¦ÑÁó¬°¥xÆWµØ¹´¤¤¤å«ÈªA¸ò¤¤¤åºô¶°µ±oÁÙ¤£¿ù ¦h¦~«eÁpµ¸¹L¦^´_ÁÙºâ¤Î®É¸ò§Ö³t 0¤âÄò¶O ¥t¥~¦³ ¦h¶µ¶}¤á ¥æ©ö ¶×´Ú Àu´f ¯ÊÂI:³W¼Òµy¤p Charles Schwab¹Å«H²z°]:ÀuÂI:¤½¥q³W¼Ò¤j ¦³¤¤¤åºô¶¸ò¤¤¤å«ÈªA ¸ê²£¦b¤@©w³W¼Ò¥i¥Ó½Ðdebit card §K¤âÄò¶O¥i ¦b¥@¬É¦U¦a¦X§@atm ´£»â²{ª÷ 0¤âÄò¶O ¯ÊÂI:¥xÆW¼ô±x«×¸ò¦U¶µ¤¤¤åªA°Èµ{«×µ¥ªA°È¸ûfirsttradeµy®z ½Æ©e°U:´IXÃÒ¨é ¦h¦~«e·í¤p§Ì¤´¬O¤p¤p©@©`¦Ì§ë¸ê¤H®É´N¦³¿ì¨ì0.12% 18¬üª÷§C®øªº±ø¥ó ÀuÂI:¥xÆWªº¨é°Ó¦³¦³¥ô¦ó°ÝÃD³£¦n³B²z ¦Ó¥B¤âÄò¤Îµ|°Èªº°ÝÃD¤ñ¸û¤p(¿ò²£µ| ÃØ»Pµ| ´Ú¶µ¶×¦^¥xÆW µ¥...) ¯ÊÂI:¤âÄò¶O¬Û¸û©ó®ü¥~¨é°Ó®t¤@¤jºI(¦ý¦b¥xÆW½Æ©e°U¤¤¤´¬O¬Û·í¦³Ävª§¤O) ¤U³æ³nÅé¸û¶§¬K³ø»ù¸ê¸ß¦³ ®É¶¡¸¨®t ¥H¤W¬°¸ô¤H¥Ò¤p§Ì«e´X¦~¬ã¨s¤ß±o ¨Ñ¦U¦ì¤j¤j°Ñ¦Ò |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/16 ¤U¤È 08:59:32²Ä 2743 ½g¦^À³
|
¤µ¦~¦³¤H·|¥h¨È·à±dªÑªF·|¶Ü? ¸¤H¤j¤µ¦~ÁÙ·|¥h¶Ü? °È¥²´À¤j®a¦n¦n°Ý¤½¥qÂà´«ADRªº®Éµ{©M¤è¦¡ ·P®¦¦X¤Q |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/16 ¤U¤È 04:45:46²Ä 2742 ½g¦^À³
|
·s¥[©Y½Ã¥Í³¡¶g¤@ (15 ¤é) «Å¥¬¡A¦Û 6 ¤ë 19 ¤é¹s®É°_¡A±N¤¹³\«ì´_¤j¦h¼Æ¸gÀÙ¬¡°Ê www.google.com/amp/s/amp-news.cnyes.com/news/id/4493455 ²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅ禬®×¥i±æ«±Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 03:58:00²Ä 2741 ½g¦^À³
|
ASLAN004 1bÁ{§É---Ó¤HÆ[¹î¦p¤U: 600mg¥Î¤£¨ì-----(没Ävª§¤O,¶È´ú@¨ü©Ê/¦w¥þ©Ê¥Î) 400mg¥Î¦b°_©l¶q,©Î¥|¶g¤@°w¤§³]p. ¨C¶g¤@°wªº1bÁ{§Éµ²ªG200mg/400mg/600mg ¹w«á«ü¼Ð¼Æ¼Æ¦r¬Û¦ü,¤£·|¦³²Îp¤WÅã©õ®ÄªG. ¦]¬°¨C¶g¤@°w¾¯¶q¶W«. ¥¼¨Ó¬On©é 4¶g¤@°w200mg/400mg 2¶g¤@°w 200mg/ ---------------------------- §Æ±æ¬Ì]§Ö°Ý¥@. ³Ì«n¬O¬ü°ê 2b (250¤H),Á{§É, ©ú¦~1 H ¶}©l. ¨ä¥L¤p¨Æ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/16 ¤U¤È 03:46:40²Ä 2740 ½g¦^À³
|
·í°È¤§«æ,ASLN004ªºÁ{§É°£¤F¿D¬w¤Î·s¥[©Y¦¬®×ºÉ§Ö«ì´_¤§¥~,»°§Ö¦A¶}¥xÆW©Î¨ä¥¦¬Ì±¡¼vÅT¸û¤pªº°ê®a¦A¶}®×¦¬¯f¤H,§¹¦¨3¾¯¶qªº´Á¤¤¼Æ¾Ú,¦b²Ä¥|©uªì´Á´N¸Ñª¼§¹¦¨,¤£µM¬î¥V¬Ì±¡¦A°_,¤£¯à¦¬®×®É,¤½¥q¨â¤â¤@Åu¨S¨Æ§@,¤SnªÑªF¦Aµ¥°Ú~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 03:03:31²Ä 2739 ½g¦^À³
|
¨Ì¾Ú¤½¥q¥Ø«e¥i¯àp¹º ¤½¥q¥²©w¦b©ú¦~2¤ë«e¡A¤½¶}¶Ò¸êADR §¹¦¨ ,Äw¸ê °µASLAN004 AD 2bÁ{§É(¬ù250¤H¡^. ©Î³\·|¼W¥[¤@Ó ASLAN004 ý³Ý 2aÁ{§É(¦Ê¤H) µM«áÂà13¸U±i¥xªÑ¬°2.6¸U±i¡]¤dªÑ) ADR |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 02:39:50²Ä 2738 ½g¦^À³
|
¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦ôp¤UÂd»Oªº¤é´Á:¦b 2020¦~8¤ë16~23¤é¶¡¡C Âà´«ADR¤§¤é´Á³Ì§Ö 2021¦~ ,2¤ë ¤¤¦¯¥ª¥k¡ã2021¦~8¤ë¤¤¦¯. ¦¹¨ä¶¡¡A¤£·QÂà´«ADRªº¤j¤j¡A´N¨Ó¥²´Iºô¥æ©ö¡A6497¨È·à±d. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 02:29:43²Ä 2737 ½g¦^À³
|
¥¼¨Ó¥xÆW¨È·àªÑ²¼´«ADR ªº¤ñ¨Ò 5:1 ,À³¸Ó·|ºû«ù¡C ¤w«ù¦³ªÌ¥BÄ@·N´«ADRªº¤j¤j ¤w©M¥xªÑ¥¼¨ÓªÑ»ùµLÃö. ¤jªÑªF¤£·|¥h§ï5:1 ªº´«ªÑ¤ñ¨Ò¡A¦Ó·l¥x¬üÂù¤èªÑªFÅv¯q¡C ©Ò¥H¸òµÛ¤jªÑªF¨«´N¹ï¤F¡C |
|
|
·|û¡G°Î¦WªÌ10141057 µoªí®É¶¡:2020/6/16 ¤U¤È 01:53:55²Ä 2736 ½g¦^À³
|
¨ä¹ê¥ún¶}´_©e°U ¥æ©ö¬üªÑ¤@²¼§ë¸ê¤H´N¥´¦^²¼¤F |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/16 ¤U¤È 01:47:07²Ä 2735 ½g¦^À³
|
§Ú¤]·Qª¾¹Detoro¬O§_¥i¥H¥æ©ö¨È·à±dADR ¦³ªO¤Í¨Ï¥Îetoro¥æ©ö¬üªÑªº¶Ü? |
|
|
·|û¡G°Î¦WªÌ10141057 µoªí®É¶¡:2020/6/16 ¤U¤È 01:38:24²Ä 2734 ½g¦^À³
|
¤U¥««áÁÙnµ¥6-12Ó¤ë ¦³¨Ç¤H¤£·Qµ¥ªº´N¥X²M¤F ³o¨Ç¤H¥i¯à»{¬°6-12Ó¤ë ¥L¥i¦b¥xªÑ¥«³õ²zÁȶW¹L¤@¿¥H¤W§a |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/16 ¤U¤È 01:32:48²Ä 2733 ½g¦^À³
|
¥xÆW«Ü¦h§ë¸ê¤H¬Ý¨ì±q¥xÆW¤UÂd ·Q¤]¤£·Q´Nª½±µ±þ¤F ·íªìÁp¥ÍÃÄn±q¥xÆW¤UÂd®É¤@¶}©l¤]¬O¨g±þ ¯u¥¿Ãѳfªºµ¥±þ¨ì§CÂI´N·|¨Ó±µ¤â¤F ¬Ý¥x·àªº¨«¶Õ¯uªºÄ±±o·à¤l´«¦¨ADR¯uªº¤ñ¸û¦n |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 12:38:48²Ä 2732 ½g¦^À³
|
www.marketwatch.com/investing/stock/asln/analystestimates asln Average Target Price: 5.50 ¬ü¤ÀªR®vµ¹ ASLN ADR ,¥§¡¥Ø¼Ð»ù 5.5¬ü¤¸ |
|
|
·|û¡G§_¨ì©³°Õ10148994 µoªí®É¶¡:2020/6/16 ¤U¤È 12:02:52²Ä 2731 ½g¦^À³
|
firsttrade½T©w¥i¥H§ä¨ì¸ò¥æ©ö... ¦ýetoro¤W§ä¤£¨ìASLN...¦³¤j¤j¥i¥H±Ð¤@¤U¶Ü? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤U¤È 12:02:09²Ä 2730 ½g¦^À³
|
Y¦³¤H¶R¨Ó´«ADR, ¦~©³¨Ì·Ó¬ü°ê¤ÀªR®v¥Ø¼Ð»ù5-8¬ü¤¸. ¥iÀò§Q6-8¿. |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/16 ¤W¤È 11:55:19²Ä 2729 ½g¦^À³
|
Ó¤Hı±o¨È·à±d100%·|¦b¥xÆW¤UÂd¥B¥Ã»·¤£·|¦b¥xÆW¥«³õ¦³¥æ©ö¤F ! ©Ò¥H¥xÆWÂd¶R¥«³õ¥æ©öªº»ù®æ¤]¤£«n ! ¤£¹L¤µ¤Ñ·|´é²{¶W¹L¤d±i½æÀ£ ! ³o¨Ç¤Hµ´¹ï¤£·|¤£ª¾¹D·¸»ù®M§Q»PÂà´«¨ìADRªº±ø¥ó ,¤Ï¦Ó¬O¤£p»ùªº½æ¥X .. ³o¤@ÂI¯uªº«Ü@¤H´M¨ý , ³oÓ½æÀ£À³¸ÓÁÙn¶^4~5®Ú°±ªO¥H¤W¤F ! ¤£¹L¹ïªø´Á§ë¸ê¤H¥B¨S¦³¥´ºâ¦b¤µ¦~½æªº§ë¸êªÌªÖ©w¨S®t ! ¦]¬°Y¬O¤½¥q½T©w·|100%¹ê¬IÂà´«ADRªºpµe ! ¨º»ò¥Ñ¤µ¤Ñ¶}©l Âd¶R»ù®æ¥u¬O¼oª« |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 11:12:39²Ä 2728 ½g¦^À³
|
16¥ü¥x¹ô¥«Èªº¨â¤jªÑªF(²H°¨¿ü/Àq§JÃļt) µo¥Xªº¤UÂd¥i¯à©Ê. ¦¹¦a¤£¯à¯d,¯d(American Depositary Shares, or ADS) ¥xÆWªk¥O,¯d¤£¦í°ê»Ú¤jÃÄ. ----------------------- ¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 10:58:07²Ä 2727 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 02:58:56²Ä 2686 ½g¦^À³ [¤½§i] ¨È·à±d-KY:¥»¤½¥q¸³¨Æ·|»¡©ú¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤§¼ç¦b¥i¯à¤Î¬ÛÃö·ÀI¦]À³¨Æ¶µ ¤½¶}¸ê°TÆ[´ú¯¸ (2020-06-15 14:43:32) ²Ä53´Ú 1.¨Æ¹êµo¥Í¤é:109/06/15 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q¸³¨Æ·|©ó109¦~6¤ë15¤é¥l¶}·|ij°Q½×¨Ã«Å¥¬¥i¯à©ó°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi ¶R½æ¤¤¤ß²×¤î¦³»ùÃÒ¨é¶R½æ¤§¼ç¦b¼vÅT¡A¨Ã¦P¨B©ó¬ü°êÃÒ¨é¥DºÞ¾÷Ãö«ü©wºô¯¸¤½§G¬Û Ãö·ÀI¨Æ¶µ¡C ¥»¤½¥q¸³¨Æ·|¤wª¾±x®Ú¾Ú°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ßÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³ »ùÃÒ¨é·~°È³W«h(¥H¤UºÙ¡§·~°È³W«h¡¨)²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú³W©w¡A¥»¤½¥q¨ÌÃÒ¨é¥æ ©öªk²Ä36±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼Æ¡A¤Î·~°È³W«h²Ä7´Ú³W©w ¡A¤½¥qÀç¹B¥þ±°±¹y¹O¤»Ó¤ë©Î³sÄò¤»Ó¤ë¤½§i¤§Àç·~¦¬¤J¬°¹s©Ît¼Æ¡A°]¹Îªk¤H¤¤ µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß±o¨Ì¬ÛÃö³W©w¤½§i²×¤î¥»¤½¥q¦³»ùÃÒ¨éÂdÂi¶R½æ¡A¨Ã³ø½Ð¥D ºÞ¾÷Ãö³Æ¬d¡C±©¤Wz¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤@¨Æ¨Ã¤£¼vÅT¥»¤½¥q¤§¬ü°ê¦s°U¾ÌÃÒ (American Depositary Shares, or ADS)«ùÄò©ó¬ü°ê¨º´µ¹F§J¥«³õ¤W¥«¤Î¥æ©ö¡C 6.¦]À³±¹¬I: ¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ¦p¥»¤½¥q¦³»ùÃÒ¨é²×¤î¶R½æ«á¡A±N¾ÉP¨ä¥L©Ò¦³¥xÆW±¾µPªk«ß¡]¥]¬A³W«h¡^³v¨B¤£ ¾A¥Î©ó¥»¤½¥q¡C¥»¤½¥q¸³¨Æ·|¤wª¾±x¦¹¶µ¾Aªk©ÊÅÜ°Ê¥B¦P·N¦¹¶µÅܰʱN¦³§Q©ó¥»¤½¥q ¥R¤À¾A¥Î¬ü°ê¦h¤¸Äw¸ê¤u¨ã¡B´£¤É¥»¤½¥q¶Ò¶°¸êª÷¯à¤O¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: «e¤©Ê³¯z ¥»«¤j°T®§¥]§t¦U¶µ«e¤©Ê³¯z¡C¤Wz³¯z¨Æ¶µ«Y¥»¤½¥q°ò©ó¥Ø«e²z©À¡B¹w´Á©Ò§@¥X ¤§Án©ú¡C¤Wz«e¤©Ê³¯z¥]¬A¦ý¤£©ó¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¡F¥»¤½¥q¨îq¨Ã ¹ê¬I¥þ±Âà´«pµe¤§¯à¤O¡F²×¤îÂdÂi¶R½æ«á¤§¼ç¦b§U¯q©ÎÄw¸ê¯à¤O¡F¤Î¥»¤½¥q·~°Èµ¦ ²¤¡C ¥»¤½¥q¤§«e¤©Ê³¯z«Y°ò©óºÞ²z¶¥¼h¥Ø«e¹ï¥¼¨Ó¨Æ¥ó©MÁͶժº·í«e°²³]©M¹w´Á¡A³o¨Ç ¥i¯à¼vÅT¤½¥q·~°È¡Bµ¦²¤¡B¹BÀç©Î°]°ÈÁZ®Ä¡A¨Ã¥B¥ý¤Ñ©Ê¯A¤Î«¤j¤wª¾©M¥¼ª¾ªº·ÀI »P¤£½T©w©Ê¡C°ò©ó³o¨Ç·ÀI©M¤£½T©w©Ê¥i¯à¾ÉP¹ê»Úµ²ªG©Î¨Æ¥ó»P¹w´Á«¤j¤£¦P¡C ³o¨Ç¤£½T©w©Ê¥]§t¦ý¤£©ó¥»¤½¥q©ó¬ü°êÃÒ¨é¥æ©ö©eû·| (U.S. Securities and Exchange Commission)¥Ó³ø¤§¤å¥ó (Commission File No. 001-38475)¡B¥]§t¥»¤½¥q©ó2020¦~4¤ë16¤é´£¥æ¤§20-Fªí®æ¡C °£¾ú¥v©Ê¨Æ¹ê³¯z¥~¡A¨ä¥L©Ò¦³³¯z§¡¬°«e¤©Ê³¯z¡A¬ÛÃö¥Î»y½Ñ¦p¡¨¬Û«H¡¨¡A ¡¨¥i¥H¡¨¡A¡§¥i¯à¡¨¡A¡§±N¡¨¡A¡§¥Ø¼Ð¡¨¡A¡§¦ôp¡¨¡A¡§«ùÄò/Ä~Äò¡¨¡A¡§¹w´Á¡¨¡A ¡§¥´ºâ¡¨¡A¡§´Á±æ¡¨¡A¡§p¹º¡¨µ¥¡A¤Î¨ä¥LÃþ¦ü·N¸qªº§_©wµü»y¨ÓÃѧO³o¨Ç«e¤©ÊÁn ©ú¡C ¥»¤½¥q¹ï¤Wz¦ôp¡B¹w´ú¡B¤Î©Ò¦³«e¤©ÊÁn©úªþ¦³§K³d«OÅ@¡A¤£©Ó¾á§ó·s©Î¼f¾\¥ô¦ó «e¤©Ê³¯z¤§¸q°È¡C -------------------- ¤µ¤ÑASLN ¦¬1.92¬ü¤¸,§é¦X¥xªÑ 11.4/ªÑ.(1:5) ¥xªÑ´«ADR ²{ÁÈ100% ¤£ª¾ªº¤H¥s¾À¯È finance.yahoo.com/quote/ASLN/ |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2020/6/16 ¤W¤È 10:53:03²Ä 2726 ½g¦^À³
|
½Ð°Ý¬On¤UÂd¶Ü¡H«ç»ò³£Å¥¦U¦ì¤j¤jnÂà¶ÜADR©O¡Hn«ç»ò°µ©O¡H¥i¥H±Ð±Ð¶Ü¡H¤£nµ¥ÅܾÀ¯È¤~ª¾¹D¡CÁÂÁ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 10:33:23²Ä 2725 ½g¦^À³
|
¦ôp «ù¦³¶W¹L50±i ¥xªÑªº³¡¥÷,2022¦~©³¤½§G2b Á{§É¼Æ¾Ú«á½æ,¤~¦³¾÷·|½Òªº¨ì20%¥xÆW®ü¥~©Ò±oµ|. 50±i¥H¤º,À³¸Ó¤£©ö½Ò¨ìµ|. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 10:16:08²Ä 2724 ½g¦^À³
|
®ü¥~Àò§Q¶W¹L ¶W¹L670¸U,n½Ò20%©Ò±oµ|. ¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~06¤ë12¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 108 14,670 0.00 2 1,000-5,000 3,488 7,101,234 3.73 3 5,001-10,000 581 4,704,698 2.47 4 10,001-15,000 210 2,747,416 1.44 5 15,001-20,000 167 3,132,000 1.64 6 20,001-30,000 130 3,337,549 1.75 7 30,001-40,000 55 1,990,952 1.04 8 40,001-50,000 43 2,003,000 1.05 9 50,001-100,000 76 5,390,368 2.83 10 100,001-200,000 34 4,920,483 2.59 11 200,001-400,000 16 4,309,849 2.26 12 400,001-600,000 13 6,285,967 3.30 13 600,001-800,000 2 1,330,000 0.70 14 800,001-1,000,000 3 2,673,155 1.40 15 1,000,001¥H¤W 25 140,013,629 73.70 ¦X¡@p 4,951 189,954,970 100.00 www.tdcc.com.tw/smWeb/QryStockAjax.do ¤£ª¾·¸»ù100% Âà´«ªº¤H ·|½æ. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/16 ¤W¤È 10:15:14²Ä 2723 ½g¦^À³
|
¨ä¹ê·ÀI¯uªº«Ü°ª,¦ý¦Ñ·à¤Íªº¦¨¥»´¶¹M³£°ª(¥]§t«Ü¦h¤jªÑªF),±þ¤F«á®³¦^¨Óªº¤]¤£¦h...¥u¯à³µÛª±¤U¥h¤F... |
|
|
·|û¡G¤ý¸I¥J10148138 µoªí®É¶¡:2020/6/16 ¤W¤È 10:09:35²Ä 2722 ½g¦^À³
|
¶^°±⋯¤å³¹¬Ý§¹®tÂI¶R¤U¥h ³o¼Ë·N«ä¬O¥ý¦©20%¦A¥hÂà¬üªÑ ©Ò¥H¥«³õ¤£¶R³æ¡H ³ÌÃa¥´ºâ¯uªº¬O Á`¤ñÅܾÀ¯È¦n |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/16 ¤W¤È 10:09:15²Ä 2721 ½g¦^À³
|
¦n¤[¨S¦³¶R³o¨È·à±dªºªÑ²¼ ¥»¨Ó·Q¤µ¤Ñ¶RÓ´X±i¨Ó©ñ©ñ ¦ý¥Ø«eÁÙ¶^°±Âꦺ§Ön¤d±i §Ú²q¥i¯à¬O¦³¬Y¨Ç¤jªÑªF ©Òª¾ªº®ø®§§óÆF³q ¤~·|¤£p»ùªº±þ¥X ¥Ø«eÁÙ¬OÆ[±æ¦n¤F ¤ñ¸û¦w¥þ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 10:05:48²Ä 2720 ½g¦^À³
|
www.berich.com.tw/dp/TalkTalk/Talk_Detail.asp?ii=204490&CNpg=1#reply_a eToro(e§ëºÍ)§ë¸ê¶R¶i¡u¬üªÑ¡v¥æ©ö¥þ±¡u0¤âÄò¶O¡v(±q2020/5/18°_) 2020.05.18 ETF§ë¸ê ¥~¶×±Ð¾Ç ¥~¶×¥æ©ö°Ó §ë¸ê¬üªÑ eToro(e§ëºÍ) ¶R¶i¡u¬üªÑ¡v¥æ©ö¥þ±¡u¹s¤âÄò¶O¡v eToro¶R¬üªÑ¹s¤âÄò¶O¸ê°T(³Ì·s§ó·s) ¦b2020/5/18¡AeToro(e§ëºÍ)¦b¨È¬w°Ïµo¥¬¤F¤@¶µ·sªº½Õ¾ã¡G¬üªÑ¥æ©ö§ï¬°0¤âÄò¶O¡C •¤âÄò¶O½Õ¾ã¤º®e¡G¦b¥¼ºb±ì(¥æ©ö®É¿ï¾Üºb±ì¡Ñ1¿)ªº±¡ªp¤U¡A¥¼¨Ó±q®t»ù¦X¬ùCFD§ï¬°¹ê»ÚªÑ²¼¥æ©ö¡A±qì¥ý¶R½æ0.18%ÂI®t¡A§¡§ï¬°¹s¤âÄò¶O(¹sÂI®t¡AÅܦ¨¦¨¥æ¦b¤¤¶¡»ù)¡C •½Õ¾ã½d³ò¡G©ó¨º´µ¹F§JNasdaq¡B¯Ã¬ùÃÒ¥æ©ÒNYSE¤W¥«ªº¬ü°êªÑ²¼¡A¨ä¹ê´N¬O¤j³¡¤À¬üªÑ¡C¦ýn¯d·N«D¬üªÑ(´äªÑ¡B³°ªÑ¡B¼ÚªÑµ¥µ¥)¡A¥H¤ÎETF¡A¨Ã¤£¦b¥»¦¸ªº½Õ¾ã½d³ò¤¤¡C •½Õ¾ã¹ï¶H¡Gì¥ý¦ì©óASICºÊºÞ(¿D¬wÃÒ¨é§ë¸ê©eû·|)©³¤Uªº«È¤á¡A¥H¤Î¥¼¨Ó·sµù¥U¥Î¤á¡C¬J¦³¥Î¤á·|»ÝnñqW-8Benªí®æ¡C •½Õ¾ã¤è¦¡¡G·sµù¥U¥Î¤á«h¤£¥Î°µ¤°»ò¡Aª½±µ´N¬O¬üªÑ¹s¤âÄò¶O¡C즳¥Î¤á¦bÂI¿ïªÑ²¼¤U³æ®É¡A·|¼u¥Xñ¸pW-8Benªí®æ³qª¾¡A¤§«á§Y·|Åܦ¨¹s¤âÄò¶O¡C •¶}©l®É¶¡¡G¥Ø«e¬O©ó2020/5/18¬üªÑ¶}½L«á§Y°µ½Õ¾ã(»ÝñqW8Benªí®æ)¡C ·s¥Î¤á©ó¦¹³sµ²µù¥U§Y¥i¡GeToro¤@¤ÀÄÁ§K¶O±b¸¹µù¥U³sµ²(³Ì·s) eToro¹s¤âÄò¶O ¦Ñ¥Î¤áÂI¿ï¥ô¤@ªÑ²¼¡A¿ïºb±ì¡Ñ1¿±¡ªp¤U´N·|¸õ¥X©³¤U¼uµ¡¡A¤Ä¿ï½T»{§Y¥i¡C ¤Ä¿ï¦P·N«á¡A·|±µµÛ¸õ¥XW-8Benªí®æ¡A·|»Ýnñ¦W¡A¤§«á§Y¥i§¹¦¨¾ãÓ¬yµ{¡C(¦³¨Ç¤H¥H«e´¿Ã±¹LW-8Ben´N¤£¥Î¦A«Ã±¤@¦¸) ¹s¤âÄò¶O¡A·N«ä¬O¬üªÑ³ø»ù·|Åܦ¨¥H¡u¤¤¶¡»ù¡v¨Ó¦¨¥æ ¥Ø«e¦bÅã¥Ü¤W¡AªÑ²¼§AÁÙ¬O·|¬Ý¨ì¤@Ó¡u¶R¤J»ù¡v©M¡u½æ¥X»ù¡v¡A ¦Ó³o¨âÓ»ù®æªº¤¤¶¡È´N¬O¡u¤¤¶¡»ù¡v¡A¶W¥X©Î§C©ó¤¤¶¡»ùªº³¡¤À´N¬O¡uÂI®t¡v¡A¥H©¹¬üªÑÂI®t³æÃä¬O0.09%¡A¤@¶R¤@½æ´N¬O0.18%¡C ¥H©¹¦³ÂI®t®É¡A·|¥Î¶R¤J»ù¶R¶i¡B½æ¥X»ù¨Ó½æ¥X¡A§A¥i¥H§â¥¦·í¦¨¤âÄò¶O¡C ¤£¹L³o¦¸§ïª©«á¡A¥Ø«e´ú¸Õ¤F¤@¤Uµo²{¡A¥¦¬O·|Åܦ¨¡u¥Î¤¤¶¡»ù¦¨¥æ¡v¡A´«¥y¸Ü»¡¡A´N¬O¨S¦³ÂI®t¶O¥Î¡B¹s¤âÄò¶O¤F¡I ¤£¹L¥Ñ©ó¤¶±¤W¥Ø«eÁÙ¨S¿ìªkª½±µÅã¥Ü¤¤¶¡»ù¡A³£¥u¯àÅã¥Ü¶R¤J»ù©M½æ¥X»ù¡A©Ò¥H¥æ©ö®ÉÁÙ¬On¯d·N¤@¤U¡C ¦³»Ýnı±o§x´bªº¤H¡A¥i¥H¥ÎeToroªº¼ÒÀÀ§ë¸ê¥\¯à¥ý°µ´ú¸Õ¡C etoro ¬üªÑ ¹ê»ÚªÑ²¼¥æ©ö ³o¦¸½Õ¾ã¥Dn¬O§t»\¨º´µ¹F§JNasdaq¡B¯Ã¬ùÃÒ¥æ©ÒNYSE¤W¥«ªº¬ü°êªÑ²¼¡A¤£¹L¦]¬°eToro¤WªºªÑ²¼¥]§t¥þ²yªÑ²¼¡A¨ä¥L¼Ú¬w¡B»´ä¡B¤é¥»ªÑ¥«ªº¥ø·~¡A³£¨Ã«D¬üªÑ¡A¦]¦¹¨Ã¥¼²[»\¦b¤º¡C¥t¥~ETF¤]¨S¦³²[»\¦b¥»¦¸ªº½Õ¾ã¤¤¡A¦pªG¬O©ñªÅªÑ²¼¡B¦³¥Îºb±ìªº¥æ©ö¡A¤]³£¤£ºâ¬O¯u¹êªÑ²¼¥æ©ö¡A¨Ã¤£·|¹sÂI®t¡A³o¨Ç³¡¤Àn¯d·N¡C eToro¥æ©öªºªÑ²¼²[»\¥þ²y¡A©x¤è¤å¥ó´£¨ì¦b¥æ©ö¤@¨Ç¼Ú¬wªÑ²¼®É¡A¬Æ¦Ü·|¾A®É§l¦¬«È¤áªº¦Lªáµ|©Mª÷¿Ä¥æ©öµ|¡G¦b^°ê¥i¦A¬Ù0.5% ¡B·Rº¸Äõ1% ¡Bªk°ê0.3% ¡B¸q¤j§Q0.1% ¡A©Ò¥H§Úı±o§Y¨Ï³o¦¸ÁÙ¨S¦³²[»\¥þ²y¡A¦ý¤]ºâ«Ü¼s¤F¡C ¥»¦¸¨ä¥L¼vÅT¡G 1. ¦pªG¬O쥻CFDsªº¥æ©ö¡A¦b¥Ü«e¨Ã¤£·|¦³ÅÜ°Ê¡A¥u¦³¦bªÑ²¼·s¤U³æ®É·|Åܦ¨¹s¤âÄò¶Oªº¹ê»ÚªÑ²¼¥æ©ö¡C 2. ¦p§Ú¬O쥻¨S¦³¦¨¥æªºCFDs±¾³æ¡A¦pªG¶i¦æ¹s¤âÄò¶OªºÂà´«¡A±¾³æ·|³Q¨ú®ø¡A»Ýn«·s³]©w±¾³æ¡C 3. ¥Ø«e·sªº¼Ò¦¡¤U¡A¥Ø«eÆ[¹î¤jP³W«h³£»Pì¥ý¼Ú¬wºÊºÞ¤@P¡C¥Ñ©ó¼Ú¬wºÊºÞ¤Uªº¬üªÑETF¤]¬O¹ê»ÚªÑ²¼¥æ©ö¡A¦ôp¥¼¨Ó³o³¡¤À¤]·|³°Äò±qCFD½Õ¾ã¦¨¹ê»ÚªÑ²¼¡C ¨ä¥L¸ê°Tµ¥«Ý©x¤è¦³µo¥¬§ó·s¦b³°Äò¸É¥R¡A¦pªG§Aªº±b¤á¦³ºÃ°Ý¥i¥Hµn¤J«á¶ñ¼g¤u³æµ¹«ÈªA¬d¸ß¡C ¥»¤å¸ê°T¬°¸ê°T´ú¸Õ¬ö¿ý¡A¤@¤Á¹ê»Ú¸ê°T»P¥æ©ö³W«h¥H©x¤è¤½§i³W«h¬°·Ç¡A¨Ï¥Î«e½Ð¥ý¦Û¦æ½T»{¡C eToro(e§ëºÍ)¬O¥þ²y»â¥ýªºªÀ¸s¥æ©ö¥¥x¤§¤@ eToro¦¨¥ß©ó2007¦~¡A¦ÑÁó¬O¥H¦â¦C¤H¡C ¥¥x¤W¥i¥æ©ö¥]§t¡G¦UºØ«ü¼Æ¡B°Ó«~¡B¥~¶×¡BªÑ²¼¡BETF¡BµêÀÀ³f¹ôµ¥µ¥ªº®t»ù¦X¬ù(CFD)¡A µù¥U¥Î¤á¶W¹L¤d¸U¤H¡A¥æ©ö¶q¦b¥þ²y®t»ù¦X¬ù¥æ©ö°Ó¤¤¯à±Æ¶i«e50¤j¡C §ó¸Ô²Óµû»ù¡B¦w¥þ©Ê¤ÀªR¥i¬Ý³o½g¡G eToro§¹¾ãµû»ù¡BÀuÂI¯ÊÂI¤ÀªR ¥H¤U¶¶±a¸Ñµª¤@¨ÇeToro¥Î¤á±`¨£°ÝÃD»P¬d¸ßºÞ¹D¡G Q: ¬°¤°»òeToro쥻¬O¦b¨Sºb±ì±¡ªp¤U¡A¬O®t»ù¦X¬ùCFDs¤£¬O¹ê»ÚªÑ²¼¡H A: §Ú¦Û¤v¬O¦b2017¦~¶}©l¨Ï¥ÎeToro¡A·í®É¥xÆWÁÙ¨S¤°»ò¤H¨Ï¥Î¡A¦Ó§Ú·í®É¦³Ã±W-8Benªí®æ¡A¥æ©öªº¤]¬O¯u¹êªÑ²¼(¤£¨Ï¥Î¥ô¦óºb±ì)¡C¦ý«á¨Ó¨È¬w¥]§t¥xÆW¶V¨Ó¶V¦h¤H¥Î¡A¥B¨È¬wªº¥Î¤á¬°¤F²Å¦XºÊºÞn¨D¡A´N±q쥻¼Ú¬wºÊºÞ(CySEC)§ï¨ì¿D¬wºÊºÞ(ASIC)©³¤U¡A¦ÓµLºb±ìªº¥æ©ö¤]Åܬ°¥²¶·¨Ï¥ÎCFDs¡C·í®É¦]¬°¤@¨Çºô¤Í¦³´£°Ý¡A§Ú´N¥h¸ß°Ý©x¤è¡A±o¨ìªºµªÂЬO³o¬O¦]¬°n°t¦XºÊºÞn¨D¡C «Ü¦h¥xÆW¥Î¤á³£¬O¦b2018¦~«á¶}©l¨Ï¥Î¡A¦]¦¹ªÑ²¼©ÎETF¥æ©ö³£¬O®t»ù¦X¬ù¡A¹ï¦¹·P¨ì§x´b¡C¤£¹L¦b§Úªº²z¸Ñ¸Ì±¡AeToro쥻¬O¥i¥H¦³¹ê»ÚªÑ²¼¥æ©öªº¡A¦p¦¹¦Ó¤w¡C§Y¨Ï§ï¦¨®t»ù¦X¬ù¥æ©ö¡A¦b·l¯qpºâ¤W¨ä¹ê¤]©M쥻¹ê»ÚªÑ²¼¤@¼Ë¡C ¦ÓeToro¸ò¤@¯ë±Mªù°µ®t»ù¦X¬ù¥æ©ö°Ó²¤¦³¤£¦P¦b©ó¡A¥¦¬O²V©M¤F¤@¯ëªÑ²¼¨é°Ó¡A¦ý¤]¥]§t¦³®t»ù¦X¬ùºb±ìªº·~°È¡C Q: ¤°»ò¬OW-8Benªí®æ¡H ¥ô¦ó¨é°Ó¶}¤á¹Lµ{·|¶ñ¼g¡A¨C®a¨é°Ó³£¤@¼Ë¡A¥NªíÁn©ú§A¤£¬O¬ü°ê¤H¡A¤£¥Î½Ò¬ü°êµ|(¸ê¥»§Q±oµ|)¦Ó¬O¾A¥Î¥~°ê¤Hªºµ|²v(¶ÈªÑ§Qn½Ò¹w¦©µ|)¡C ¤£¶ñ¼g¬O¨S¿ìªk¥æ©ö¬üªÑªº³á¡C ¥i¾\Ū¡G¤°»ò¬OW-8Benªí®æ Q: eToroªºªÑ²¼·|°t®§¶Ü¡H A: ·|¡A°t®§·|ª½±µ¶i¨ì±b¤á¾lÃB¡Aµ|°È»P¤@¯ë¬üªÑ¨é°Ó¤@¼Ë¡C ¥i¾\Ū¡GeToroªº²{ª÷ªÑ§Q°t®§«ç»ò¬d¸ß¡H Q: ¤£¦PºÊºÞ¾÷ºc¦³¤°»ò®t§O¡H ¹ï©ó¤£¦P¦a°Ïªº¥Î¤á¡A·|¦³¤£¦PªººÊºÞ¾÷ºc°µºÊºÞ¡C¨é°Ó¦b·í¦a»Ýn²Å¦XºÊºÞ³W©w¡C·íµM¤]¦³¨Ç°ê®a¦³±Æ¥L©Ê¡A¨Ò¦p¬ü°ê¬Y¨Ç¦{¬F©²³W©w·í¦a¬ü°ê¤H¤£¯à¶}«D¬ü°ê¥»¤gªº¨é°Ó(µ|°È¦Ò¶q)¡C ¥t¥~¤£¦PºÊºÞ¾÷ºc¤¹³\ªººb±ì°ª§C¡BÁ|¿ì¬¡°Ê¡A³o¨Ç¤]³£»Ýn²Å¦XºÊºÞ¾÷ºcªº³W«h¡A©Ò¥H¹L©¹¥u¦³¨È¬w·s¥Î¤á¦³·s¬¡°Ê¡A¤Ï¦Ó«Ü¦hì¥ý¼Ú¬wºÊºÞ¥Î¤á¨S¦³¤°»ò¯S§OªºÀu´f¬¡°Ê¡C ¥HeToro¨Ó»¡¡A¥Ø«e±`¨£ºÊºÞ¦³^°êFCAºÊºÞ¡B¼Ú¬w¶ë®ú¸ô´µCySECºÊºÞ¡B¿D¬wÃҺʷ|ASICºÊºÞ¡C ³o³¡¤À§Ú¨S¦³¹ê»Ú´ú¸Õ¹L¡A¥H«e¬OFCAºÊºÞªº¤âÄò¶O·|²¤§C¤@ÂI¡A¦ý¾Ú»¡¥\¯à©M°Ó«~·|¤Ö«Ü¦h¡C¦b2020/5/18½Õ¾ã¥H«á¡A¥Ø«e¤TªÌ¤w¸g¨S¦³¤Ó¤j®t²§¡A¥¼¨ÓÀ³¸Ó·|³v¨BÁͩ󧹥þ¤@P¡C eToroªº¥Î¤á¥i¥H¥Ó½Ð´«ºÊºÞ¡A¦ý®Ú¾Úºô¤Í¸gÅç¦^õX¡A¤£¤@©w·|³q¹L´N¬O¤F¡A §ÚÓ¤H»{¬°¥H²{¶¥¬q¨Ó»¡¡A¦UºÊºÞ´X¥G¨S¤Ó¤j®t²§¡A¤Ï¦Ó¼Ú¬wºÊºÞ´X¥G¨S¦³¤°»òÀu´f¬¡°Ê¡A¨ä¹ê¨Ã¤£¥²n¡C Q: §A±ÀÂËeToro¶Ü¡HÁÙ¦³±ÀÂË¥Îþ®a¨é°Ó¡H A: §Úı±o¨é°Ó¬O§ë¸ê¸Ì±¼vÅT¨S¨º»ò¤jªº¤@³¡¤À¡A¦]¬°¥un¬O³W¼Ò°÷¤jªº¨é°Ó¨ä¹ê³£¤j¦P¤p²§¡B¶O¥Î¤]³£«Ü§C¡C¨é°Ó¥u¬O¶}©l§ë¸ê²Ä¤@¨B¡AÃöª`§ë¸ê¤èªk¤~¬O«ÂI¡AÀH«K¤@Ó§ë¸ê¤èªk¿ù»~¼vÅT´N«Ü¥¨¤j¡C §Ú¦Û¤v¿ï¾Ü¨é°Ó¥Dn¬O¬Ý¦Û¤v¥Îªº¬O§_²ßºD¶¶¤â¡B¹ïªA°È¬O§_º¡·N²Å¦X¦Û¤v»Ý¨D¡A¤£º¡·N´N´«¡C eToroªºÀu¶Õ¦b©ó¤¶±Â²³æ¡B·s¤â«D±`®e©ö¤Jªù¤W¤â¡B¦³¥þ²yªº°Ó«~¡B¶O¥Î§C¬üªÑ¹s¤âÄò¶O¡B¥i¥æ©ö¤p¼ÆÂI³æ¦ìªº«ùªÑ¡B¤Jª÷¦¨¥»§C¡C¯ÊÂI«h¬O¨S¦³©Ò¦³¼Ðªº³£¦³¡C §Ú¦Û¤v¦³¦h®a¨é°Óªº¬üªÑ±b¤á¡AeToroÓ¤H¨Ï¥Î¤U¨Óı±oµû»ù«D±`¤£¿ù¡A·íµM³o¤£¤@©w¾A¦X§A¡A«Øij¦Û¦æÅéÅç§PÂ_¡C «Øij§A¥i¥H§K¶O¶}¤@Ó¼ÒÀÀ±b¤á¼ô±xÅéÅ礶±¡A¦A§PÂ_¬O§_¾A¦X¦Û¤v¨Ï¥Î¡C¥H¤U¤]ªþ¤W±`¥Îªº¦U¤j¬üªÑ¨é°Ó¤ñ¸û¡C eToro¼ÒÀÀ±b¤á¤@¤ÀÄÁµù¥U¶}¤á³sµ² §K¶O§Ö³tµù¥U¤@Ó10¸U¬üª÷ªºeToro§ë¸ê¼ÒÀÀ±b¤á(¹Ï¸Ñ±Ð¾Ç) ¬üªÑ§ë¸ê¶}¤á±`¥Î¨é°ÓTop5¤ñ¸û Q: ¨Ï¥ÎeToro«e¦³¨ä¥L«Øij¶Ü¡H A: ·s¤â«Øij³£¥ý¥Î¼ÒÀÀ¥æ©ö¥\¯à¼ô±x¤¶±¡A¤§«e¦beToroªºFB°Q½×ªÀ¹Î¸Ì±`±`¦³·s¤â¦]¬°¤£¼ô±x¤¶±°µ¿ù¥æ©ö (·Q¶R¶i«oÂI¿ï¦¨½æ¥X¡B¤£¤p¤ß³]©wÅܦ¨ºb±ì¥æ©ö¡B¤U¿ù³æ¡B³]¿ù°±·l°±§Qµ¥µ¥)¡A¤£ºÞ§A¥¼¨Ó¥Îþ®a¨é°Ó¡A³o¨Ç°ò¥»°ÝÃDºÉ¶q¥ý¸Ñ¨M¤£n·d¿ù¡C¥i¾\Ū¡GeToro¤U³æ¥æ©ö±Ð¾Ç |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 10:01:01²Ä 2719 ½g¦^À³
|
¤°»ò¬O¡u½Æ©e°U¡v¡HªÑ²¼¤âÄò¶O«ç»òºâ¡H(¬üªÑ¡BETF) 2018.12.05 §ë¸ê²z°]±M¦³¦Wµü §ë¸ê¬üªÑ ·Q§ë¸ê¤@¨Ç¬üªÑ¡A¨Ò¦pAmazon¡BGoogle³o¨Ç¤½¥qªºªÑ²¼¡A °£¤F¶}®ü¥~ªºÃÒ¨é±b¤á¥H¥~¡A³z¹L°ê¤ºªÑ²¼¨é°Ó½Æ©e°U¤]¬O¤@ºØ¶R¶i¤è¦¡¡C ³o½g¤å³¹¥«³õ¥ý¥Í¾ã²z½Æ©e°U±`¹J¨ìªº°ÝÃD¡A ¨ä¤¤¥]§t³Ì«nªº¤âÄò¶O²v«ç»òpºâ¡C 1. ¤°»ò¬O½Æ©e°U¡H 2. n«ç»ò°µ½Æ©e°U¤U³æ¶R®ü¥~ªÑ²¼¡H 3. ½Æ©e°Uªº¤âÄò¶O¤Î¦UºØ¶O¥Î«ç»òpºâ¡H 4. ½Æ©e°U¥æ©önª`·Nªº¨Æ±¡¡H 5. ½Æ©e°UªºÀu¯ÊÂI¤ÀªR¡H Ä~Äò©¹¤U¬Ý¡K 1. ¤°»ò¬O½Æ©e°U (Sub-brokerage)¡H ¡u½Æ©e°U¡vªº§¹¾ãºÙ©I¥s°µ¡u¨ü°U¶R½æ¥~°ê¦³»ùÃÒ¨é·~°È¡v ²³æ¨Ó»¡¡A´N¬O³z¹L°ê¤ºªº¨é°Ó¥h®ü¥~À°§A¤U³æ¶R¶iªÑ²¼©ÎETF¡C (¤]¥i¥H¶R®ü¥~°òª÷¡A¦ý°òª÷¤£«Øij¦bªÑ²¼¨é°Ó¶R¡A³z¹L°òª÷¥¥x¶R¤ñ¸û¬Ù¤âÄò¶O¡C) ¦b¥xÆW¶R¥xªÑ®É¡AªÑ²¼¨é°Ó·|©M³z¹L¥xÆWªºÃÒ¥æ©Ò¥h¤U³æ¶RªÑ²¼¡A ¦P¼Ëªº¡A ¶R®ü¥~ªÑ²¼¡A´N¬O¨é°Ó¥h°ê¥~ªº¥æ©ö©Ò(¨Ò¦p¡G¯Ã¬ùÃÒ¥æ©Ò¡B¨º´µ¹F§J¥æ©ö©Ò)¥h¤U³æ¶R¶i§Anªº¼Ðªº¡C 2. n«ç»ò°µ½Æ©e°U¤U³æ¶R®ü¥~ªÑ²¼¡H ¤j¦h¼ÆªÑ²¼¨é°Ó³£¦³½Æ©e°UªºªA°È¡A ¦pªG§AÁÙ¨S¶}¤á¡A¥i¾\Ū¡G³Ì·sªÑ²¼¶}¤áÀu´f±ÀÂ˨é°Ó³o½g¤å³¹ ¶}¤á©Î¥Ó½Ð½Æ©e°U¦P¼Ën±aÂùÃÒ¥ó¡A ®t§O¦b©ó»È¦æ¤áÀY°£¤F°ê¤º¥x¹ô¦s´Ú±b¤á¡A³q±`ÁÙn¦³¥~¹ô¦s´Ú±b¤á (¨S¦³»È¦æªº¸ÜÀç·~û³q±`·|À°§A¤¶²Ð¤@Ó¥L̦³°t¦Xªº»È¦æ¡A©¡®É¤@°_¶}¤á)¡C ¶}§¹¤á¤§«á¡A ¨é°Ó³nÅé³q±`³£¦³¤ä´©¥i¥H¬Ý®ü¥~ªÑ²¼ªº¸ê°T (¦³ªº¨é°Ó¦³¦n´XÓ³nÅé¡An½T»{¤@¤U¬Oþ¤@Ó¦³¤ä´©®ü¥~ªÑ²¼)¡A ±µµÛ§A·|»Ýn¶}³q½Æ©e°U¥æ©öªºªA°È¡C ¦]¬°¦U®a¨é°Óªº¾÷¨î²¤»P¶O¥Î¦³¤£¦P¡A¥æ©ö«e³Ì¦n°Ý¤@¤U¡A ¦³ªÑ²¼±b¤á©Î¶}¦n¤á¤§«á¡A¥´¹q¸Ü¥hµ¹Àç·~û©Î¤½¥q«ÈªA»¡§An½Æ©e°U¥æ©ö§Y¥i¡C 3. ½Æ©e°Uªº¤âÄò¶O¤Î¦UºØ¶O¥Î«ç»òpºâ¡H ½Æ©e°U¤âÄò¶O¸ò¶R½æ¥xªÑ¦³¤°»ò®t²§¡H ¦]¬°¤j³¡¤À¤H½Æ©e°U³£¬O¥H¬üªÑ¬°¥D¡A¥H¤U¥H¤é²±ÃҨ骺¥æ©ö¬°¨Ò¡A ¥H¤U¬O¤@¨Ç½Æ©e°U®É¥i¯à²£¥Íªº¦¨¥»¶O¥Î¡G 1. ¤âÄò¶O¡G¤U³æª÷ÃBªº0.5%(¥¼§é¦©ªº¼Æ¦r¡A§é¦©¥i¥H½Í)¡A³Ì§CUSD 37.9¬ü¤¸ 2. ¥æ©ö©Ò¶O(¥i©¿²¤)¡G¥æ©ö»ùª÷¤§ 0.0013%¡A³Ì§C¬° USD 0.01¬ü¤¸(½æ¥X®É¦¬¨ú) 3. TAF ¶O¥Î(¥i©¿²¤)¡G¨CªÑ¦¬¨ú USD 0.000119¡A³Ì§C¬° USD 0.01¡A³Ì°ª¬° USD 5.95 (½æ¥X®É¦¬¨ú 4. ²{ª÷ªÑ§Qµ|¡G¬üªÑ©ÎETF¦pªG¦³°t²{ª÷ªÑ§Q»Ý¦©30%ªºµ|ª÷¡A³oÓ¬O¶]¤£±¼ªº ³Æµù1. TAF(trading ative fee)¡G¥æ©ö¬¡°Ê¶O¡A¥Iµ¹¬ü°êª÷¿ÄºÊ·þ§½ªº¶O¥Î ³Æµù2. ¶×¼·ªÑ²¼¡V>³o¸Ì¨S¦³¦C¥X¨Ó¡A¦pªG§A¦³®ü¥~ªÑ²¼nÂà´«¨ì¤£¦P¨é°Óªº±b¤á¥i¥H¨Ï¥Î¶×¼·ªÑ²¼¡A»Ýn¥I¤@µ§³B²z¶O ¦Ü©óþ¤@®a³Ì«K©y¡A ¨ä¹ê¥«³õ¥ý¥Í°Ý¤F¤@¤U¡A¥Ø«e¦U®a¨ä¹ê³£®t¤£¦h¡C ²¦³º¦pªG§A¬O·Q¬Ù¤âÄò¶O¡A ¥i¯à´N·|¦Ò¼{®ü¥~ªº¤@¨Ç¨é°Ó°µ¥æ©ö¡C 4. ½Æ©e°U¥æ©önª`·Nªº¨Æ±¡¡H ¦³´X¶µ¤£¦PÂI¡A ¬O®ü¥~¥æ©ö©M¥xªÑ¥æ©ö¤£¦Pªº¦a¤è»Ýn¯d·N¡G 1. ®ü¥~ªÑ²¼¥æ©ö®É¶¡¤£¦P ¨Ò¦p¬üªÑ¶}½L®É¶¡¬O21:30-4:00(®L¥O®É¶¡)¡B22:30-5:00(¥V¥O®É¶¡) ¥t¥~nª`·N¡uº²Â_¾÷¨î¡v¡A ¦]¬°«Ü¦h®ü¥~¥«³õ¬O¨S¦³º¦¶^´T¨î¡A ·íº¦¶^´T¤Ó¤j®É(¨Ò¦p¤@¤Ñ¤º¶W¹L10%)¡A®ü¥~·|±j¨î¼È°±¥æ©ö¡Aµ¥¹L¤@¬q®É¶¡¤~¯à¶R½æ¡C 2. ¶R½æ³æ¦ì¼Æ¤£¦P ¥xÆW¶RªÑ²¼³q±`¬O¤@¦¸¶R¤@±i(1000ªÑ)¡A ¦ý®ü¥~¬O¤@¦¸¶R1ªÑ©Î100ªÑ 3. ¥æ³Î¹ô§O¤£¦P ¥Î¥x¹ô¥æ³Î©Î¬O¥Î¬ü¤¸¥æ³Î¡H ³o¨M©w§A³Ì«á±b¤áªº¹ô§O¡A¨Æ¥ý¨M©w¦n§Y¥i¡A ·|¥Î½Æ©e°Uªº¤H³\¦h³£¬O¥Î¥x¹ô¥æ³Î¡C 4. «H¥Î¥æ©ö¤£¦P ³z¹L¥xÆW¨é°Ó¥h°µ®ü¥~½Æ©e°U¡A ³q±`³£¤£¯à«H¥Î¥æ©ö(¿Ä¸ê¡B¿Ä¨é)¡C 5. ½Æ©e°UªºÀu¯ÊÂI¤ÀªR¡H ½Æ©e°UªºÀuÂI¡G¤ñ¸û¿Ë¤Á(?) ¦w¥þ©Ê°ª¡B¼ô±xªºÃÒ¨é©M»È¦æ¡B¥æ©ö³nÅé¼ô±x¡A ¤j®a³Ì¾á¤ßªº³q±`¬O¤H¥X¤F·N¥~®aÄÝ®e©ö¨ú¦^¸êª÷¡C ½Æ©e°Uªº¯ÊÂI¡G¶O¥Î°ª ©M®ü¥~¨é°Ó¤ñ¨Ó»¡ªº½T¤ñ¸û¶Q¡A ¦pªG¸êª÷¤jªº¤H¤ñ¸û¨S°ÝÃD¡A ¦ý¸êª÷¤p¡A¥Î½Æ©e°U¤âÄò¶O«Ü¥i¯à·|«D±`©ù¶Q¡C §Ö³tÁ`µ²¡GÀ³¸Ón¥Î½Æ©e°U¶Ü¡H §Ú¨£¹L¤@¨Ç«Ü¦³¿úªº§ë¸ê¤H¬O¥Î½Æ©e°U¦b°µªø½u¾Þ§@¡A ¦]¬°ªø´Á¨Ó»¡¨º¤@¨Ç¤âÄò¶O¬O¯à±µ¨üªº¡C(¦ýµu½u¤£¦æ) ¤]¦³¤@¨Ç¾÷ºc§ë¸ê¤H¡A¤â¤W¸êª÷«Ü¤j¦Ó¥B¬O§O¤Hªº¿ú¡A ¨º´N¤£·|³z¹L½Æ©e°U¡A¦Ó¬O¥h§ä¦¨¥»§C¥B¾Þ§@¤è«Kªº¨é°Ó¤U³æ¡C ¬O§_n¥Î½Æ©e°U¡A¥«³õ¥ý¥Í»{¬°¨£¤¯¨£´¼¡A ³\¦h°ê¥~¥þ²y¨é°Ó³W¼Ò¨ä¹ê³£»·¤j¹L¥xÆW¥»¤g¨é°Ó¡A¯àµ¹ªºÀu´f¤]¤£¤Ö¡A¤]¦³¤¤¤å«ÈªA¡C ¦ý¦]¬°¥xÆWªk«ß¨S¶}©ñ¡A©Ò¥H¤@¦ý¦³¸U¤@¤]¨S¦³«O»Ù¡A¦³°ÝÃD¥u¯à¾a¦Û¤v¥h³B²z¡C rich01.com/what-sub-brokerage/ |
|
|
·|û¡GNancy10149567 µoªí®É¶¡:2020/6/16 ¤W¤È 09:35:05²Ä 2718 ½g¦^À³
|
Âà´«ADR·|«Ü³Â·Ð¶Ü¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 08:20:37²Ä 2717 ½g¦^À³
|
ªvÀø¤¤-««×AD¼Ð¹v¦U·sÃÄÁ{§Éªº¹ï·Ó组¡A¬Ò¥Î«D¼Ð¹vÃĪ«©Î¨ä¥L¥ú·Óª«²zÀøªk¡C ©Ò¥H¦U预«á«ü¼Ð¡A¼Ð¹vÀø®Ä¬ÒÀu©ó¹ï·Ó组2-4¿¡A PÈ<0.001¡A¨úÃĵý¡AYµL¦w©Ê°ÝÃD¡A¹LÃöÉó²v°ª¡C ¦ý¦b¬ü°ê/¥xÆWªk¥O 规©w«K©yªºÃÄ¥ý¥Î¡AµL®Ä«á¤~¯à¥Î°ª»ù¼Ð¡A¹vÃÄ¡C ¦]¦¹¹³Dupilumab ¤]¬O¡C ¬ü°ê¥Ø«e¤¤¤@««×AD¯f±w¡Aªñ¤z¸U¤H¡A¦ÓDupliumab,¤w½æ2¦~¦h¡A¥þ²y¥u²Öp°â¥Xªñ20¸U¤H¡C ¦Xxx¡AOx101¡A©Ò¨Ï¥Î¤TºØÃÄ¡A§@¬°¹ï·Ó组¡C ¤@¼Ë«K©yªºÃÄ¥ý¥Î¡C ¥«³õ36»õ¬ü¤¸¡A¥Ø«e¬O«K©yªº¥ÎÃĬ°°ò¦¡C ¯à·m¨ì¦h¤Ö¥«³õ¡H ¤£ª¾¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/16 ¤W¤È 07:49:28²Ä 2716 ½g¦^À³
|
¥i¥Hªø§ë¨ì2022¦~ªº¤j¤j¡A«Øij¸ò¤jªÑªFÂà´«ADR¡A¨É¨ü¦¨¥\ªG¹ê¡A¥Ø¼Ð»ù12-14e¬ü¤¸¡Aµ´¹ï¬O¦X²zªº°ê»Ú¨ÖÁʦ污¡C ¤µ¦~¦~©³¡A¥²须¤½¶}¨p¶Ò¡A¥h¦~11¤ë©³ªºÀ¸«ºt¤@¦¸ªºÉó·|¤j¡C ·¸»ù90´X%¡Aªº¨Mµ¦¡I¡I¡I¡I |
|
|
·|û¡GJCY10146705 µoªí®É¶¡:2020/6/16 ¤W¤È 01:58:27²Ä 2715 ½g¦^À³
|
·¸»ù«Ü¦hC ¤£¶û³Â·Ðªº¸ÜÀ³¸Ó·|«Ü¤H¶i³õ®M§Q ¦ý¦³Ó°ÝÃD¬O¤£¾å±oÂà´«ªº®Éµ{·|¦h¤[ |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2020/6/15 ¤U¤È 10:00:19²Ä 2714 ½g¦^À³
|
¬üªÑªº¥æ©ö¬O¥H1ªÑ¬°³æ¦ì¡A©Ò¥H¤£¤@©wn¬O5ªº¿¼Æªº±i¼Æ¡A¥xªÑ,1±i,µ¥¦PADR,200ªÑ ³o¼Ë»¡ªk¥¿½T§a¡I¡H |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/15 ¤U¤È 08:41:45²Ä 2713 ½g¦^À³
|
¤Ñ©R¤j¬O¹ïªº¡A¦]¬°ÁÙ¬O¤@¤dªÑ¡A¥u¬O¤±i¥xªÑ´«¤@±i¬üADR... ÁÂÁ¤ѩR¤jªº²Óºâ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 08:40:27²Ä 2712 ½g¦^À³
|
·¸»ù87% |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/15 ¤U¤È 08:35:44²Ä 2711 ½g¦^À³
|
¤Ñ©R¤Kªººâªk¬O¥¿½Tªº ½Ð°Ý¤j®a ¦b¤¤¤î¥æ©ö«e¶R¨ìªºªÑ²¼³£¦³Åv§QÂà´«¦¨¬üªÑADR¡H ·|¤£·|¦³®M§Qªº¸êª÷¶i¨Ó¡H ¡]¦]¬°¥H¥Ø«eÂà´«»ù¡A¦pªG¨Sºâ¿ù»ù®t¶W¹L¤K¦¨¡^ ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/15 ¤U¤È 08:13:06²Ä 2710 ½g¦^À³
|
©t¨à¤j ¤£±o¤£»¡±zªººâ¼Æ¦³ÂI°ÝÃD ¤Ñ©R¤jºâªº¤~¬O¥¿½Tªº°Õ ´«¦¨¬üªÑADR¦^¥»¾÷²v¤ñ«Ý¦b¥xªÑ°ª±o¦h ¥u¬On¥ý¥h¶}¤á©MÂà´«¹Lµ{¥i¯à·|Ácº¾¤@ÂI ¤W¯ZÁÙn½Ð°²¥h§Ë |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 08:08:24²Ä 2709 ½g¦^À³
|
ADR»ù®æ*30(¶×²v)*20*1000ªÑ(Âà´«¦¨ADR«á)=4,000,000, ¬O¬üª÷6.7/ªÑ...... ¥xªÑ100±i=100*1000ªÑ ¥i´«ADR 100*1000/5=20*1000ªÑ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 08:01:10²Ä 2708 ½g¦^À³
|
Y±zªº¥xªÑ¨CªÑ¥§¡¦¨¥»40¶ô(³o»ù®æ¬O¤j¶q®M¨c°Ï), ¬ù40/6=6.7 --¬ü¤¸/ªÑ ADR 6.7¬ü¤¸/ªÑ=¥xªÑ40¤¸/ªÑ 6.7*30/5=40 ----------------------- ADR 33.3¬ü¤¸*30¶×²v/5=198¤¸/ªÑ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/15 ¤U¤È 07:42:58²Ä 2707 ½g¦^À³
|
Y±zªº¥xªÑ¨CªÑ¥§¡¦¨¥»40¶ô(³o»ù®æ¬O¤j¶q®M¨c°Ï),100±iµ¥©ó4000000 ¥¼¨ÓADR»ù®æ»Ý¤Wº¦¨ì¦h¤Ö¤~·l¯q¨â¥?(¦p¤Ñ©R¤j»¡,µL¸ê¥»§Q±oµ|°ÝÃDªº±¡§Î¤U) ADR»ù®æ*30(¶×²v)*20±i*200ªÑ(Âà´«¦¨ADR«á)=4000000, ¨Sºâ¿ùÀ³¸Ó¬O¬üª÷33.33/ªÑ......¤j®an§V¤OÄ~Äòµ¥«Ý¤F 6/29¥xÆW³Ì«áªÑªF·|½Ð°Ý¤j®a·|¥h°Ñ¥[¶Ü ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/6/15 ¤U¤È 07:00:11²Ä 2706 ½g¦^À³
|
¶^²`¥[¤W¤µ¤Ñªº¤j§Q¦h¡AªÑªFªº¾á¤ßªº°ÝÃD¸Ñ°£¤F¡A¯uªº¬O«Üt³d¥ôªº¥Í§Þ¤½¥q¡A¾À¯È¥i¯àÅܶÀª÷¡A¥u©Ç¦Û¤v²Â¤W¬P´Á¥|¤¨S¦³¦A¥[½X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 05:59:21²Ä 2705 ½g¦^À³
|
¥xÆW¤H¡A§ë¸ê¬üªÑªº¸ê¥»§Q±oµ|¬°¹s¡A§Kµ|¡C¡X¡X-¤j§Q¦h¡A (©M¥xÆW¤@¼Ë¡A¶R½æ¥xªÑ»ù®t§Kµ|¡C) ¡X¡X- ¥u¼ ¤U¥xÆW®ü¥~©Ò±oµ|¡C ³Ì°ª670¸U¦©©èÃB¡A¥B¥i¦X¨Ö°ê¤º¦¬¤J³øµ|¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 05:38:56²Ä 2704 ½g¦^À³
|
¬üªÑ§ë¸ê¡n°t®§ªº²{ª÷ªÑ§Qµ|ª÷n«ç»òpºâ¡H30%¹w¦©µ|¬O¤°»ò¡H(¬ü°êªÑ²¼¡BETF) 2019.03.28 §ë¸ê¬üªÑ ¤§«e¦³³\¦hŪªÌ¸ß°Ý¥«³õ¥ý¥ÍÃö©ó§ë¸ê¬ü°êªÑ²¼©ÎETF®É¡A ³\¦h¤H·|¹J¨ì¡uµ|ª÷¡v¤Wªº°ÝÃD¡A ¨ä¤¤³Ì«nªº´N¬O²{ª÷ªÑ§Q(dividend)ªºªÑ®§n«ç»ò½Òµ|¡A ³o½g¤å³¹¥«³õ¥ý¥Í·|¾ã²z§ë¸ê¬üªÑ·|¹J¨ìþ¨Çµ|°È°ÝÃD¡B¸Ó¦p¦ópºâ¡B¹ï§ë¸êªº¼vÅT¡C 1. §ë¸ê¬ü°êªÑ²¼®É°t®§¦p¦ó½Òµ|¡H¥xÆWn³øµ|¶Ü¡H 2. ¬üªÑ°t®§30%ªºµ|¬O«ç»òpºâ¡H 3. ¬O§_¥i¥H¸`µ|°hµ|¡H 4. ¨ä¥L¨Ò¥~±¡ªpªºµ|°È 1. §ë¸ê¬ü°êªÑ²¼®É°t®§¦p¦ó½Òµ|¡H¥xÆWn³øµ|¶Ü¡H º¥ýn´£ªº¬O¡A¬ü°ê¬O¤@Ó·|Âù«½Òµ|ªº°ê®a(¬ü°ê©M¥xÆW§A³£n¦U³Q½Ò¤@¦¸µ|) ³oÂI¤£¥u¬O¤ÏÀ³¦b§ë¸êªÑ²¼¤W¡A¦b¦U¦æ¦U·~¤]³£·|¹J¨ì¡C ¤£¹L©¯¦n¥xÆW¥Ø«e¹ï®ü¥~©Ò±oªº½Òµ|¨Ã¤£«¡A ¦p¹ê¥Ó³øªº¸Ü°£«D¬O¤j¤á¤£µM¥xÆW³oÃä³q±`¤£·|³Q½Ò¨ìµ|¡A ¦]¦¹§ë¸ê®ü¥~®É³q±`¥u¦³¬ü°ê¨ºÃä·|³Q½Òµ|¡C ¬ü°ê¡G¬ü°êªÑ²¼¤ÎETFµo©ñ²{ª÷ªÑ§Q®É¹w¦©30%µ|´Ú µL½×¬O³z¹L®ü¥~¬üªÑ¨é°Ó¤U³æ¡A©Î¬O³z¹L°ê¤º¨é°Ó½Æ©e°U¡A ¶R¶i¬ü°êªÑ²¼¡BªÑ²¼ETF¡B¶Å¨éETFµ¥µ¥¡A ¥unµo©ñ²{ª÷ªÑ§Q³£n³Q½Òµ|(¬ü°ê¨S¦³ªÑ²¼ªÑ§Q)¡A ¥Ø«e½Òµ|¬O·|¹w¦©30%ªºµ|´Ú(30%³o¼Æ¦r·|®Ú¾Ú·í®Éª¬ªpÅÜ°Ê¡A¦ý¤jP¬O30%~40%³oÓ½d³ò)¡A µ|²v¤]¬O30%¡A¤£¹L¦³¨Ç¨Ò¥~±¡ªp¤£·|½Ò¨ìµ|ªº³¡¥÷¨Æ«á¹L¤@¬q®É¶¡·|°h¦^¡A ¥t¥~¦³¨Ç¨é°Ó·|À°§A°h¤@¨Çµ|(¨Ò¦p¡GFirstrade¡B TD Ameritrade)¡A¦ý¨Ã¤£¬O¥þÃB¡A¥i¯à¥u¦³¤p³¡¤À¡C ¥i¾\Ū¡G 1. ¥xÆW¤H³Ì±`¶}¤áªºTop5¬üªÑ¨é°Ó 2. ¤°»ò¬O½Æ©e°U¥æ©ö? ¥xÆW¡G¦¬¨ì°t®§«á¨C¦~©Ò±oµ|»Ýn¥Ó³ø®ü¥~¦¬¤J ¥xÆW¥Ø«e®ü¥~©Ò±o¤]»Ýn½Òµ|¡A¤£¹Lpºâ¤è¦¡¸ò°ê¤º©Ò±o¤£¤@¼Ë¡A ³o³¡¤À¦³«Ü°ªªº§K¥Ó³øÃB(100¸U¥x¹ô¥H¤U§K¥Ó³ø)¡A¥H¤Î«Ü°ªªº¦©©èÃB(670¸U¦©©èÃB)¡A ·í§A®ü¥~¨C¦~ªº¦¬¤J¤j©ó100¸U®É´Nn¶}©l¯d·N³o¤@¶ô¥Ó³ø(¦³¥Ó³ø¤£¤@©w¥Nªínúµ|)¡C nª`·Nªº¬O¡A¦©©èÃB¬Ý¦ü«Ü°ª¦ý¦¬¤J³¡¥÷¤£¬O¥u¦³ºâ®ü¥~¦¬¤J¡A ¦Ó¬O®ü¥~»P°ê¤º¦¬¤J¦X¨Öpºâ¡A ¥t¥~³o³¡¤Àªºµ|ª÷¡A¸ò쥻°ê¤ºªºÓ¤Hºî¦X©Ò±oµ|¥u·|¨ú¨ä¤¤³Ì°ªÈú¥æ¡A ¸gÅç¤W°£«D§A¦~¦¬¤J¹L1000¸U§_«h¤£¤j·|½Ò¨ì³o¤@¶ô¡C Ãö©ó®ü¥~µ|°È¥i¾\Ū¡G®ü¥~¦¬¤J©Ò±oµ|«ç»òpºâ¡H 2. ¬üªÑ°t®§30%ªºµ|¬O«ç»òpºâ¡H ¬ü°ê¹ï²{ª÷ªÑ§Q½Òµ|·|¥ý¹w¦©30%ªºµ|ª÷ ¤ñ¤è»¡²{ª÷ªÑ§Q¦ûÁ`¸ê²£2%¡A¨C100¤¸¦³2¤¸ªÑ§Q¡A¨ä¤¤30%¤]´N¬O0.6¤¸¬Oµ|ª÷¡C ³oÃä½Íªº¬O«D¬ü°ê¤Hªºª¬ªp¡A¦b®ü¥~¨é°Ó¶}¤á®É¬yµ{¤¤³£·|¶ñ¼g¤@ÓW-8Benªí®æ¡A ¥Dn¬O¥Ó©ú§A¨Ã«D¬ü°ê¤H¨¤À¡A©Ò¥H¤£¥Îú¬ü°ê¤@¨Çµ|(¨Ò¦p¸ê¥»§Q±oµ|)¡A ¬ü°êªºµ|°ò¥»´N¬OÀ°§A¹w³]30%¡A¦Ó¥B°t®§®É³£·|¦Û°Ê¹w¦©¡A°£¦¹¤§¥~§A¤£¥Î³B²z¥ô¦óµ|°È¤âÄò¡C 1. §ë¸ê²Õ¦X¤¤¡A«D¬ü°êªº³¡¥÷¤£·|½Òµ|(©Îµ|²v¤£¦P)¡A¦ý»Ýn¥Ó½Ð°hµ|¤~®³ªº¨ì ¤ñ¤è»¡§A§ë¸êªºETF¡A¨ä¤¤¦³«Ü¤j¤@³¡¤Àªº«ùªÑ¬O«D¬ü°êªº¼Ðªº¡A¨Ò¦p¼Ú¬w©Î¤é¥»ªº¼Ðªº¡A ³o¨Ç´N¤£·|½Òµ|¡A¦ý¦]¬°ÁÙ¬O·|¹w¦©30%¡A©Ò¥H¶·¥Ó½Ð°hµ|¤~·|°h¦^¡C §ë¸ê¦b«D¬ü°ê¦a°Ïªº¼Ðªº¡A¤£¦P¦a°Ïµ|²v¤£¦P¡A¨Ò¦p¥xÆW¬O20%¡A^°êU.K.ªºªÑ²¼¬O0%¡A ¥i¾\Ū¡G®ü¥~¦U°êªºªÑ®§¹w¦©µ|²v ¤£¹L¥Ñ©ó¥Ó½Ð°hµ|³Â·Ð¡AÓ¤H¬O¤£«Øij¤@¯ë¤H¥hÁÈ°hµ|¡A«á±·|´£¨ì¡C 2. «Dµù¥U©ó¬ü°êªºETF¡A®Ú¾Úµù¥U°ê®a·|¦³¤£¦Pªºµ|²v ¦³¨Ç¤H·|¬G·N¿ï¾Üµù¥U¦b«D¬ü°ê¡A¦ý§ë¸ê¦b¬ü°êªºETF¡A ¸`¬Ù³¡¥÷µ|°È(¨Ò¦pµù¥U¦b^°êªº¬üªÑETF ¥N¸¹VUSD)¡C ¤£¹L¦]¬°¼vÅTªºª÷ÃB¤£¤j¡A¹ïÁ`¸ê²£¼vÅT¤j·§¦b0.2%¥H¤º¡A«Ü¦h®ÉÔ¨ä¥LÀH«K¤@¨Ç¦¨¥»´N¶W¹L±a¨Óªº¦n³B¡A ¦pªG¤£¬O¸êª÷«D±`¤j(100¸U¬üª÷¥H¤W)¡A©Î§A¥»¨Ó´N¦³¦b¥ÎIBªº¤áÀY¡A¤£µM¤£»Ýn³o»ò³Â·Ð¡C 3. ¬ü°êªº²{ª÷ªÑ§Q´Þ§Q²v¤j·§¸¨¦b2%¤W¤U¡A§Y¨Ï½Òµ|¼vÅT¤]¤£¤j ¬ü°ê¤£¹³¥xÆW¤½¥q³o»ò·Rµo²{ª÷ªÑ§Q¡A¦]¬°¥L̤]ª¾¹D¦Û¤vµ|«Ü«¡A ¤½¥q¸gÀçªÌ³q±`·|¥Î¨ä¥L¾Þ§@¤è¦¡¨ú¥Nµo©ñ²{ª÷ªÑ§Q(¨Ò¦pÁʶR®wÂêѤ§Ãþ)¡C ²{ª÷´Þ§Q²v³q±`¬O1%~2%¤W¤U¡A³\¦hª¾¦W¥ø·~¬Æ¦Ü§¹¥þ¤£°t®§¡C ¦]¦¹1%~2%°t®§ªº30%µ|°È¨C¦~¶È¦ûÁ`¸ê²£0.3%~0.6% ÁöµM¹ï¬Y¨Ç¤H¨Ó»¡³o¼Ë¤£¤Ö¡A¦ý¨ä¹ê¤]¤£¦h¬OÁÙ¥i¥H±µ¨ü¡C ¥i¾\Ū¡G¤°»ò¬O²{ª÷´Þ§Q²v¡H 4. ¤£°Ñ¥[°£Åv®§¡B¿ï¾Ü¤£°t®§ªº§ë¸ê¼Ðªº¡A¥i¥HÁקK³Q½Òµ| ¬üªÑ¦³«Ü¦h¤½¥q¬O¤£°t®§ªº(¨Ò¦p¡G¤Úµá¯Sªºªi§J®L BRK.B)¡A §ë¸ê³oÃþ¼Ðªº¡A¦ÛµM¤]´N¨S¦³µ|°È°ÝÃD¡A¦Ó¥B¥~°ê¤H¤]¤£·|³Q½Ò¸ê¥»§Q±oµ|(ÁÈ»ù®t)¡C ¦Ó¤£°Ñ¥[°£®§¤]¥i¥H¡A¥u¬O¤ñ¸û³Â·Ð¡A ¦]¬°¬ü°ê¸ò¥xÆW¤£¦P¦b©ó°t®§ªºÀW²v«Ü°ª¡A¥xÆW¤@¦~³q±`°t¤@¨â¦¸¡A¬ü°ê¨C¤ë©Î¨C©u°t®§ªº¼Ðªº¤]¬O¦³¡A ¥i¥H¯d·N¤@¤U§Aªº§ë¸ê¼Ðªº°t®§ª¬ªp¡A¦pªG¤£©È³Â·Ð¥i¥H¥Î³oӤ覡¡C ¥i¾\Ū¡G¤£°Ñ¥[°£Åv®§¦p¦ó¸`µ|(¥xÆWª©) 3. ¬O§_¥i¥H¸`µ|°hµ| (Tax Return)¡H ¥ýÁ¿µ²½×¡G¤£«Øij¨«°hµ|¬yµ{ ¦b¬ü°ê³øµ|ºÙ¬° Tax Return¡A¤]´N¬O°hµ|¡Aì¦]¬O¥L̦³³\¦h¹w¦©µ|´Ú¡A©ó³øµ|®É¦A½T»{¥i°h¦^ªº³¡¤À¡C «e±´£¨ìªÑ§QµL½×§A¬O¥ô¦óª¬ªp³£¬O¹w¦©30%ªºµ|ª÷¡A ¦³¤@ºØ¸`µ|¤è¦¡¬O§A¥D°Ê¥Ó³ø¡A´N¥i¥H®Ú¾Ú¹ê»Ú¦¬¤J»P§Kµ|ÃB¥h¨«½Òµ|¬yµ{¡A³Ì«á·|±N¦h½Òªºµ|°hµ¹§A¡C ¦Ó¥B³q±`§A¥un¥h¥Ó½Ð¡A´N¤@©w·|³q¹L¡A¦]¬°¬ü°êªº¨î«×¬O·|Àu¥ý«H¥ô§Aªº¥Ó³ø¡C ¬°¤°»ò¤£«Øij°hµ|¡H ì¦]1. ¯à°hªºª÷ÃB¦³¡A°hµ|¦¨¥»°ª ¹ï¬ü°ê¨Ó»¡¡A¥~°ê¤Hªº¹w¦©µ|(NRA withholding)¬O¥~°ê¤H¥»¨Ó´Nnúªºµ|¡A ´«¨Óªº¦n³B¬O¥~°ê¤H¸ê¥»§Q±o(Capital Gains)§Kµ|¡A¤]´N¬O¶R§C½æ°ªªº»ù®t§Kµ|¡C ºô¸ô¤W¤j¦h¼Æ¤H¹L©¹¦b¥Ó½Ð°hµ|³£¬O¥Î¡u¹w¦©µ|ÃB§C©ó§Kµ|ÃB¡v§@¬°°hµ|²z¥Ñ¡A§Kµ|ÃB¬O$4050¬üª÷¡A ¤ñ¤è»¡§A³Q¹w¦©¤F1000¬üª÷ªºªÑ®§¡A¦ý³o¼Æ¦r§C©ó§Kµ|ÃB¡A¦]¦¹³q±`¥i¥H¦¨¥\¥Ó½Ð°hµ|¡C ¤£¹L¬ü°ê©ó¤t´¶¤W¥ô«á¡A2018¦~¤w¸g¨ú®øÓ¤H§Kµ|ÃB$4050¤¸¡A ¥Ø«e¤w¸gµLªk¥Î§Kµ|ÃB³oÓ²z¥Ñ¥D±i°hµ|¡A¤§«á¥Î§Oªº²z¥Ñ¥Ó½Ð¬O§_¯à¹L¨Ã¤£½T©w¡A¯à°hªºª÷ÃB¤]¦³¡C(¦pªG§A¦³ªñ¦~¦¨¥\°hµ|ªº¸gÅç¤]Åwªï©M§Ú¤À¨É) ¥Ó½Ð¹Lµ{¤]¦³¦¨¥»¡A¦pªG¬O¦Û¤v¶ñ¤å¥ó¡B±H°e¦¨¥»¥i¯à¤@¨â¤d¥ª¥k¡A¥H¤Î®É¶¡¦¨¥»¤]¬O³Â·Ð¡A ¥t¥~¥X¿ùªº¸Ü³Â·Ð§ó¤j¡A ¦pªG§ä·|p®vÀ°§A¶ñ¼g¥Ó³ø¡A¤§«eÅ¥¨ì¦æ±¡»ù¥i¯àn600¬üª÷¥H¤W¡A¼ô±x¬ü°êÓ¤Hµ|ªkªº·|p®v¤]¤£¦h¡C ¥H¬ü°ê§C°t®§²v¨Ó»¡¡A³Q¹w¦©1000¬üª÷ªºµ|¡A¤j·§n§ë¸ê500¸U¥x¹ô¥H¤W¡A°hµ|¤]¤£¨£±o¯à¥þÃB®³¦^¡A §ÚÓ¤Hı±o¦b§ë¸ê2000¸U¥x¹ô¥H¤U³£¤£¤j»Ýn·Ð´o°hµ|³oÓ°ÝÃD¡A ¦Ó2000¸U¥H¤W§Ú«Øij§A¿Ô¸ß·|p®v¡C ©Î¬Oª÷ÃB¦A¤j¤@ÂI¡A¨ä¹ê¦³¨ä¥L¸Ñªk¡A ¨Ò¦p¥Î¯È¤W¤½¥q¥h§ë¸ê¡A·|¦³ºû«ù¦¨¥»(¨C¦~5¸U~15¸U¤£µ¥)¡A 5000¸U¥H¤Wªº§ë¸ê¸êª÷¥i¥H¸ò·|p®v°Q½×¬Ý¬Ý¡C ì¦]2. °hµ|¦¨¥\¡H¤§«á¼ç¦bªº·ÀI ³o¬O¥«³õ¥ý¥Íı±o§ó³Â·Ðªº³¡¤À¡A ¥un§A¥Ó½Ð¤@¦¸°hµ|¦¨¥\¡A§AªºÓ¤HÀÉ®×´N·|¶i¤J¬ü°ê°êµ|§½(IRS)°lÂÜ¡A ¤§«á§A¨C¤@´Á³£n¦p¹ê³øµ|¡A ¦pªG¦³¥ô¦ó§Ñ°O©Î¤£¹ê¥Ó³øª¬ªp³Q¬d¨ì¡A ¥i¯à¦³°kº|µ|°ÝÃD¡A·|³Q«»@©Î§¤¨c(¤£¯à¤J¹Ò¬ü°ê³o¼Ë)¡C ¦pªG¶ñ¼gªº¸ê®Æ¤£¥¿½T¡A¦³¥i¯à·|³Q©â¬d(¾÷²v¬O15%)¡A·|n§A¸É¸ê®Æ¡A ¦pªG§AµLªk´£¥XÃÒ©ú¡B¥Ó³ø¤£¹ê¡B¹O´Á¨S¦^ÂСA¦³¥i¯à·|³Q¶}»@¡A»@ª÷¬O1¸U¬üª÷°_¸õ¡A ³o¤]¬O¬°¤°»ò«e±»¡¤£«Øij§AÓ¤H¦Û¤v³ø¡A³Ì¦n§ä·|p®vªºì¦]¡C ÁȦ^´X¦Ê©Î´X¤d¬üª÷°hµ|¡AI«á´«¨ì³o¨Ç·ÀI¬O§_ȱo¡H§Úı±o´N¦Û¤vµû¦ô¤F¡C ¸ß°Ý¨Ãä´X¦ì°µ¸ê²£ºÞ²z©Î¾Þ½L¤âªB¤Í¡A ¥Ø«eÁÙ¨S¦³¤H¥h¨«³oÓ°hµ|¬yµ{¡A ¤j®aªº·Qªk¬Oµ|ª÷¥»¨Ó´N¸Óú¡A¤£¥Îµ¹¦Û¤v§ä¤£¦Û¦b¡C ·íµM³o¥u¬O¥«³õ¥ý¥ÍÓ¤Hªº¬Ýªk¡A¨Ã¤£¤@©w¾A¥Î¨CÓ¤Hª¬ªp¡A ¦pªG§A·Q¨«°hµ|¬yµ{ÁÙ¬O¥i¥H¥h°õ¦æ¡C 4. ¨ä¥L¨Ò¥~±¡ªpªºµ|°È ¦]¬°ºô¯¸ÅªªÌ¥]§t¥@¬É¦U¦aµØ¤H¡A¦]¦¹¸É¥R¤@¤U¨Ò¥~ª¬ªpªºµ|°È¡G ¦pªG§A¤£¬O¥xÆW¤H ¥H¤U´XÓ°ê®a¦³©M¬ü°êñqµ|°È¨óij¡A¦]¦¹µ|²v¤ñ¸û§C ¤¤°ê10%¡A¥[®³¤j15%¡A¤é¥»10%¡A¿D¤j§Q¨È15%¡A·s¦èÄõ15% ¥xÆW©M¬ü°ê¨S¦³µ|°È¨óij¡A©Ò¥H¥xÆW¤H¬O30%¡C ¦pªG§A¥i¥H¨ú±o³o¨Ç¦³¯²µ|¨ó©w°ê®aªº°êÄy¡A¤]¬O¤@ºØ¸Ñªk¡C ¦pªG§A¬O¬ü°ê¤H ¬ü°ê¤H·Ó¤@¯ë³øµ|¬yµ{¥Ó¿ì´N¦n¡Anª`·Nªº¬O¬ü°ê¤H·|¦h¤@Ó¡u¸ê¥»§Q±oµ|¡v¡A ´N¬O¶R§C½æ°ªÁȨì»ù®t¤]núµ|¡A µ¥©óÅܬ۹ªÀy¤j®a¤£nµu½u¶i¥X¡AºÉ¥i¯àªø´Á§ë¸ê´N¥i¥H§â³oÓµ|©µ«á¡C n¯d·Nªº¬O¬ü°ê¤Húµ|ªº»{©w¤£¬O¥u¦³¬Ýºñ¥d¡AÁÙn¬Ý¥X¤J¹Ò¡A¦pªG§A¤£²Å¦X¥H¤U´XºØª¬ªp¡A §A¥i¯à·|³Q»{¬°¦¨nú¬ü°êªºµ|¡G 1. ¦b¯Çµ|¦~«×´Á¶¡¤¤ªº¥ô¦ó®ÉÔ¡A¯Çµ|¤H³£¤£«ù¦³¬ü°êºñ¥d¡C 2. ¦b¹L¥h3¦~¤¤ªº¥ô¦ó¤@¦~¸Ì¡A¯Çµ|¤H¦b¬ü°ê¹Ò¤ºªº®É¶¡¤£¶W¹L183¤Ñ¡C §Ö³tÁ`µ²¡G 1. ¬ü°ê²{ª÷ªÑ§Q°t®§®Én½Òµ|¡A¨é°Ó·|¹w¦©30% 2. §ë¸ê¼Ðªº¤¤¡A«D¬ü°êªº§ë¸ê¤£·|½Òµ| 3. ¬ü°êªºªÑ§Q³Q½Òµ|«á¡A¥xÆWÁÙ¬On¥Ó³øÁÙ¥~©Ò±o(ª÷ÃB¤p©ó100¸U¥i¥H¤£³ø) 4. ¬ü°ê°t®§¤£°ª¡A©Ò¥HªÑ§Qªºµ|¼vÅT¤£¤j 5. Ó¤H¤£«Øij¨«°hµ|¬yµ{ 6. «D¬ü°ê¤H¸ê¥»§Q±oµ|¥i¥H§Kµ|¡A¬OӫܤjªºÀu¶Õ¡A·Q¬Ùµ|¥i¥H¦h©¹³o¤è¦V«ä¦Ò¤ñ¸û²³æ rich01.com/us-dividend-tax/ |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/15 ¤U¤È 05:37:00²Ä 2703 ½g¦^À³
|
§ë¸ê¬üªÑ ¹ïúµ|¦³ºÃ°Ýªº¬Ý³o¤ä¼v¤ù§a www.youtube.com/watch?v=MZte_pR8qks |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 05:32:28²Ä 2702 ½g¦^À³
|
6. «D¬ü°ê¤H¸ê¥»§Q±oµ|¥i¥H§Kµ|¡A¬OӫܤjªºÀu¶Õ¡A·Q¬Ùµ|¥i¥H¦h©¹³o¤è¦V«ä¦Ò¤ñ¸û²³æ ©Ò¥H¤é«á,ASLN ADR ³Q¨ÖÁÊ,¥xÆWªÑªFµ¥¦P,¶R½æÁÊ®t»ù,§Kµ|. ¦U¦ì¤j¤j ,½Ð¦A¦V劵°Ó½T»{. ³o¬O¤j§Q¦h. ------------------------------------------- ¤£¹L¥xÆW®ü¥~¦¬¤J¶W¹L670¸U,n½Ò20%©Ò±oµ|. ------- §Ö³tÁ`µ²¡G 1. ¬ü°ê²{ª÷ªÑ§Q°t®§®Én½Òµ|¡A¨é°Ó·|¹w¦©30% 2. §ë¸ê¼Ðªº¤¤¡A«D¬ü°êªº§ë¸ê¤£·|½Òµ| 3. ¬ü°êªºªÑ§Q³Q½Òµ|«á¡A¥xÆWÁÙ¬On¥Ó³øÁÙ¥~©Ò±o(ª÷ÃB¤p©ó100¸U¥i¥H¤£³ø) 4. ¬ü°ê°t®§¤£°ª¡A©Ò¥HªÑ§Qªºµ|¼vÅT¤£¤j 5. Ó¤H¤£«Øij¨«°hµ|¬yµ{ 6. «D¬ü°ê¤H¸ê¥»§Q±oµ|¥i¥H§Kµ|¡A¬OӫܤjªºÀu¶Õ¡A·Q¬Ùµ|¥i¥H¦h©¹³o¤è¦V«ä¦Ò¤ñ¸û²³æ rich01.com/us-dividend-tax/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 05:17:19²Ä 2701 ½g¦^À³
|
³oÃä½Íªº¬O«D¬ü°ê¤Hªºª¬ªp¡A¦b®ü¥~¨é°Ó¶}¤á®É¬yµ{¤¤³£·|¶ñ¼g¤@ÓW-8Benªí®æ¡A ¥Dn¬O¥Ó©ú§A¨Ã«D¬ü°ê¤H¨¤À¡A©Ò¥H¤£¥Îú¬ü°ê¤@¨Çµ|(¨Ò¦p¸ê¥»§Q±oµ|)¡A rich01.com/us-dividend-tax/ ¬°¤°»ò¤£«Øij°hµ|¡H ì¦]1. ¯à°hªºª÷ÃB¦³¡A°hµ|¦¨¥»°ª ¹ï¬ü°ê¨Ó»¡¡A¥~°ê¤Hªº¹w¦©µ|(NRA withholding)¬O¥~°ê¤H¥»¨Ó´Nnúªºµ|¡A --------------------------------------------------------------------------- ´«¨Óªº¦n³B¬O¥~°ê¤H¸ê¥»§Q±o(Capital Gains)§Kµ|¡A¤]´N¬O¶R§C½æ°ªªº»ù®t§Kµ|¡C ------------------------------------------------------- ¬ü°ê°t®§/¸ê¥»§Q±o,¥~°ê¤Hn½Òµ|30% ©Ò¥H¥¼¨ÓASLN ADR ,³Ì¦n¦b«Å§G¨ÖÁÊ»ù«á,¥«³õ¤ÏÀ³¨ì¦ì«á½æ±¼,»ù®t§Kµ|. Yµ¥²Mºâ,¥~°ê¤H¸ê¥»§Q±oµ|30% |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/15 ¤U¤È 05:03:16²Ä 2700 ½g¦^À³
|
to ©t¨àÃĤj ¨S¿ù°Ú~¬O´«¦¨20±iADR ¦ý¬OÁ`»ùȨèS¦³´î¤Ö°Ú ! 100±i(100,000ªÑ) ´«ºâ¦¨ 20±iADR(20,000) ADRªÑ¼Æ 20,000(´«ºâ«áªÑ¼Æ) * 1.85(ADR»ù®æ) * 30(¶×²v) = 1,110,000 ¨ä¹ê«ÂI¬OY§A¦³100±i¥xªÑ,«o¥u¯à´«20±iADR,¦ÓÁö¤j®aªº¦¨¥»¤£¤@,¦ýªÖ©w¬OÁY¤ô¦¨1/5 |
|
|
·|û¡Gonly10135877 µoªí®É¶¡:2020/6/15 ¤U¤È 05:00:46²Ä 2699 ½g¦^À³
|
¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ? ½Ð°Ý³o¥þ±Âà´«ªº·N«ä¬O ªÑªF¨S¦³¥hÂà·|¦Û°ÊÅܦ¨ ADR¶Ü ?Y¤£·|¨º¨S¦³¥hÂà¬O§_12¤ë«á ÁÙ¦³¾÷·|¥hÂà? Y«áªÌ¥i¥H,«h¤]³\¥i¥H©ñµÛ¥H«á¦b¥²´Iºô¥æ©ö? |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/6/15 ¤U¤È 04:57:23²Ä 2698 ½g¦^À³
|
ADR. 1ªÑªí¹ü5ªÑ¥xªÑ ADR1ªÑ1.85¬ü¤¸§é¥x¹ô¬ù55.5¤¸¡]1.85*30¡^ 55.5¤¸/5ªÑ=11.1¡]¬P´Á¤p¡^ °¨¤Wº¦90w §Q¦h ¦U¤H¬Ýªk |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/15 ¤U¤È 04:53:17²Ä 2697 ½g¦^À³
|
©t¤j±zºâ¿ù¤F§a ADRÁöµM±i¼Æ¤Ö¥i¬O¬O¬ü¤¸p»ù ÁÙn¼¤W30¤¸¶×²v ¨Ì¥Ø«eªº»ùÈ 20±iADRÁÙ¤ñ100±i¥x·à°ª¤£¤ÖC |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/15 ¤U¤È 04:52:57²Ä 2696 ½g¦^À³
|
¸U¤@¯uªº¥i¥HÂà´«10±i¨È·à±d´«2±iALSN Âà´«»ùȤ£ÅÜ°ò¦¤U, ¨º©ú¤Ñ¶}©l¨È·à±dÀ³¸Ó´Â¦V¬üª÷1.85´«ºâ«áªº¥x¹ô»ù®æ10¶ô»ù¦ì¾aªñ,¨Ì¥Ø«e·¸»ù´T«×¨Ó¬Ý¦³¤@¿¥ª¥kªºº¦´T ! ³o§Ú¦³²z¸Ñ¿ù»~¶Ü ? |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/15 ¤U¤È 04:49:38²Ä 2695 ½g¦^À³
|
¨ä¹ê«ÂI¬OY§A¦³100±i¥xªÑ,«o¥u¯à´«20±iADR,¦ÓÁö¤j®aªº¦¨¥»¤£¤@,¦ýªÖ©w¬OÁY¤ô¦¨1/5.... |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/15 ¤U¤È 04:42:27²Ä 2694 ½g¦^À³
|
¦pªG¨Ì¥¿±`pºâ¨Ó»¡ 10±i6497¨È·à±d À³¸Ó´«ºâ¦¨ 2±iASLN NASDAQ ªº»ùȤ~¹ï ! ¦Ó¤£¬O©t¨à¤j¤j»¡ªº ¥ýÁY¤ô20%¦A¥h´«ºâ ...³o¼Ë¤@¨Ó¤@©¹»ù®t¦n´X¿Åo !! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/15 ¤U¤È 04:38:37²Ä 2693 ½g¦^À³
|
To:T¤j ´N¬O¥HADR1ªÑ´«5ªÑ¥xªÑ¨Ó¦ôºâ...·íªì¦¨¥»Y¬O40¶ô,§Aªº«ùªÑ´Nnº¦¨ì¬Û·í¥x¹ô200¶ô¤~·l¯q¨â¥,¦Ü©ó®ü¥~½Òµ|´N¥Î15%pºâ.. |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/15 ¤U¤È 04:29:07²Ä 2692 ½g¦^À³
|
©t¤jªº·N«ä¬O5:1 ±i¼Æ°£¥H5=20%ªº·N«ä ¤£¹L»ùȨèS§ïÅܪü ¦Ó¥B¤½¥qÄ@·N¨î©wÂà´«¿ìªk §Ú¬O§Q¦h¬Ý«Ý |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/6/15 ¤U¤È 04:18:40²Ä 2691 ½g¦^À³
|
©t¨à¤j ? ±z³oÁY¤ô¦¨20%¬O«ç¼Ëºâ¥X¨Óªº©O ? ¦³¤½¦¡¨Ì´` ? ·N«ä´N¬O¤j®aªÑ²¼¥ýÁY¤ô¦¨20%,µM«á¥i¥H¦bADR¥æ©ö,¦pªG§Aªº¥xÆWªÑ²¼¦¨¥»¬O40¶ô,ADRnº¦¨ì38.333©p¤~¦^¥»(¥[¤W®ü¥~½Òµ|)...ü...ªº½T¬O¥v¤W¤Ö¨£ªº¤âªk,¤j®a¦U¦Û«O«¤F... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 04:14:27²Ä 2690 ½g¦^À³
|
´«ADR ¤ñ²v : À³¸Ó5¥xªÑ´«1ªÑADR . ¨º©ú¤Ñ¶}©l, ¥xªÑªÑ»ùÀ³¸Ó¦^Âk¥¿±` , ´ÂADR 1.85¬ü¤¸/§é¦X¥xªÑ10.5¤¸, ©Ôªñ¤ñ¸û¦X²z????? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/6/15 ¤U¤È 04:11:24²Ä 2689 ½g¦^À³
|
¥un¯àÂà´«´N¦n¤F Á`¤ñÅܾÀ¯È¦n |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/6/15 ¤U¤È 04:05:41²Ä 2688 ½g¦^À³
|
·N«ä´N¬O¤j®aªÑ²¼¥ýÁY¤ô¦¨20%,µM«á¥i¥H¦bADR¥æ©ö,¦pªG§Aªº¥xÆWªÑ²¼¦¨¥»¬O40¶ô,ADRnº¦¨ì38.333©p¤~¦^¥»(¥[¤W®ü¥~½Òµ|)...ü...ªº½T¬O¥v¤W¤Ö¨£ªº¤âªk,¤j®a¦U¦Û«O«¤F... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 03:07:44²Ä 2687 ½g¦^À³
|
¸òµÛ¤jªÑªF¨« ¥þ±´« ASLN / ADR ªÑ²¼. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 02:58:56²Ä 2686 ½g¦^À³
|
[¤½§i] ¨È·à±d-KY:¥»¤½¥q¸³¨Æ·|»¡©ú¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤§¼ç¦b¥i¯à¤Î¬ÛÃö·ÀI¦]À³¨Æ¶µ ¤½¶}¸ê°TÆ[´ú¯¸ (2020-06-15 14:43:32) ²Ä53´Ú 1.¨Æ¹êµo¥Í¤é:109/06/15 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q¸³¨Æ·|©ó109¦~6¤ë15¤é¥l¶}·|ij°Q½×¨Ã«Å¥¬¥i¯à©ó°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi ¶R½æ¤¤¤ß²×¤î¦³»ùÃÒ¨é¶R½æ¤§¼ç¦b¼vÅT¡A¨Ã¦P¨B©ó¬ü°êÃÒ¨é¥DºÞ¾÷Ãö«ü©wºô¯¸¤½§G¬Û Ãö·ÀI¨Æ¶µ¡C ¥»¤½¥q¸³¨Æ·|¤wª¾±x®Ú¾Ú°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ßÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³ »ùÃÒ¨é·~°È³W«h(¥H¤UºÙ¡§·~°È³W«h¡¨)²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú³W©w¡A¥»¤½¥q¨ÌÃÒ¨é¥æ ©öªk²Ä36±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼Æ¡A¤Î·~°È³W«h²Ä7´Ú³W©w ¡A¤½¥qÀç¹B¥þ±°±¹y¹O¤»Ó¤ë©Î³sÄò¤»Ó¤ë¤½§i¤§Àç·~¦¬¤J¬°¹s©Ît¼Æ¡A°]¹Îªk¤H¤¤ µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß±o¨Ì¬ÛÃö³W©w¤½§i²×¤î¥»¤½¥q¦³»ùÃÒ¨éÂdÂi¶R½æ¡A¨Ã³ø½Ð¥D ºÞ¾÷Ãö³Æ¬d¡C±©¤Wz¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤@¨Æ¨Ã¤£¼vÅT¥»¤½¥q¤§¬ü°ê¦s°U¾ÌÃÒ (American Depositary Shares, or ADS)«ùÄò©ó¬ü°ê¨º´µ¹F§J¥«³õ¤W¥«¤Î¥æ©ö¡C 6.¦]À³±¹¬I: ¥»¤½¥q¸³¨Æ·|½T»{Y¦³»ùÃÒ¨é¸gÃÒ¨é¥DºÞ¾÷Ãö²×¤îÂdÂi¶R½æ¡A¬°ºûÅ@¤Î¨ó§UªÑªF¹ê²{ »ùÈ¡A¸³¨Æ·|±ÂÅv¥»¤½¥qºÞ²z¶¥¼h¨îqªÑ¥÷¥þ±Âà´«pµe¡A³z¹L¸ÓÂà´«pµe½á¤©¥»¤½ ¥qªÑªF¦³Åv¨Ì§Ç©ó¥¼¨Ó6¦Ü12Ӥ뤺±N¨ä©Ò«ùªÑ¥÷Âà´«¬°©ó¨º´µ¹F§J±¾µP¤§¬ü°ê¦s°U ¾ÌÃÒ¡C¸Ó¥þ±Âà´«pµe±N©ó¸³¨Æ·|³Ì²×¨Mij«á¤½¥¬¬ÛÃö²Ó¸`¡C ¦p¥»¤½¥q¦³»ùÃÒ¨é²×¤î¶R½æ«á¡A±N¾ÉP¨ä¥L©Ò¦³¥xÆW±¾µPªk«ß¡]¥]¬A³W«h¡^³v¨B¤£ ¾A¥Î©ó¥»¤½¥q¡C¥»¤½¥q¸³¨Æ·|¤wª¾±x¦¹¶µ¾Aªk©ÊÅÜ°Ê¥B¦P·N¦¹¶µÅܰʱN¦³§Q©ó¥»¤½¥q ¥R¤À¾A¥Î¬ü°ê¦h¤¸Äw¸ê¤u¨ã¡B´£¤É¥»¤½¥q¶Ò¶°¸êª÷¯à¤O¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: «e¤©Ê³¯z ¥»«¤j°T®§¥]§t¦U¶µ«e¤©Ê³¯z¡C¤Wz³¯z¨Æ¶µ«Y¥»¤½¥q°ò©ó¥Ø«e²z©À¡B¹w´Á©Ò§@¥X ¤§Án©ú¡C¤Wz«e¤©Ê³¯z¥]¬A¦ý¤£©ó¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¡F¥»¤½¥q¨îq¨Ã ¹ê¬I¥þ±Âà´«pµe¤§¯à¤O¡F²×¤îÂdÂi¶R½æ«á¤§¼ç¦b§U¯q©ÎÄw¸ê¯à¤O¡F¤Î¥»¤½¥q·~°Èµ¦ ²¤¡C ¥»¤½¥q¤§«e¤©Ê³¯z«Y°ò©óºÞ²z¶¥¼h¥Ø«e¹ï¥¼¨Ó¨Æ¥ó©MÁͶժº·í«e°²³]©M¹w´Á¡A³o¨Ç ¥i¯à¼vÅT¤½¥q·~°È¡Bµ¦²¤¡B¹BÀç©Î°]°ÈÁZ®Ä¡A¨Ã¥B¥ý¤Ñ©Ê¯A¤Î«¤j¤wª¾©M¥¼ª¾ªº·ÀI »P¤£½T©w©Ê¡C°ò©ó³o¨Ç·ÀI©M¤£½T©w©Ê¥i¯à¾ÉP¹ê»Úµ²ªG©Î¨Æ¥ó»P¹w´Á«¤j¤£¦P¡C ³o¨Ç¤£½T©w©Ê¥]§t¦ý¤£©ó¥»¤½¥q©ó¬ü°êÃÒ¨é¥æ©ö©eû·| (U.S. Securities and Exchange Commission)¥Ó³ø¤§¤å¥ó (Commission File No. 001-38475)¡B¥]§t¥»¤½¥q©ó2020¦~4¤ë16¤é´£¥æ¤§20-Fªí®æ¡C °£¾ú¥v©Ê¨Æ¹ê³¯z¥~¡A¨ä¥L©Ò¦³³¯z§¡¬°«e¤©Ê³¯z¡A¬ÛÃö¥Î»y½Ñ¦p¡¨¬Û«H¡¨¡A ¡¨¥i¥H¡¨¡A¡§¥i¯à¡¨¡A¡§±N¡¨¡A¡§¥Ø¼Ð¡¨¡A¡§¦ôp¡¨¡A¡§«ùÄò/Ä~Äò¡¨¡A¡§¹w´Á¡¨¡A ¡§¥´ºâ¡¨¡A¡§´Á±æ¡¨¡A¡§p¹º¡¨µ¥¡A¤Î¨ä¥LÃþ¦ü·N¸qªº§_©wµü»y¨ÓÃѧO³o¨Ç«e¤©ÊÁn ©ú¡C ¥»¤½¥q¹ï¤Wz¦ôp¡B¹w´ú¡B¤Î©Ò¦³«e¤©ÊÁn©úªþ¦³§K³d«OÅ@¡A¤£©Ó¾á§ó·s©Î¼f¾\¥ô¦ó «e¤©Ê³¯z¤§¸q°È¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 02:33:24²Ä 2685 ½g¦^À³
|
¦¸n«ü¼ÐB.C.D,¤Î±´¯Á©Ê«ü¼Ð¡B¦w¥þ©Ê, µ¥¬Ò»P¹ï·Ó²Õ¬Û·í¡A¥¼¹F²Îp¤W顕µÛ®t²§¡C Y¥¼¨Ó¦X¤@ªºON101 q»ù , Y °ª©óAQUACEL 1.5¿,, ¦b¬ü°ê(¤½/¨p)«OÀI¤½¥q¡A À³¸Ó·|¥ý®Ö¥Î¹ï·Ó²Õ¥ÎÃÄAquacel, ªvÀøµL®Ä¡A¤~·|¨Ï¥ÎON101. ¥Dn«ü¼Ð : ¶Ë¤f§¹¥þ¡¦X ¹ï·Ó²Õ34%, ON101 63.6%. ¡X¡X¡X¡X¡X¡X¡X¡X pchome.megatime.com.tw/news/cat7/20200615/9700004743202006151.html 6¤ë15¤é ¦X¤@:¤½§i¥»¤½¥q¤µ¤é¥l¶}«¤j°T®§°OªÌ·|¤§·s»D½Z¤º®e , 1)¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: A.¥þ¤ÀªR¼Æ¾Ú¶°(FAS)¤§¼Æ¾ÚÅã¥Ü¡AON101²Õ62.2%¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡A¹ï·Ó²Õ (Aquacel)34.7% ¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡F¨â²Õ¶Ë¤f§¹¥þ¡¦X²v®t²§27.5%¡A¹F ¨ì²Îp¤WÅãµÛ®t²§(p=0.0001¡Õ0.03476 £\¬ÉÈ)¡C ¡i¥þ¤ÀªR¼Æ¾Ú¶°(FAS)¡G³QÀH¾÷¤À¬£¤§¨ü¸ÕªÌ¡A¤£½×¦³µL±µ¨ü¸ÕÅçÃĪ«¡A¬Ò·|³Q¯Ç ¤J¥Dnµû¦ô«ü¼Ðªº¤ÀªR¡j B.×¥¿«¬·N¹ÏªvÀø(mITT)¤ÀªR±Ú¸s¼Æ¾ÚÅã¥Ü¡AON101²Õ63.6%¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X ¡A¹ï·Ó²Õ(Aquacel)33.3% ¨ü¸ÕªÌ¶Ë¤f§¹¥þ¡¦X¡F¨â²Õ¶Ë¤f§¹¥þ¡¦X²v®t²§30.3% ¡A¹F¨ì²Îp¤WÅãµÛ®t²§(p<0.0001)¡C ¡i×¥¿«¬·N¹ÏªvÀø(mITT)±Ú¸s¡G³QÀH¾÷¤À¬£¤§¨ü¸ÕªÌ¡A¤£½×¦³µL±µ¨ü¸ÕÅçÃĪ«¡A ¨ä¥Ø¼Ð¶Ë¤f¬Ò²Å¦Xpµe®Ñ±ø¥óªÌ¡A©l±o¯Ç¤J¥Dnµû¦ô«ü¼Ðªº¤ÀªR¡j (2)¦¸nµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: A.16¶gªºªvÀø´Á¶¡¡AON101²Õªº¥Ø¼Ð¶Ë¤f§¹¥þ¡¦X¤¤¦ì¼Æ¬°14.0¶g(·N§Y¦³50%ªº¨ü ¸ÕªÌ¦b±µ¨üªvÀø14¶g®É¡A¥Ø¼Ð¶Ë¤f§Y§¹¥þ¡¦X)¡C¹ï·Ó²Õ«h¥¼¯à¦b16¶gªºªvÀø´Á ¤ºÆ[¹î¨ì¥Ø¼Ð¶Ë¤f§¹¥þ¡¦X¤¤¦ì¼Æ(·N§Y¥¼¯à¦³50%ªº¨ü¸ÕªÌ¦b16¶gªºªvÀø´Á¹F¥Ø ¼Ð¶Ë¤f§¹¥þ¡¦X®ÄªG)¡A¹F¨ì²Îp¤WÅãµÛ®t²§(p=0.001)¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- B.©ó¨âªvÀø²Õ·í¤¤¡A»P°ò¦Ȭ۸û¡A¦bµ²§ôªvÀø´Á«e¡A¶Ë¤f±¿nªºÅܤơAON101²Õ ÁY¤p76.0%¡A¹ï·Ó²Õ(Aquacel)ÁY¤p77.0%¡A¨ü¸ÕªÌ¶Ë¤f±¿nÁY¤p¤ñ²v¡A¨â²Õ®t²§ ¬°1.0%¡A¥¼¹F²Îp¤WÅãµÛ®t²§(p=0.866)¡C¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¡X¡X¡X¡X- C.©ó¨âªvÀø²Õ·í¤¤¡A¦bµ²§ôªvÀø´Á«e¡A¶Ë¤f±¿nÁY¤p50%ªº¤ñ²v¡AON101²Õ81.1% ¡A¹ï·Ó²Õ(Aquacel)85.2%¡F¶Ë¤f±¿nÁY¤p50%ªº¤ñ²v¡A¨â²Õ®t²§¬°4.1%¡A¥¼¹F²Î p¤WÅãµÛ®t²§(p=0.4419)¡C¡X¡X- ¡X¡X¡X D.©ó¨âªvÀø²Õ·í¤¤¡A¥Ø¼Ð¶Ë¤f·P¬Vµo¥Í²v¡AON101²Õ5.4%¡A¹ï·Ó²Õ(Aquacel)5.9%¡F ¥Ø¼Ð¶Ë¤f·P¬Vµo¥Í²v¡A¨â²Õ®t²§¬°0.5%¡A¥¼¹F²Îp¤WÅãµÛ®t²§(p>0.999)¡C¡X¡X¡X- ¡X¡X¡X¡X- (3)±´¯Á©Ê«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: ©ó¨âªvÀø²Õ·í¤¤¡A§¹¥þ¡¦Xªº¥Ø¼Ð¶Ë¤f´_µoªº¤ñ²v¡AON101²Õ20.3%¡A¹ï·Ó²Õ (Aquacel)17.1%¡F¥Ø¼Ð¶Ë¤f´_µoªº¤ñ²v¡A¨â²Õ®t²§¬°3.2%¡A¥¼¹F²Îp¤WÅãµÛ®t ²§(p=0.797)¡C¡X¡X¡X¡X- (4)¦w¥þ©Êµû¦ôµ²ªG A.©ó¨âªvÀø²Õ·í¤¤¡AON101²Õ©ó¶}©lªvÀø«á¥X²{ªº¤£¨}¨Æ¥ó(treatment emergent adverse event, TEAE)¤ñ¨Ò60.4%¡A¹ï·Ó²Õ(Aquacel)69.3%¡A¥¼¹F²Îp¤WÅãµÛ®t ²§(p= 0.1968)¡C B.©ó¨âªvÀø²Õ·í¤¤¡A¶}©lªvÀø«áµo¥Í»PªvÀøÃĪ«¦³Ãöªº¤£¨}¤ÏÀ³(related TEAE) ¤ñ¨Ò¡AON101²Õ¬°3.6%¡A¹ï·Ó²Õ(Aquacel) ¬°4.0%¡A¥¼¹F²Îp¤WÅãµÛ®t²§ (p>0.999)¡C C.ªvÀø´Á¶¡¡AON101²Õ¨Ã¥¼µo¥Í¥ô¦ó»PªvÀøÃĪ«¬ÛÃö¤§ÄY«¤£¨}¤ÏÀ³¨Æ¥ó(related serious adverse event, related SAE)¡C ¨Ì¾Ú¬ü°êFDAªvÀøºC©Ê¶Ë¤f²£«~¬ãµo·Ç«h(Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds ¡X Developing Products for Treatment)¡A«P¶iºC©Ê¶Ë¤f¡ ¦XªºÀø®Äµû¦ô«ü¼Ð¡A¬°¶Ë¤f§¹¥þ¡¦X²v[Incidence of complete wound closure ¡A½Ð °Ñ¨£²Îpµ²ªG(1)]¤Î¹F¦¨¶Ë¤f§¹¥þ¡¦X©Ò»Ý®É¶¡[time to complete wound closure¡A ½Ð°Ñ¨£²Îpµ²ªG(2)A ]¡C¥H¤W²Îpµ²ªGÅã¥Ü¡AON101²Õ¦b³o¨â¶µÀø®Ä«ü¼Ð¡A¬ÒÅãµÛÀu©ó ¹ï·Ó²ÕAquacel¡A¹F¦¨¬ü°êFDAµû¦ô«P¶iºC©Ê¶Ë¤f¡¦XªºÁ{§ÉÀø®Ä«ü¼Ð¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/6/15 ¤U¤È 02:03:59²Ä 2684 ½g¦^À³
|
¥xÆW·s°ê¯f¡I¿}§¿¯f±wöt¯}230¸U¤H¡@Âå®v¡GªvÀøn±q®a¤H¶}©l 2019-11-05|Âå¥Í»¡, ¿}§¿¯f±M°Ï, ¿}§¿¯f±MÃD, ÀY±ø, °·±d·sª¾, ³Ì·s¤å³¹, ±M®a»¡, ±MÃD³ø¾É ¥xÆW·s°ê¯f¡I¿}§¿¯f±wöt¯}230¸U¤H¡@Âå®v¡GªvÀøn±q®a¤H¶}©l | Heho°·±d heho.com.tw/archives/59131 ¿}§¿¯f±w¨C¦~¨¬³¡¼ìºÅ ªºµo¥Í²v¬ù¬° 3% www.tsim.org.tw/journal/jour23-6/07.PDF 230x3%=6.9 ¸U¤H¡C¡X¡X¥xÆW¨C¦~¨¬³¡¼ìºÅ¤H¼Æ¦ôp. 6.9x ConvaTecAQUACEL EXTRA Hydrofiber Dressing(Sterile) ¨C¤ù¥x¹ô 410¤¸ 410x7x16=45920 ¥x¹ô(16¶gÀøµ{) 6.9¸U¤Hx 4.59¸U¤¸=31.67 »õ ¥x¹ô¡X¡X¥i¯àªº¥xÆW¦a°ÏÃĪ«¤ä¥X¦ôp¡C |
|
|
|